Gentherm (THRM) 10-K 19 Feb 25 2024 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Feb. 13, 2025	Jun. 28, 2024
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	FY
Trading Symbol	THRM
Entity Registrant Name	GENTHERM INCORPORATED
Entity Central Index Key	0000903129
Entity Current Reporting Status	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Common Stock, Shares Outstanding		30,788,989
Entity Shell Company	false
Entity File Number	0-21810
Entity Tax Identification Number	95-4318554
Entity Address, Address Line One	28875 Cabot Drive
Entity Address, City or Town	Novi
Entity Address, State or Province	MI
Entity Address, Postal Zip Code	48377
City Area Code	248
Local Phone Number	504-0500
Entity Interactive Data Current	Yes
Entity Incorporation, State or Country Code	MI
Security Exchange Name	NASDAQ
Title of 12(b) Security	Common Stock, no par value
Document Transition Report	false
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Public Float			$ 1,519,329,529
Document Annual Report	true
Auditor Firm Id	42
Auditor Name	ERNST & YOUNG LLP
Auditor Location	Detroit, Michigan
Documents Incorporated by Reference	DOCUMENTS INCORPORATED BY REFERENCE Portions of the proxy statement for the 2025 annual meeting of shareholders are incorporated by reference into Part III of this Annual Report to the extent described herein.
Document Financial Statement Error Correction [Flag]	false
Auditor Opinion [Text Block]	Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Gentherm Incorporated (the Company) as of December 31, 2024 and 2023, the related consolidated statements of income, comprehensive income, changes in shareholders' equity and cash flows for each of the three years in the period ended December 31, 2024, and the related notes and financial statement schedule listed in the Index at Item 15 (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles. We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated February 19, 2025, expressed an unqualified opinion thereon. Opinion on Internal Control Over Financial Reporting We have audited Gentherm Incorporated’s internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Gentherm Incorporated (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2024, based on the COSO criteria. We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2024 and 2023, the related consolidated statements of income, comprehensive income, changes in shareholders' equity and cash flows for each of the three years in the period ended December 31, 2024, and the related notes and financial statement schedule listed in the Index at Item 15 and our report dated February 19, 2025 expressed an unqualified opinion thereon.

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Current Assets:
Cash and cash equivalents	$ 134,134	$ 149,673
Accounts receivable, net	258,112	253,579
Inventory, net	227,356	205,892
Other current assets	64,413	78,420
Total current assets	684,015	687,564
Property and equipment, net	252,970	245,234
Goodwill	99,603	104,073
Other intangible assets, net	57,251	66,482
Operating lease right-of-use assets	43,954	27,358
Deferred income tax assets	75,041	81,930
Other non-current assets	34,722	21,730
Total assets	1,247,556	1,234,371
Current Liabilities:
Accounts payable	226,815	215,827
Current lease liabilities	7,517	7,700
Current maturities of long-term debt	137	621
Other current liabilities	105,824	100,805
Total current liabilities	340,293	324,953
Long-term debt, less current maturities	220,064	222,217
Non-current lease liabilities	37,052	16,175
Pension benefit obligation	4,017	3,209
Other non-current liabilities	29,183	23,095
Total liabilities	630,609	589,649
Common Stock:
No par value; 55,000,000 shares authoeized 30,788,639 and 31,542,001 issued and outstanding at December 31, 2024 and December 31,2023, respectively	2,049	50,503
Paid-in capital	4,290
Accumulated other comprehensive loss	(85,193)	(30,160)
Accumulated earnings	695,801	624,379
Total shareholders’ equity	616,947	644,722
Total liabilities and shareholders’ equity	$ 1,247,556	$ 1,234,371

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Common Stock, par value
Common Stock, shares authorized	55,000,000	55,000,000
Common Stock, shares issued	30,788,639	31,542,001
Common Stock, shares outstanding	30,788,639	31,542,001

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Product revenues	$ 1,456,124	$ 1,469,076	$ 1,204,656
Type of Revenue [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember
Cost of sales	$ 1,089,693	$ 1,117,452	$ 931,006
Gross margin	366,431	351,624	273,650
Operating expenses:
Net research and development expenses	88,697	94,358	85,722
Selling, general and administrative expenses	155,108	155,579	132,693
Restructuring expenses, net	13,110	4,739	637
Impairment of intangible assets and property and equipment	2,501		6,291
Impairment of goodwill		19,509
Total operating expenses	259,416	274,185	225,343
Operating income	107,015	77,439	48,307
Interest expense, net	(15,300)	(14,641)	(4,294)
Foreign currency gain (loss)	9,599	(5,918)	(6,778)
Other income (loss)	951	(1,926)	1,147
Earnings before income tax	102,265	54,954	38,382
Income tax expense	37,318	14,611	13,941
Net income	$ 64,947	$ 40,343	$ 24,441
Basic earnings per share	$ 2.08	$ 1.23	$ 0.74
Diluted earnings per share	$ 2.06	$ 1.22	$ 0.73
Weighted average number of shares – basic	31,293,113	32,778,055	33,126,202
Weighted average number of shares – diluted	31,476,486	33,066,917	33,503,154

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Statement of Comprehensive Income [Abstract]
Net income	$ 64,947	$ 40,343	$ 24,441
Other comprehensive (loss) income:
Pension benefit obligations, net of tax	(840)	56	1,826
Foreign currency translation adjustments, net of tax	(45,266)	13,439	(14,081)
Unrealized (loss) gain on foreign currency derivative securities, net of tax	(8,927)	2,834	2,693
Unrealized loss on commodity derivative securities, net of tax			(5)
Other comprehensive (loss) income, net of tax	(55,033)	16,329	(9,567)
Comprehensive income	$ 9,914	$ 56,672	$ 14,874

Consolidated Statements of Chan

Consolidated Statements of Changes In Shareholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Paid-in Capital	Accumulated Other Comprehensive (Loss) Income	Accumulated Earnings
Beginning Balance at Dec. 31, 2021	$ 653,806	$ 118,646	$ 5,866	$ (36,922)	$ 566,216
Beginning Balance (in shares) at Dec. 31, 2021		33,008,000
Net income	24,441				24,441
Other comprehensive income (loss)	(9,567)			(9,567)
Stock compensation, net	3,593	$ 4,012	(419)
Stock compensation, net, shares		194,000
Ending Balance at Dec. 31, 2022	672,273	$ 122,658	5,447	(46,489)	590,657
Ending Balance (in shares) at Dec. 31, 2022		33,202,000
Net income	40,343				40,343
Other comprehensive income (loss)	16,329			16,329
Stock compensation, net	9,079	$ 9,147	(68)
Stock compensation, net, shares		129,000
Stock repurchase	(93,302)	$ (81,302)	(5,379)		(6,621)
Stock repurchase (in shares)		(1,789,000)
Ending Balance at Dec. 31, 2023	$ 644,722	$ 50,503		(30,160)	624,379
Ending Balance (in shares) at Dec. 31, 2023	31,542,001	31,542,000
Net income	$ 64,947				64,947
Other comprehensive income (loss)	(55,033)			(55,033)
Stock compensation, net	12,919	$ 14,153	$ (1,055)		(179)
Stock compensation, net, shares		266,000
Stock repurchase	(50,608)	$ (62,607)			6,654
Stock repurchase (in shares)		(1,019,000)	5,345
Ending Balance at Dec. 31, 2024	$ 616,947	$ 2,049	$ 4,290	$ (85,193)	$ 695,801
Ending Balance (in shares) at Dec. 31, 2024	30,788,639	30,789

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Operating Activities:
Net income	$ 64,947	$ 40,343	$ 24,441
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	52,975	50,948	44,394
Deferred income taxes	10,580	(13,072)	(7,322)
Stock based compensation	10,432	11,627	6,599
Provisions for inventory	6,437	6,867	15,923
Impairment of intangible assets and property and equipment	2,501		6,291
(Gain) loss on disposition of property and equipment	(1,603)	721	771
Impairment of goodwill		19,509
Other	(1,156)	2,920	721
Changes in assets and liabilities:
Accounts receivable, net	(12,077)	(4,195)	(44,221)
Inventory	(34,195)	6,907	(40,322)
Other assets	(44,696)	(26,179)	(11,906)
Accounts payable	16,222	31,029	28,314
Other liabilities	39,279	(8,160)	(8,736)
Net cash provided by operating activities	109,646	119,265	14,947
Investing Activities:
Purchases of property and equipment	(73,314)	(37,602)	(39,703)
Proceeds from the sale of property and equipment	7,862	391	248
Acquisition of businesses, net of cash acquired			(205,487)
Proceeds from deferred purchase price of factored receivables	12,876	13,903	5,538
Cost of technology investments	(955)	(815)	(495)
Net cash used in investing activities	(53,531)	(24,123)	(239,899)
Financing Activities:
Borrowings on debt	68,000	60,000	207,000
Repayments of debt	(70,615)	(72,280)	(13,272)
Proceeds from the exercise of Common Stock options	5,791	263	1,670
Taxes withheld and paid on employees' share-based payment awards	(3,296)	(2,940)	(5,471)
Cash paid for the repurchase of Common Stock	(51,585)	(91,094)
Net cash (used in) provided by financing activities	(51,705)	(106,051)	189,927
Foreign currency effect	(19,949)	6,691	(1,690)
Net decrease in cash and cash equivalents	(15,539)	(4,218)	(36,715)
Cash and cash equivalents at beginning of period	149,673	153,891	190,606
Cash and cash equivalents at end of period	134,134	149,673	153,891
Supplemental disclosure of cash flow information:
Cash paid for taxes	20,837	23,273	21,645
Cash paid for interest	13,007	13,242	6,338
Non-Cash Investing Activities [Abstract]
Period-end balance of accounts payable for property and equipment	5,154	7,754	2,526
Deferred purchase price of receivables factored in the period	$ 9,276	$ 13,885	$ 3,769

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Dec. 31, 2024
Trading Arrangements, by Individual
Title	directors or Section 16 officers
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Cybersecurity Risk Management,

Cybersecurity Risk Management, Strategy, and Governance	12 Months Ended
	Dec. 31, 2024
Cybersecurity Risk Management, Strategy, and Governance [Line Items]
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]	ITEM 1C. CYBERSECURITY Our corporate information technology, communication networks, enterprise applications, accounting and financial reporting platforms, and related systems are necessary for the operation of our business. We use these systems, among others, to manage our product development and manufacturing, to communicate internally and externally, to operate our accounting and record-keeping functions, and for many other key aspects of our business. Our business operations rely on the secure collection, storage, transmission, and other processing of proprietary, confidential, and sensitive data. Risk Management and Strategy We recognize the importance of assessing, identifying, and managing material risks associated with cybersecurity threats, as such term is defined in Item 106(a) of Regulation S-K. These risks include, among other things: operational risks, intellectual property theft, fraud, extortion, harm to employees or customers, violation of data privacy or security laws, litigation, and legal, financial and reputational risk. We have implemented and maintain various information security processes designed to identify, assess and manage material risks from cybersecurity threats to our critical systems and our proprietary, strategic or competitive data. Depending on the environment, we implement and maintain various technical, physical, and organizational measures, processes, standards, and/or policies designed to manage and mitigate material risks from cybersecurity threats to our information systems and data, including risk assessments, incident detection and response, vulnerability management, disaster recovery and business continuity plans, internal controls within our accounting and financial reporting functions, encryption of data, network security controls, access controls, physical security, asset management, systems monitoring, vendor risk management program and employee training. We conduct regular reviews and tests of our information security program and also leverage audits by our internal audit team, tabletop exercises, penetration and vulnerability testing, and other exercises to evaluate the effectiveness of our information security program and improve our security measures and planning. We have an incident response process that relies on a multidisciplinary team for assessing and managing cybersecurity incidents, including an escalation framework based on the materiality of incidents. The multidisciplinary team includes members of our IT security function, executive management of our legal, finance, human resources, corporate communications and internal audit/risk functions and third party service providers of technical, legal and insurance services, as well as coordination with law enforcement as appropriate. Our IT security function also addresses cybersecurity threats through regular vulnerability reviews, risk registry reviews and global team meetings. Our information security processes are integrated into our overall enterprise risk management (“ERM”) process and system. Our ERM process relies on designated risk managers to identify and assess material risks from cybersecurity threats. The risk managers form a multidisciplinary group including members of our IT security, finance, human resources and legal functions, operations and executive management, and are responsible for timely reporting of risks on an ongoing basis. Our ERM process includes an annual evaluation and ranking of the top risks captured in our ERM system against leading third party benchmark reports on global risks. We work with third parties from time to time that assist us to identify, assess, and manage cybersecurity risks, including professional services firms, consulting firms, threat intelligence service providers, and penetration testing firms. To operate our business, we utilize certain third-party service providers to support a variety of functions. We seek to engage reliable, reputable service providers that maintain cybersecurity programs. Depending on the nature of the services provided, the sensitivity and quantity of information processed, and the identity of the service provider, our vendor management process may include reviewing the cybersecurity practices of such provider, contractually imposing obligations on the provider, conducting security assessments, and conducting periodic reassessments during their engagement. Our systems periodically experience directed attacks that may be intended to lead to financial loss, interruptions and delays in our operations as well as loss, misuse or theft of personal information (of third parties, employees, and other stakeholders) and other data, confidential information or intellectual property. These attacks are increasing in frequency, uniqueness and sophistication to evade detection and remove forensic evidence of the incident, including due to emerging technologies such as artificial intelligence and machine learning, which may cause cybersecurity incidents to be more difficult to detect for periods of time or at all. However, we are not aware of any risks from cybersecurity threats, including as a result of any cybersecurity incidents, which have materially affected or are reasonably likely to materially affect our Company, including our business strategy, results of operations, or financial condition. Refer to “Item 1A. Risk factors” in this annual report on Form 10-K for additional discussion about cybersecurity-related risks. Governance Our Board of Directors holds oversight responsibility for the Company’s strategy and risk management, including material risks related to cybersecurity threats. This oversight is executed directly by the Board of Directors and through its committees. Our Board members also engage in ad hoc conversations with management on cybersecurity-related news events and discuss any updates to our cybersecurity risk management and strategy programs. The Audit Committee of the Board of Directors (the “Audit Committee”) oversees the quality and effectiveness of the control and enterprise risk management processes of systemic risks, including cybersecurity, in accordance with its charter. The Audit Committee receives reports and engages in regular discussions with management regarding the Company’s significant financial risk exposures and the measures implemented to monitor and reasonably manage these risks, including those that may result from material cybersecurity threats. The Audit Committee also receives reports on material cybersecurity and data privacy incidents (if any), which would include plans to mitigate and respond to such incidents, and status on key information security initiatives. These discussions include the Company’s enterprise risk assessment and risk management policies. The Technology Committee of the Board of Directors oversees the management of risks associated with the Company’s products and technologies, including cybersecurity risks related to new product technologies or significant innovations to existing product technologies, in accordance with its charter. Our Vice President & Chief Information Officer (the “CIO”) leads our global information security organization and reports to the Board of Directors on matters related to cybersecurity on behalf of the Company’s management. Our CIO has over 20 years of industry experience, including serving in similar roles leading and overseeing cybersecurity programs at other public companies. Team members who support our information security program have relevant educational and industry experience, including holding similar positions at large industrial and technology companies. Our CIO leads an internal IT Security Committee that meets regularly to oversee company-wide efforts to address cybersecurity threats, to assess the effectiveness of our information security program and to prioritize efforts to improve our security measures and planning. Our IT Security Committee includes members of our IT security function and executive management of our legal, finance and internal audit/risk, human resources and corporate communications and technology functions.
Cybersecurity Risk Management Processes Integrated [Flag]	true
Cybersecurity Risk Management Processes Integrated [Text Block]	Our information security processes are integrated into our overall enterprise risk management (“ERM”) process and system. Our ERM process relies on designated risk managers to identify and assess material risks from cybersecurity threats.
Cybersecurity Risk Management Third Party Engaged [Flag]	true
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]	true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]	false
Cybersecurity Risk Board of Directors Oversight [Text Block]	Governance Our Board of Directors holds oversight responsibility for the Company’s strategy and risk management, including material risks related to cybersecurity threats. This oversight is executed directly by the Board of Directors and through its committees. Our Board members also engage in ad hoc conversations with management on cybersecurity-related news events and discuss any updates to our cybersecurity risk management and strategy programs. The Audit Committee of the Board of Directors (the “Audit Committee”) oversees the quality and effectiveness of the control and enterprise risk management processes of systemic risks, including cybersecurity, in accordance with its charter. The Audit Committee receives reports and engages in regular discussions with management regarding the Company’s significant financial risk exposures and the measures implemented to monitor and reasonably manage these risks, including those that may result from material cybersecurity threats. The Audit Committee also receives reports on material cybersecurity and data privacy incidents (if any), which would include plans to mitigate and respond to such incidents, and status on key information security initiatives. These discussions include the Company’s enterprise risk assessment and risk management policies. The Technology Committee of the Board of Directors oversees the management of risks associated with the Company’s products and technologies, including cybersecurity risks related to new product technologies or significant innovations to existing product technologies, in accordance with its charter. Our Vice President & Chief Information Officer (the “CIO”) leads our global information security organization and reports to the Board of Directors on matters related to cybersecurity on behalf of the Company’s management. Our CIO has over 20 years of industry experience, including serving in similar roles leading and overseeing cybersecurity programs at other public companies. Team members who support our information security program have relevant educational and industry experience, including holding similar positions at large industrial and technology companies. Our CIO leads an internal IT Security Committee that meets regularly to oversee company-wide efforts to address cybersecurity threats, to assess the effectiveness of our information security program and to prioritize efforts to improve our security measures and planning. Our IT Security Committee includes members of our IT security function and executive management of our legal, finance and internal audit/risk, human resources and corporate communications and technology functions.
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]	The Audit Committee of the Board of Directors (the “Audit Committee”) oversees the quality and effectiveness of the control and enterprise risk management processes of systemic risks, including cybersecurity, in accordance with its charter. The Audit Committee receives reports and engages in regular discussions with management regarding the Company’s significant financial risk exposures and the measures implemented to monitor and reasonably manage these risks, including those that may result from material cybersecurity threats. The Audit Committee also receives reports on material cybersecurity and data privacy incidents (if any), which would include plans to mitigate and respond to such incidents, and status on key information security initiatives. These discussions include the Company’s enterprise risk assessment and risk management policies. The Technology Committee of the Board of Directors oversees the management of risks associated with the Company’s products and technologies, including cybersecurity risks related to new product technologies or significant innovations to existing product technologies, in accordance with its charter.
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]	Our Vice President & Chief Information Officer (the “CIO”) leads our global information security organization and reports to the Board of Directors on matters related to cybersecurity on behalf of the Company’s management.
Cybersecurity Risk Role of Management [Text Block]	Risk Management and Strategy We recognize the importance of assessing, identifying, and managing material risks associated with cybersecurity threats, as such term is defined in Item 106(a) of Regulation S-K. These risks include, among other things: operational risks, intellectual property theft, fraud, extortion, harm to employees or customers, violation of data privacy or security laws, litigation, and legal, financial and reputational risk. We have implemented and maintain various information security processes designed to identify, assess and manage material risks from cybersecurity threats to our critical systems and our proprietary, strategic or competitive data. Depending on the environment, we implement and maintain various technical, physical, and organizational measures, processes, standards, and/or policies designed to manage and mitigate material risks from cybersecurity threats to our information systems and data, including risk assessments, incident detection and response, vulnerability management, disaster recovery and business continuity plans, internal controls within our accounting and financial reporting functions, encryption of data, network security controls, access controls, physical security, asset management, systems monitoring, vendor risk management program and employee training. We conduct regular reviews and tests of our information security program and also leverage audits by our internal audit team, tabletop exercises, penetration and vulnerability testing, and other exercises to evaluate the effectiveness of our information security program and improve our security measures and planning. We have an incident response process that relies on a multidisciplinary team for assessing and managing cybersecurity incidents, including an escalation framework based on the materiality of incidents. The multidisciplinary team includes members of our IT security function, executive management of our legal, finance, human resources, corporate communications and internal audit/risk functions and third party service providers of technical, legal and insurance services, as well as coordination with law enforcement as appropriate. Our IT security function also addresses cybersecurity threats through regular vulnerability reviews, risk registry reviews and global team meetings. Our information security processes are integrated into our overall enterprise risk management (“ERM”) process and system. Our ERM process relies on designated risk managers to identify and assess material risks from cybersecurity threats. The risk managers form a multidisciplinary group including members of our IT security, finance, human resources and legal functions, operations and executive management, and are responsible for timely reporting of risks on an ongoing basis. Our ERM process includes an annual evaluation and ranking of the top risks captured in our ERM system against leading third party benchmark reports on global risks. We work with third parties from time to time that assist us to identify, assess, and manage cybersecurity risks, including professional services firms, consulting firms, threat intelligence service providers, and penetration testing firms. To operate our business, we utilize certain third-party service providers to support a variety of functions. We seek to engage reliable, reputable service providers that maintain cybersecurity programs. Depending on the nature of the services provided, the sensitivity and quantity of information processed, and the identity of the service provider, our vendor management process may include reviewing the cybersecurity practices of such provider, contractually imposing obligations on the provider, conducting security assessments, and conducting periodic reassessments during their engagement. Our systems periodically experience directed attacks that may be intended to lead to financial loss, interruptions and delays in our operations as well as loss, misuse or theft of personal information (of third parties, employees, and other stakeholders) and other data, confidential information or intellectual property. These attacks are increasing in frequency, uniqueness and sophistication to evade detection and remove forensic evidence of the incident, including due to emerging technologies such as artificial intelligence and machine learning, which may cause cybersecurity incidents to be more difficult to detect for periods of time or at all. However, we are not aware of any risks from cybersecurity threats, including as a result of any cybersecurity incidents, which have materially affected or are reasonably likely to materially affect our Company, including our business strategy, results of operations, or financial condition. Refer to “Item 1A. Risk factors” in this annual report on Form 10-K for additional discussion about cybersecurity-related risks.
Cybersecurity Risk Management Positions or Committees Responsible [Flag]	true
Cybersecurity Risk Management Positions or Committees Responsible [Text Block]	Our CIO leads an internal IT Security Committee that meets regularly to oversee company-wide efforts to address cybersecurity threats, to assess the effectiveness of our information security program and to prioritize efforts to improve our security measures and planning.
Cybersecurity Risk Management Expertise of Management Responsible [Text Block]	Our CIO has over 20 years of industry experience, including serving in similar roles leading and overseeing cybersecurity programs at other public companies. Team members who support our information security program have relevant educational and industry experience, including holding similar positions at large industrial and technology companies.
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]	We conduct regular reviews and tests of our information security program and also leverage audits by our internal audit team, tabletop exercises, penetration and vulnerability testing, and other exercises to evaluate the effectiveness of our information security program and improve our security measures and planning. We have an incident response process that relies on a multidisciplinary team for assessing and managing cybersecurity incidents, including an escalation framework based on the materiality of incidents. The multidisciplinary team includes members of our IT security function, executive management of our legal, finance, human resources, corporate communications and internal audit/risk functions and third party service providers of technical, legal and insurance services, as well as coordination with law enforcement as appropriate. Our IT security function also addresses cybersecurity threats through regular vulnerability reviews, risk registry reviews and global team meetings.
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]	true

Overview

Overview	12 Months Ended
	Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Overview	Note 1 — Overview Gentherm Incorporated, a Michigan corporation, and its consolidated subsidiaries (“Gentherm”, “we”, “us”, “our” or the “Company”) is the global market leader of innovative thermal management and pneumatic comfort technologies for the automotive industry and a leader in medical patient temperature management. Automotive products include variable temperature Climate Control Seats, heated interior systems (including heated seats, steering wheels, armrests and other components), battery performance solutions, cable systems, lumbar and massage comfort solutions, fuel management valve systems and other valve systems, and other electronic devices. Our automotive products can be found on vehicles manufactured by nearly all the major original equipment manufacturers (“OEMs”) operating in North America and Europe, and several major OEMs in Asia. We operate in locations aligned with our major customers’ product strategies to provide locally enhanced design, integration and production capabilities. Medical products include patient temperature management systems. Our medical products can be found in hospitals throughout the world, primarily in the U.S., China, Germany and Brazil. The Company is also developing a number of new technologies and products that will help enable improvements to existing products, improve health, wellness and patient outcomes and will lead to new product applications for existing and new and adjacent markets.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 — Summary of Significant Accounting Policies Basis of Presentation The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Principles of Consolidation The consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries and those entities in which it has a controlling financial interest. The Company evaluates its relationship with other entities for consolidation and to identify whether such entities are variable interest entities (“VIE”) and to assess whether the Company is the primary beneficiary of such entities. Investments in affiliates in which Gentherm does not have control but does have the ability to exercise significant influence over operating and financial policies are accounted for under the equity method. When Gentherm does not have the ability to exercise significant influence (generally when ownership interest is less than 20 %), investments in affiliates are measured at cost, less impairments, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. Intercompany transactions and balances between consolidated businesses have been eliminated. Use of Estimates In preparing these consolidated financial statements, management was required to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. These estimates and assumptions are based on our historical experience, the terms of existing contracts, our evaluation of trends in the industry, information provided by our customers and suppliers and information available from other outside sources, as appropriate. These estimates and assumptions are subject to an inherent degree of uncertainty. We are not presently aware of any events or circumstances that would require us to update such estimates and assumptions or revise the carrying value of our assets or liabilities. Our estimates may change, however, as new events occur and additional information is obtained. As a result, actual results may differ significantly from our estimates, and any such differences may be material to our financial statements. Business Combinations In accordance with ASC Topic 805, “Business Combinations,” acquisitions are recorded using the acquisition method of accounting. The Company includes the operating results of acquired entities from their respective dates of acquisition. The Company recognizes and measures the identifiable assets acquired, liabilities assumed, and any non-controlling interest as of the acquisition date fair value. The excess, if any, of total consideration transferred in a business combination over the fair value of identifiable assets acquired, liabilities assumed and any non-controlling interest is recognized as goodwill. Costs incurred as a result of a business combination other than costs related to the issuance of debt or equity securities are recorded in the period the costs are incurred. During the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to assets acquired and liabilities assumed with the corresponding offset to goodwill. Revenue Recognition Revenue is recognized from agreements containing enforceable rights and obligations, when promised goods are delivered or services are completed. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from product revenues. Shipping and handling fees billed to customers are included in product revenues, while costs of shipping and handling are included in cost of sales. Automotive Revenues The Company generates revenue from the production of automotive parts sold to its customers under long-term supply agreements (“LTAs”). The duration of an LTA is generally consistent with the life cycle of a vehicle; however, a LTA does not reach the level of a performance obligation until Gentherm receives either a purchase order and/or a materials release from its customer for a specific number of production parts at a specified price, at which point an enforceable contract exists. Revenue is recognized when control of the production parts has transferred to the customer according to the terms of the contract, which typically occurs at a point in time when the parts are shipped or delivered to the customer’s premises. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring production parts. Transaction price is determined based on the price and quantity of parts specified in the contract with the customer at the time of shipment, adjusted for discrete price adjustments and consideration payable to a customer. Discrete price reductions may occur to remain competitive with market prices. These price reductions are negotiated based on changes in product specifications, product content/cost or other commercial factors. Some of these amounts include estimates of variable consideration which are recorded at the most likely amount to which the Company expects to be entitled based on historical experience and input from customer negotiations. From time to time, the Company provides cash incentives to customers in exchange for new business awards. The Company evaluates the underlying economics of each amount of consideration payable to a customer to determine the proper accounting by understanding the reasons for the payment, the rights and obligations resulting from the payment, the nature of the promises in the contract, and other relevant facts and circumstances. When the Company concludes that the payment is incurred only if the new business is obtained and the Company expects to recover the amounts from the customer over the term of the new business arrangement, the Company recognizes these payments as an asset. The Company amortizes the asset as a reduction of revenue as products related to the payment are transferred to the customer, based on the total amount of products expected to be sold over the term of the arrangement (generally 5 to 10 years following start of production). The Company evaluates the amounts capitalized each reporting period for recoverability and recognizes a reduction of revenue for any amounts that are no longer expected to be recovered over the term of the business arrangement. Payments to customers that are not capitalized are recognized as a reduction to revenue at the time of the commitment to make such payments. As of December 31, 2024 and 2023 , total capitalized payments to customers were $ 14,276 and $ 7,305 , respectively. There have been no impairment losses in relation to the costs capitalized. During the year ended December 31, 2024 and 2023 , $ 447 and $ 179 , respectively, was amortized into product revenues. The Company has no material contract assets or contract liabilities as of December 31, 2024. Medical Revenues Revenues from our patient temperature management business unit are generated from the sale of products and equipment. Our medical products and equipment focus on patient temperature management. The Company sells medical products and equipment primarily through distributor and group purchasing organization agreements. These agreements allow member participants to the distributor or group purchasing organization to make purchases at discounted prices negotiated by the distributor or group purchasing organization. A rebate is incurred at the point in time a member participant purchases product covered under these types of agreements. Rebates are accounted for as variable consideration, using an expected value, probability weighted approach, based on the level of sales to the distributor and the time lag between the initial sale and the rebate claim in determining the transaction price of a contract. Revenue is recognized when control of the medical products or equipment has transferred to the customer according to the terms of the contract, which typically occurs at the point in time when the parts are either shipped or delivered to the customer’s premises. Cash and Cash Equivalents The Company considers all highly liquid investments purchased with original maturities of less than 90 days to be cash equivalents. The Company had cash and cash equivalents of $ 106,905 and $ 125,251 held in foreign jurisdictions as of December 31, 2024 and 2023 , respectively. Concentration of Credit Risk The following is a summary of the percentage of product revenues and accounts receivable from the Company's customers with a percentage of net sales greater than 10 percent: Percentage of Total Product Revenues Percentage of Total Net Accounts Receivable Year Ended December 31, Year Ended December 31, 2024 2023 2022 2024 2023 Lear 16 % 15 % 16 % 16 % 17 % Adient 11 % 13 % 15 % 11 % 19 % Accounts Receivable Accounts receivable are stated at the invoiced amount, less allowance for doubtful accounts for estimated amounts not expected to be collected, and do not bear interest. The Company establishes and maintains allowances for the inability or unwillingness of customers to make required payments on their accounts receivable balances. These allowances reflect management's estimate of credit losses over the remaining expected life of such assets, measured primarily using historical write-off experience by industry and regional economic data, as well as current conditions and forecasts that affect the collectability of the reported amount. We write-off accounts receivable when they become uncollectible. As of December 31, 2024 and 2023 , the Company’s accounts receivable are reflected net of reserves of $ 1,605 and $ 1,171 , respectively. Changes in the allowance for doubtful accounts were not significant during the years ended December 31, 2024 and 2023. In the Asia-Pacific region, the Company receives bank notes from certain customers to settle trade receivables. The collection of such bank notes is included in operating cash flows based on the substance of the underlying transactions, which are operating in nature. Bank notes held by the Company are classified as notes receivable within other current assets. The Company may hold such bank notes until maturity, exchange them with suppliers to settle liabilities, or sell them to third-party financial institutions in exchange for cash. Inventory The Company’s inventory is measured at the lower of cost or net realizable value. Raw materials, components and consumables are measured using the weighted average cost method. Work-in-process and finished goods are measured using the first-in first-out method. If the net realizable value expected on the reporting date is below cost, a write-down is recorded to adjust inventory to its net realizable value. We recognize a reserve for obsolete and slow-moving inventories based on estimates of future sales and an inventory item’s capacity to be repurposed for a different use. We consider the number of months' supply on hand based on current planned requirements, uncommitted future projections and historical usage in estimating the inventory reserve. Property and Equipment Property and equipment is recorded at cost less accumulated depreciation. Expenditures for general repairs and maintenance are charged to expense as incurred. When property or equipment is retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the accounts. Gains or losses from retirements and disposals are recorded as operating income or expense. Depreciation is computed using the straight-line method. The estimated useful lives of the Company’s property and equipment are as follows: Asset Category Useful Life Buildings and improvements 1 to 30 years Plant and equipment 10 years Production tooling 2 to 10 years Leasehold improvements Term of lease Information technology 1 to 5 years The Company recognized depreciation expense of $ 45,503 , $ 42,186 and $ 33,730 for the years ended December 31, 2024, 2023 and 2022 , respectively. Tooling The Company incurs costs related to tooling used in the manufacture of products sold to its customers. In some cases, the Company enters into contracts with its customers whereby the Company incurs the costs to design, develop and purchase tooling and is then reimbursed by the customer under a reimbursement contract. Tooling costs that will be reimbursed by customers are included in other current assets in the accompanying consolidated balance sheets at the lower of accumulated cost or the customer reimbursable amount. As of December 31, 2024 and 2023 , the Company had $ 19,740 and $ 16,877 , respectively, of reimbursable tooling costs capitalized. Company-owned tooling is included in property and equipment and depreciated over its expected useful life, generally two to ten years . Goodwill and Other Intangible Assets Goodwill and other intangible assets recorded in conjunction with business combinations are based on the Company’s estimate of fair value, as of the date of acquisition. Amortization of other intangible assets is computed using the straight-line method. The fair value and corresponding useful lives for acquired intangible assets are listed below as follows: Asset Category Useful Life Customer relationships 8 to 15 years Technology 5 to 12 years Product development costs 5 to 10 years Trade names Indefinite Software development costs 4 to 5 years Our business strategy largely centers on designing products based upon internally developed and purchased technology, and we protect certain technology with patents that have value to our business strategy. All costs associated with the development and issuance of new patents are expensed as incurred. Such costs are classified as net research and development expenses in the accompanying consolidated statements of income. Valuation of Long-lived Assets The carrying value of long-lived assets held for use, including definite-lived intangible assets, is periodically evaluated when events or circumstances warrant such a review. The carrying value of a long-lived asset held for use is considered impaired when the anticipated separately identifiable undiscounted cash flows from the asset are less than the carrying value of the asset. In that event, a loss is recognized based on the amount by which the carrying value exceeds the estimated fair value of the long-lived asset. Impairment losses on long-lived assets held for sale are recognized if the carrying value of the asset is in excess of the asset’s estimated fair value, reduced for the cost to dispose of the asset. Impairments of Other Intangible Assets and Goodwill Goodwill is tested for impairment at least annually as of December 31 and whenever events or changes in circumstances indicate that the carrying value may not be recoverable. In conducting our annual impairment assessment testing, we first perform a qualitative assessment of whether it is more likely than not that a reporting unit’s fair value is less than its carrying amount. If not, no further goodwill impairment testing is performed. If it is more likely than not that a reporting unit’s fair value is less than its carrying amount, or if we elect not to perform a qualitative assessment of a reporting unit, we then compare the fair value of the reporting unit to the related net book value. If the net book value of a reporting unit exceeds its fair value, an impairment loss is measured and recognized. The Company utilizes an income approach to estimate the fair value of a reporting unit and a market valuation approach to further support this analysis (level 3). The income approach is based on projected debt-free cash flow that is discounted to the present value using discount factors that consider the timing and risk of cash flows. We believe that this approach is appropriate because it provides a fair value estimate based on the reporting unit’s expected long-term operating cash flow performance. This approach also mitigates the impact of cyclical trends that occur in our industry. Fair value is estimated using internally developed forecasts, as well as commercial and discount rate assumptions. The discount rate used is the value-weighted average of our estimated cost of equity and of debt (“cost of capital”) derived using both known and estimated customary market metrics. Our weighted average cost of capital is adjusted to reflect risk, if necessary. Other significant assumptions include terminal value growth rates and terminal value margin rates. While there are inherent uncertainties related to the assumptions used and to management’s application of these assumptions to this analysis, we believe that the income approach provides a reasonable estimate of the fair value of a reporting unit. The Company performs its indefinite-lived intangible asset impairment assessment annually as of December 31, and between annual assessments if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. See Note 7, "Goodwill and Other Intangibles," for additional information about the goodwill impairment analysis. Investments in Non-consolidated Affiliates During 2021, the Company’s Automotive segment invested $ 5,200 for an ownership interest in Carrar Ltd. (“Carrar”), an Israel-based technology developer of advanced thermal management systems for the electric mobility market. In June 2023, the Company made an additional investment in Carrar of $ 500 . In December 2023, we recorded a non-cash impairment charge of $ 2,900 in other income (loss). In 2024 there was an increase in the fair value of the Company's investment in Carrar of $ 1,097 due to observable transactions, resulting in a carrying value of $ 3,897 as of December 31, 2024. The Company determined that Carrar is a VIE; however, the Company does not have a controlling financial interest or have the power to direct the activities that most significantly affect the economic performance of the investment. Therefore, the Company has concluded that it is not the primary beneficiary. Gentherm’s investment in Carrar is measured at cost, less impairments, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer, and is recorded in other non-current assets. During 2021, the Company’s Automotive segment invested $ 2,357 for an ownership interest in Forciot Oy (“Forciot”), a Finland-based technology developer of sensors for touch, motion and force measurement. Gentherm’s investment in Forciot is measured at cost, less impairments, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer, and is recorded in other non-current assets. In December 2021, the Company committed to make a $ 5,000 investment in Autotech Fund III, L.P., pursuant to a limited partnership agreement. As a limited partner, the Company will periodically make capital contributions toward this total commitment amount over the expected ten-year life of the fund. The Company has made contributions totaling approximately $ 1,765 to the Autotech Fund III, L.P. as of December 31, 2024 . This fund focuses broadly on the automotive industry and compliments the Company’s innovation strategy. Research and Development Expenses Research and development activities are expensed as incurred. Such costs and related reimbursements are classified as net research and development expenses in the accompanying consolidated statements of income. Leases The Company determines whether a contractual arrangement is or contains a lease at contract inception. A lease liability and corresponding right-of-use asset are measured and recognized based on the present value of lease payments. To determine the present value of lease payments, the Company uses its incremental borrowing rate as of the lease commencement date, unless there is a rate implicit in the lease agreement. The incremental borrowing rate is based on the Company’s credit rating, determined on a fully collateralized loan basis from information available at commencement date, and the duration of the lease term (the “reference rate”). For leases at foreign subsidiaries denominated in U.S. Dollars, a risk premium associated with the borrower subsidiary’s country is added to the reference rate. For significant leases at foreign subsidiaries denominated in a foreign currency, the U.S. Dollar risk free rate with a duration similar to that of the lease term is subtracted from the reference rate and a corresponding foreign currency risk free rate with a duration similar to that of the lease term is added to the reference rate. Operating lease assets are included in operating lease right-of-use assets and the related liabilities are included in current lease liabilities and non-current lease liabilities in the accompanying consolidated balance sheets. Assets under finance leases are included in property and equipment, net, and the related liabilities are included in current maturities of long-term debt, and long-term debt on the Company’s consolidated balance sheets. For all classes of underlying assets, the Company accounts for leases that contain separate lease and non-lease components as containing a single lease component. The Company does not recognize lease right-of-use assets and lease liabilities from leases with an original lease term of 12 months or less and, instead, recognizes rent payments on a straight-line basis over the lease term in the consolidated statements of income. Income Taxes The Company records income tax expense using the liability method which specifies that deferred tax assets and liabilities be measured each year based on the difference between the financial statement and tax base of assets and liabilities at the applicable enacted tax rates. A valuation allowance is provided for deferred tax assets when management considers it more likely than not that the asset will not be realized. At December 31, 2024 and 2023, a valuation allowance has been provided for certain deferred tax assets which the Company has concluded are more likely than not to not be realized. If future annual taxable income were to be significantly less than current and projected levels, there is a risk that certain of our deferred tax assets not already provided for by the valuation allowance would expire prior to utilization. The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognizes interest and penalties related to income tax matters in income tax expense. Derivative Financial Instruments – Hedge Accounting All derivative instruments are required to be reported on the balance sheet at fair value unless the transactions qualify and are designated as normal purchases or sales. Changes in fair value are reported currently through earnings unless they meet hedge accounting criteria. The Company’s designated hedging relationships are formally documented at the inception of the hedge, and hedges must be highly effective in offsetting changes to future cash flows on hedged transactions both at the inception of a hedge and on an ongoing basis to be designated for hedge accounting treatment. The Company accounts for its designated derivative financial instruments as cash flow hedges. For derivative contracts which are designated as a cash flow hedge, the effective portion of the change in the fair value of the derivative contract is recorded to accumulated other comprehensive loss (“AOCI”) in the accompanying consolidated balance sheets. When the underlying hedge transaction is realized, the gain or loss included in AOCI is recorded into earnings in the accompanying consolidated statements of income on the same line as the gain or loss on the hedged item attributable to the hedged risk. Any ineffective portion of the gain or loss is recognized in the accompanying consolidated statements of income under cost of goods sold for foreign currency derivatives and commodity derivatives. These hedging transactions and the respective correlations meet the requirements for hedge accounting. Exposure to fluctuations in interest rates and certain commodity prices are managed by entering into swaps with various counterparties. The Company does not enter into derivative transactions for speculative or trading purposes. As part of the hedging program approval process, Gentherm identifies the specific financial risk which the derivative transaction will minimize, the appropriate hedging instrument to be used to reduce the risk and the correlation between the financial risk and the hedging instrument. Hedge positions, as well as the correlation between the transaction risks and the hedging instruments, are reviewed on an ongoing basis. Earnings per Share Basic earnings per share is computed by dividing net income by the weighted average number of shares of the Company's common stock, no par value ("Common Stock") outstanding during the respective period. The Company’s diluted earnings per share give effect to all potential shares of Common Stock outstanding during a period that do not have an anti-dilutive impact to the calculation. In computing the number of diluted shares outstanding, the treasury stock method is used in order to arrive at a net number of shares created upon the conversion of Common Stock equivalents. Stock Based Compensation Stock based payments that involve the issuance of Common Stock to employees, including grants of employee stock options, restricted stock, and time-based and performance-based restricted stock units, are recognized in the consolidated financial statements as compensation expense based upon the fair value on the date of grant. Stock based payments that are satisfied only by the payment of cash, such as stock appreciation rights, are accounted for as liabilities. The liability is reported at market value of the vested portion of the underlying units. During each period, the change in the liability is recorded as compensation expense.

New Accounting Pronouncements

New Accounting Pronouncements	12 Months Ended
	Dec. 31, 2024
Accounting Standards Update and Change in Accounting Principle [Abstract]
New Accounting Pronouncements	Note 3 — New Accounting Pronouncements Recently Adopted Accounting Pronouncements Segment Reporting In November 2023, the FASB issued ASU 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures". ASU 2023-07 requires a public entity to disclose, on an annual and interim basis, significant segment expenses that are included within each reported measure of segment profit or loss and regularly reviewed by the chief operating decision maker ("CODM"), the title and position of the CODM, clarification regarding the CODM's use of multiple measures of a segment's profit or loss in assessing segment performance (this must include a measure that is consistent with the measurement principles under GAAP, but may also include additional measures of a segment's profit or loss), and a description of the composition of amounts within an "Other" segment line item. Further, ASU 2023-07 requires that all annual disclosures about a reportable segment's profit or loss and assets currently required by Topic 280 to be provided in interim periods. The Company adopted ASU 2023-07 as of December 31, 2024. See Note 20, “Segment Reporting” for the disclosures related to the adoption of ASU 2023-07. Recently Issued Accounting Pronouncements Not Yet Adopted Income Taxes In December 2023, the FASB issued ASU 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures". ASU 2023-09 enhances income tax disclosures to further disaggregate the effective tax rate reconciliation and income taxes paid. This update is effective for fiscal years beginning after December 15, 2024. ASU 2023-09 should be adopted prospectively, but retrospective application is permitted. Further, early adoption is permitted. We are currently in the process of determining the impact the implementation of ASU 2023-09 will have on the Company’s financial statement disclosures. Disaggregation of Income Statement Expenses In November 2024, the FASB issued ASU 2024-03, "Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40) ". ASU 2024-03 enhances disclosures around certain costs and expenses. This update is effective for annual reporting periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027. ASU 2024-03 should be adopted retrospectively to all periods presented in the financial statements and early adoption is permitted. We are currently in the process of determining the impact the implementation of ASU 2024-03 will have on the Company’s financial statement disclosures.

Acquisitions

Acquisitions	12 Months Ended
	Dec. 31, 2024
Business Combinations [Abstract]
Acquisitions	Note 4 – Acquisitions Alfmeier Präzision SE On August 1, 2022 , the Company acquired 100 % of the equity interests of Alfmeier Präzision SE (“Alfmeier”) , a global leader in automotive lumbar and massage comfort solutions and a leading provider of advanced valve systems technology, integrated electronics and software. The total consideration transferred was $ 170,700 . The results of Alfmeier's operations are reported within the Automotive segment from the acquisition date. The following table provides product revenues and operating income from Alfmeier that are included in our consolidated financial statements for the year ended December 31, 2022, following the August 1, 2022 acquisition date: Year Ended December 31, 2022 Product revenues $ 98,960 Net loss ( 2,675 ) The following unaudited pro forma information represents our product revenues and net income as if the acquisition of Alfmeier had occurred as of January 1, 2022: Year Ended December 31, 2022 Product revenues $ 1,348,295 Net income 17,645 Jiangmen Dacheng Medical Equipment Co. Ltd On July 13, 2022 , the Company acquired 100 % of the equity interests of Jiangmen Dacheng Medical Equipment Co. Ltd (“Dacheng”) and its wholly owned subsidiary, IOB Medical, Inc. Dacheng, is a manufacturer of medical materials and medical equipment, including patient temperature management solutions, for numerous local and international customers. The total consideration was $ 35,048 . The results of Dacheng's operations are reported within the Medical segment from the acquisition date. The following table provides product revenues and operating income from Dacheng that are included in our consolidated financial statements for the year ended December 31, 2022, following the July13, 2022 acquisition date: Year Ended December 31, 2022 Product revenues $ 3,499 Net loss ( 217 ) The pro forma effects of this acquisition would not materially impact the Company’s reported results for any period presented, and as a result no pro forma financial statements are presented.

Restructuring

Restructuring	12 Months Ended
	Dec. 31, 2024
Restructuring and Related Activities [Abstract]
Restructuring	Note 5 — Restructuring The Company continuously monitors market developments, industry trends and changing customer needs and in response, may undertake restructuring actions, as necessary, to execute management’s strategy, streamline operations and optimize the Company’s cost structure. Restructuring actions may include the realignment of existing manufacturing footprint, facility closures, or similar actions, either in the normal course of business or pursuant to significant restructuring programs. These actions may result in employees receiving voluntary or involuntary employee termination benefits, which are mainly statutory requirements or other contractual agreements. Voluntary termination benefits are accrued when an employee accepts the related offer. Involuntary termination benefits are accrued upon the commitment to a termination plan and when the benefit arrangement is communicated to affected employees, or when liabilities are determined to be probable and estimable, depending on the existence of a substantive plan for severance or termination. 2023 Manufacturing Footprint Rationalization On September 19, 2023, the Company committed to a restructuring plan (“2023 Plan”) to improve the Company’s manufacturing productivity and rationalize its footprint through the closure and relocation of its existing manufacturing facility in Greenville, South Carolina to a new facility in Monterrey, Mexico. During the year ended December 31, 2024 , the Company completed the sale of its Greenville, South Carolina manufacturing facility, resulting in a gain on sale of $ 1,927 . The gain on sale was recorded as a reduction of restructuring expenses, net in the consolidated statements of income. During the year ended December 31, 2024 , the Company also recognized restructuring expense of $ 1,839 for employee separation costs and $ 2,381 for other costs. During the year ended December 31, 2023 , the Company recognized restructuring expense of $ 538 for employee separation costs and $ 159 for other costs. Since the inception of this program, the Company has recorded $ 2,990 of restructuring expenses, net, related to employee severance, retention termination costs, accelerated depreciation of fixed assets, gain on sale and other transition costs. The remaining actions under this 2023 Plan, including the consolidation of our original manufacturing site in Monterrey, Mexico into our new facility, are expected to be substantially completed by the end of 2025. The Company expects to incur less than $ 1,000 of additional restructuring costs for the 2023 Plan. Other Restructuring Activities The Company has undertaken several discrete restructuring actions in an effort to optimize its cost structure. During the year ended December 31, 2024 , the Company’s Automotive segment recognized $ 6,216 for employee separation costs related to structural cost reductions impacting the Company’s global salaried workforce. During the year ended December 31, 2024 , the Company’s Automotive segment recognized $ 1,965 for employee separation costs and $ 474 for other costs related to the relocation of electronic component manufacturing in Germany to a manufacturing facility in China. During the year ended December 31, 2024 , the Company recognized $ 876 for employee separation costs and $ 1,286 for other costs related to all other restructuring actions. These other restructuring actions are focused on the reduction of global overhead costs. The Company expects to incur less than $ 1,000 of additional restructuring costs for the other restructuring actions that have been approved as of December 31, 2024. During the years ended December 31, 2023 and 2022 , the Company recognized $ 3,208 and $ 56 for employee separation costs, respectively, and $ 834 and $ 581 for other costs, respectively. These restructuring expenses were primarily associated with restructuring actions focused on the rotation of our manufacturing footprint to best cost locations and the reduction of global overhead costs. Restructuring Expenses, net by Reporting Segment Restructuring expenses, net by reporting segment for the years ended December 31, 2024, 2023 and 2022 was as follows: Year Ended December 31, 2024 2023 2022 Automotive $ 12,238 $ 3,187 $ 637 Medical 20 363 — Corporate 852 1,189 — Total $ 13,110 $ 4,739 $ 637 Restructuring Liability The following table summarizes restructuring activity for all restructuring initiatives for the years ended December 31, 2024 and 2023: Employee Separation Costs Other Related Costs, net (a) Total Balance at December 31, 2022 $ 588 $ — $ 588 Additions, charged to restructuring expenses, net 3,892 993 4,885 Change in estimate ( 146 ) — ( 146 ) Cash payments ( 2,224 ) ( 878 ) ( 3,102 ) Non-cash utilization — ( 115 ) ( 115 ) Currency translation and other 40 — 40 Balance at December 31, 2023 $ 2,150 $ — $ 2,150 Additions, charged to restructuring expenses, net 10,896 2,214 13,110 Cash payments ( 9,593 ) ( 1,333 ) ( 10,926 ) Non-cash utilization — ( 881 ) ( 881 ) Currency translation and other ( 165 ) — ( 165 ) Balance at December 31, 2024 $ 3,288 $ — $ 3,288 (a) Includes gain on sale of the Greenville facility Exit of Non-Automotive Electronics Business On December 31, 2022, the Company approved a plan to exit its non-automotive electronics business to strengthen the Company’s core business and focus its resources and equipment with businesses and investments that are more strategic and profitable. The Company has substantially completed the exit of this business. During the year ended December 31, 2024, the Company recorded a benefit of $ 4,554 for the sale of previously reserved inventory. This benefit is recorded in product revenues in the accompanying consolidated statements of income. During the year ended December 31, 2023, the Company recorded non-cash impairment charges of $ 6,064 for the write down of inventory . This charge is recorded in cost of sales in the accompanying consolidated statements of income. During the year ended December 31, 2022, the Company recorded non-cash impairment charges of $ 9,378 , $ 5,601 and $ 690 for write downs of inventory, intangible assets and property and equipment, respectively. Write downs of inventory are recorded in cost of sales and write downs of intangible assets and property and equipment are recorded in impairment of intangible assets and property and equipment in the accompanying consolidated statements of income. Subsequent Events In February 2025, the Company committed to additional restructuring plans intended to further optimize its manufacturing footprint by realigning its manufacturing capacity. As a result of these plans, the Company will close its facility in Plzeň, Czech Republic and relocate the manufacturing activities into other existing facilities within the region. Additionally, in Asia, we will relocate certain manufacturing activities from our facility in Shanghai, China to our new facility in Tianjin, China. In connection with these plans, the Company expects to incur total costs of between $ 13,000 and $ 21,000 . The total expected costs include employee severance, retention and termination costs of between $ 7,000 and $ 11,000 and capital expenditures of between $ 3,000 and $ 5,000 . The Company also expects to incur other transition costs including recruiting, relocation, and machinery and equipment move and set up costs of between $ 3,000 and $ 5,000 .

Details of Certain Financial St

Details of Certain Financial Statement Components	12 Months Ended
	Dec. 31, 2024
Financial Statement Components [Abstract]
Details of Certain Financial Statement Components	Note 6 — Details of Certain Financial Statement Components December 31, 2024 2023 Inventory: Raw materials, net $ 137,511 $ 126,013 Work in process, net 19,059 15,704 Finished goods, net 70,786 64,175 Total inventory, net $ 227,356 $ 205,892 Other current assets: Income tax and other tax receivable $ 20,611 $ 16,017 Billable tooling 19,740 16,877 Notes receivable 11,190 18,226 Prepaid expenses 6,305 7,889 Receivables due from factor 1,111 4,422 Short-term derivative financial instruments 719 10,717 Other 4,737 4,272 Total other current assets $ 64,413 $ 78,420 Property and equipment: Machinery and equipment $ 260,578 $ 236,277 Buildings and improvements 117,953 130,374 Information technology 45,157 41,543 Production tooling 37,765 28,033 Leasehold improvements 23,262 12,269 Construction in progress 36,846 27,461 Total property and equipment 521,561 475,957 Less: accumulated depreciation ( 268,591 ) ( 230,723 ) Total property and equipment, net $ 252,970 $ 245,234 Other current liabilities: Accrued employee liabilities $ 42,277 $ 43,176 Income tax and other taxes payable 26,385 19,327 Liabilities from discounts and rebates 20,501 22,916 Restructuring 3,288 2,150 Accrued warranty 3,507 3,945 Short-term derivative financial instruments 2,037 — Other 7,829 9,291 Total other current liabilities $ 105,824 $ 100,805

Goodwill and Other Intangibles

Goodwill and Other Intangibles	12 Months Ended
	Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangibles	Note 7 — Goodwill and Other Intangibles Goodwill Changes in the carrying amount of goodwill, by reportable segment, for the years ended December 31, 2024 and 2023 were as follows: Automotive Medical Total Balance as of December 31, 2022 $ 73,069 $ 46,705 $ 119,774 Impairment of goodwill — ( 19,509 ) ( 19,509 ) Currency translation and other 3,627 181 3,808 Balance as of December 31, 2023 $ 76,696 $ 27,377 $ 104,073 Currency translation and other ( 3,942 ) ( 528 ) ( 4,470 ) Balance as of December 31, 2024 $ 72,754 $ 26,849 $ 99,603 Other Intangible Assets Other intangible assets and accumulated amortization balances as of December 31, 2024 and 2023 were as follows: Gross Accumulated Accumulated Net Carrying Definite-lived: Customer relationships $ 109,608 $ ( 67,787 ) $ ( 5,477 ) $ 36,344 Technology 43,458 ( 29,976 ) ( 24 ) 13,458 Product development costs 18,019 ( 17,849 ) — 170 Software development 1,007 ( 201 ) — 806 Indefinite-lived: Tradenames 7,003 — ( 530 ) 6,473 Balance as of December 31, 2024 $ 179,095 $ ( 115,813 ) $ ( 6,031 ) $ 57,251 Gross Accumulated Accumulated Net Carrying Definite-lived: Customer relationships $ 115,465 $ ( 67,923 ) $ ( 5,814 ) $ 41,728 Technology 45,861 ( 29,292 ) ( 25 ) 16,544 Product development costs 19,434 ( 19,270 ) — 164 Software development 1,007 — — 1,007 Indefinite-lived: Tradenames 7,039 — — 7,039 Balance as of December 31, 2023 $ 188,806 $ ( 116,485 ) $ ( 5,839 ) $ 66,482 During the first quarter of 2024, we recorded a non-cash impairment charge of $ 530 for one of our Medical tradenames. As of December 31, 2022, the estimated fair value of the Medical reporting unit exceeded its carrying value by less than 10 %. During the second quarter of 2023, the Company’s Medical reporting unit did not perform in-line with forecasted results primarily driven by slower than anticipated revenue growth. As a result, an indicator of impairment was identified and the Company performed an interim quantitative assessment as of June 30, 2023. The results of this quantitative analysis indicated the carrying value of the reporting unit exceeded the fair value of the reporting unit, and accordingly an impairment expense was recorded for $ 19,509 . The Company performed its annual assessment of the Medical reporting unit goodwill as of December 31, 2024 and 2023 utilizing quantitative approaches and determined the fair value of the Medical reporting unit exceeded its carrying value at each date. The Company utilized an income approach to estimate the fair value of the reporting unit and a market valuation approach to further support this analysis (level 3). The income approach was based on projected debt-free cash flow that was discounted to the present value using discount factors that considered the timing and risk of cash flows. Fair value was estimated using internally developed forecasts, as well as commercial and discount rate assumptions. The discount rate used was the value-weighted average of our estimated cost of equity and of debt (“cost of capital”) derived using both known and estimated customary market metrics. Our weighted average cost of capital includes a company specific risk premium to address the risks associated with achieving the projected revenue and profitability growth rates. Other significant assumptions included terminal value growth rates and terminal value margin rates. Our ability to realize the future cash flows used in our calculations is affected by factors such as the success of strategic initiatives, changes in economic conditions, changes in our operating performance and changes in our business strategies. To further support the fair value estimate determined by the income approach, the Company utilized a market valuation approach to estimate the fair value of the Medical reporting unit. The market approach considered historical and anticipated financial metrics of the Medical reporting unit and applied valuation multiples based on recent observed transactions involving companies similar enough to the Medical reporting unit from which to draw meaningful conclusions. In addition to annual impairment testing, which is performed in the fourth quarter of each fiscal year, the Company continuously monitors for events and circumstances that could negatively impact the key assumptions used in determining fair value and therefore would require interim impairment testing, including long-term revenue growth projections, profitability, discount rates, recent market valuations from transactions by comparable companies, volatility in the Company's market capitalization, and general industry, market and macroeconomic conditions. We are not presently aware of any other events or circumstances that would require us to revise the carrying value of our goodwill or other intangible assets as of December 31, 2024. A total of $ 7,019 , $ 8,290 , and $ 9,018 in other intangible assets were amortized in 2024, 2023 and 2022, respectively. An estimate of future amortization of other intangible assets, is as follows: 2025 $ 6,860 2026 6,424 2027 6,337 2028 6,276 2029 5,598

Leases

Leases	12 Months Ended
	Dec. 31, 2024
Leases [Abstract]
Leases	Note 8 — Leases The Company has operating and finance leases for real estate, office equipment, automobiles, forklifts and certain other equipment. Certain real estate leases are for land which have a remaining lease term of one to 38 years, and some of these arrangements have an end date that is at the discretion of the lessee. Excluding land leases, our leases have remaining lease terms ranging from less than one year to nine years and may include options to extend the lease. We do not have lease arrangements with related parties. Components of lease expense for the years ended December 31, 2024, 2023 and 2022 were as follows: Year Ended December 31, 2024 2023 2022 Lease cost: Operating lease cost $ 10,747 $ 9,606 $ 8,040 Amortization of ROU assets - finance leases 370 390 168 Interest on lease liabilities - finance leases 14 28 16 Short-term lease cost 3,684 2,651 1,773 Sublease income — — ( 101 ) Total lease cost $ 14,815 $ 12,675 $ 9,896 Other information related to leases is as follows: Year Ended December 31, 2024 2023 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases $ 10,428 $ 9,249 Operating cash flows for finance leases 14 81 Financing cash flows for finance leases 383 390 Right-of-use lease assets obtained in exchange for lease obligations: Operating leases $ 30,720 $ 4,704 December 31, 2024 December 31, 2023 Weighted average remaining lease term: Operating leases 9.3 years 5.6 years Finance leases 1.5 years 1.9 years Weighted average discount rate: Operating leases 6.09 % 4.96 % Finance leases 3.46 % 3.53 % A summary of operating leases as of December 31, 2024, under all non-cancellable operating leases with terms exceeding one year is as follows: 2025 $ 9,285 2026 7,450 2027 5,701 2028 5,208 2029 4,911 2030 or later 26,593 Total future minimum lease payments 59,148 Less imputed interest ( 14,579 ) Total $ 44,569 A summary of finance leases as of December 31, 2024, under all non-cancellable finance leases with terms exceeding one year is as follows: 2025 $ 137 2026 64 Total $ 201 As of December 31, 2024 the Company has various operating leases that have not yet commenced with future undiscounted payments of $ 19,878 . These operating leases will commence in 2025 and have initial lease terms of two to 15 years. The most significant of these leases relates to the Company's new corporate headquarters building in Novi, Michigan. In connection with our move to a new location, we completed the sale of our former headquarters building in Northville, Michigan in January 2025. The sale resulted in cash proceeds of $ 3,740 and is expected to result in a loss on sale of $ 2,311 that will be recognized in the first quarter of 2025.

Debt

Debt	12 Months Ended
	Dec. 31, 2024
Debt Disclosure [Abstract]
Debt	Note 9 — Debt The following table summarizes the Company’s debt as of December 31, 2024 and 2023: December 31, 2024 2023 Interest Principal Interest Principal Credit Agreement: U.S. Revolving Note (U.S. Dollar denominations) 5.86 % $ 220,000 6.58 % $ 222,000 Other loans — — 3.90 % 233 Finance leases 3.46 % 201 3.53 % 605 Total debt 220,201 222,838 Current maturities ( 137 ) ( 621 ) Long-term debt, less current maturities $ 220,064 $ 222,217 Credit Agreement On June 10, 2022, the Company entered into a Second Amended and Restated Credit Agreement (the “Second Amended and Restated Credit Agreement”) with a consortium of lenders and Bank of America, N.A. as administrative agent (the “Agent”). The Second Amended and Restated Credit Agreement amended and restated in its entirety the Amended and Restated Credit Agreement dated June 27, 2019, by and among Gentherm, certain of its direct and indirect subsidiaries, the lenders party thereto and the Agent. The Second Amended and Restated Credit Agreement provides for a $ 500,000 secured revolving credit facility (the “Revolving Credit Facility”) (a $ 25,000 increase from the revolving credit facility under the Amended and Restated Credit Agreement), with a $ 50,000 sublimit for swing line loans and a $ 15,000 sublimit for the issuance of standby letters of credit. Any amount of the facility utilized for swing line loans or letters of credit outstanding will reduce the amount available under the Second Amended and Restated Credit Agreement. The Company h ad $ 2,838 of out standing letters of credit issued as of December 31, 2024 and no out standing letters of credit issued as of December 31, 2023. Subject to specified conditions, Gentherm can increase the Revolving Credit Facility or incur secured term loans in an aggregate amount of up to $ 200,000 . The Second Amended and Restated Credit Agreement extended the maturity of the Revolving Credit Facility from June 27, 2024 to June 10, 2027 . The U.S. borrowers and guarantors participating in the Second Amended and Restated Credit Agreement also entered into a Second Amended and Restated Pledge and Security Agreement (the “Second Amended and Restated Security Agreement”). The Second Amended and Restated Security Agreement grants a security interest to the Agent in substantially all of the personal property of the Company and its U.S. subsidiaries designated as borrowers to secure their respective obligations under the Second Amended and Restated Security Agreement, including the stock and membership interests of specified subsidiaries (limited to 66 % of the stock in the case of certain non-U.S. subsidiaries). In addition to the security obligations, all obligations under the Second Amended and Restated Credit Agreement (including all obligations of any U.S. or non-U.S. loan party) are unconditionally guaranteed by certain of Gentherm’s domestic subsidiaries, and the German subsidiary borrowers and certain other foreign subsidiaries guarantee all obligations of the non-U.S. loan parties under the Second Amended and Restated Credit Agreement. The Second Amended and Restated Credit Agreement restricts, among other things, the amount of dividend payments the Company can make to shareholders. The Second Amended and Restated Credit Agreement contains covenants, that, among other things, (i) prohibit or limit the ability of the borrowers and any material subsidiary to incur additional indebtedness, create liens, pay dividends, make certain types of investments (including acquisitions), enter into certain types of transactions with affiliates, prepay other indebtedness, sell assets or enter into certain other transactions outside the ordinary course of business, and (ii) require that Gentherm maintain a minimum Consolidated Interest Coverage Ratio and a maximum Consolidated Net Leverage Ratio (based on consolidated EBITDA for the applicable trailing four fiscal quarters) as of the end of any fiscal quarter. The Second Amended and Restated Credit Agreement also contains customary events of default. As of December 31, 2024, the Company was in compliance with the terms of the Second Amended and Restated Credit Agreement. The Second Amended and Restated Credit Agreement additionally contains customary events of default. Upon the occurrence of an event of default, the amounts outstanding under the Revolving Credit Facility may be accelerated and may become immediately due and payable. Under the Second Amended and Restated Credit Agreement, U.S. Dollar denominated loans bear interest at either a base rate (“Base Rate Loans”) or Term SOFR rate (“Term SOFR Rate Loans”), plus a margin (“Applicable Rate”). The rate for Base Rate Loans is equal to the highest of the Federal Funds Rate plus 0.50 %, Bank of America’s prime rate, or the Term SOFR rate plus 1.00 %. The rate for Term SOFR Rate Loans denominated in U.S. Dollars is equal to the forward-looking Secured Overnight Financing Rate (“SOFR”) term rate administered by the CME with a term of one month. All loans denominated in a currency other than the U.S. Dollar must be Term SOFR Rate Loans. Interest is payable at least quarterly. Additionally, a commitment fee of between 0.175 % to 0.300 %, which will vary based on the Consolidated Net Leverage Ratio, as defined in the Second Amended and Restated Credit Agreement, is payable on the average daily unused amounts under the Revolving Credit Facility. The Applicable Rate varies based on the Consolidated Net Leverage Ratio reported by the Company. As long as the Company is not in default of the terms and conditions of the Second Amended and Restated Credit Agreement, the lowest and highest possible Applicable Rate is 1.125 % and 2.125 %, respectively, for Term SOFR Rate Loans and 0.125 % and 1.125 %, respectively, for Base Rate Loans. Borrowing availability is subject to, among other things, the Company’s compliance with the minimum Consolidated Interest Coverage Ratio and the maximum Consolidated Net Leverage Ratio as of the end of any fiscal quarter. Based upon consolidated EBITDA for the trailing four fiscal quarters calculated for purposes of the Consolidated Net Leverage Ratio, $ 280,000 remained available as of December 31, 2024 for additional borrowings under the Second Amended and Restated Credit Agreement subject to specified conditions that Gentherm currently satisfies. In connection with the Second Amended and Restated Credit Agreement, the Company incurred debt issuance costs of $ 1,520 , which have been capitalized and are amortized into interest expense over the term of the Revolving Credit Facility. In addition, unamortized deferred debt issuance costs of $ 144 were written off and recognized in interest expense, net during the twelve months ended December 31, 2022. The scheduled principal maturities of our debt as of December 31, 2024 were as follows: U.S. Other Debt Total 2025 $ — $ 137 $ 137 2026 — 64 64 2027 220,000 — 220,000 2028 — — — 2029 — — — Total $ 220,000 $ 201 $ 220,201

Pension and Other Post Retireme

Pension and Other Post Retirement Benefit Plans	12 Months Ended
	Dec. 31, 2024
Retirement Benefits [Abstract]
Pension and Other Post Retirement Benefit Plans	Note 10 — Pension and Other Post Retirement Benefit Plans The Company maintains a U.S. defined benefit pension plan covering a former Company executive (“U.S. Plan”) and a German defined benefit pension plan covering certain retired executive employees of the Company’s wholly owned subsidiary, Gentherm GmbH (“German Plan”). The components of net periodic benefit cost for the Company’s defined benefit plans for the years ended December 31, 2024, 2023 and 2022 were as follows: U.S. Plan German Plan Year Ended December 31, Year Ended December 31, 2024 2023 2022 2024 2023 2022 Net periodic benefit cost: Service cost $ — $ — $ — $ — $ — $ — Interest cost 101 115 56 234 217 92 Expected return on plan assets — — — ( 130 ) ( 115 ) ( 109 ) Amortization of prior service cost and actuarial loss — — 22 19 23 114 Net periodic benefit cost $ 101 $ 115 $ 78 $ 123 $ 125 $ 97 Assumptions: Discount rate 4.45 % 4.65 % 1.80 % 4.56 % 4.10 % 1.08 % Long-term return on assets N/A N/A N/A 3.20 % 3.20 % 2.90 % A reconciliation of the change in benefit obligation and the change in plan assets for the years ended December 31, 2024 and 2023 is as follows: U.S. Plan German Plan As of December 31, As of December 31, 2024 2023 2024 2023 Change in projected benefit obligation: Balance at beginning of year $ 2,602 $ 2,811 $ 5,406 $ 5,398 Interest cost 101 115 234 217 Paid pension distributions ( 342 ) ( 342 ) ( 256 ) ( 290 ) Actuarial (gain) loss ( 30 ) 18 1,259 ( 89 ) Exchange rate impact — — ( 362 ) 170 Balance at end of year $ 2,331 $ 2,602 $ 6,281 $ 5,406 Change in plan assets: Balance at beginning of year $ — $ — $ 4,145 $ 3,918 Actual return on plan assets — — 104 98 Contributions — — — — Paid pension distributions — — — — Exchange rate impact — — ( 244 ) 129 Balance at end of year $ — $ — $ 4,005 $ 4,145 Underfunded Status $ ( 2,331 ) $ ( 2,602 ) $ ( 2,276 ) $ ( 1,261 ) Balance sheet classification: Other current liabilities $ ( 342 ) $ ( 357 ) $ ( 248 ) $ ( 297 ) Pension benefit obligation ( 1,989 ) ( 2,245 ) ( 2,028 ) ( 964 ) Accumulated other comprehensive loss (pre-tax): Actuarial losses 194 223 2,063 899 Assumptions: Discount rate 4.85 % 4.45 % 3.38 % 4.56 % Pre-tax amounts included in AOCI that are expected to be recognized in net periodic benefit cost during the year ended December 31, 2025 are as follows: U.S Plan German Plan Actuarial losses $ — $ 71 The accumulated benefit obligations were as follows: U.S. Plan German Plan As of December 31, As of December 31, 2024 2023 2024 2023 Accumulated benefit obligation $ 2,331 $ 2,602 $ 6,281 $ 5,406 Interest costs are recognized in selling, general and administrative expenses in the consolidated statements of income and actuarial gains and losses are included the consolidated balance sheets as part of accumulated other comprehensive loss within shareholders’ equity. Actuarial gains or losses are amortized to selling, general and administrative expense in the consolidated statements of income based on the average future life of the U.S Plan or German Plan using the corridor method. Prior service cost is included in selling, general and administrative expenses in the consolidated statements of income. Plan assets – German Plan Plan assets are comprised of Gentherm GmbH’s pension insurance policies and are pledged to the beneficiaries of the German Plan. A market valuation technique, based on observable underlying insurance charges, is used to determine the fair value of the pension plan assets (Level 2). The expected return on plan assets assumption used to calculate Gentherm GmbH’s pension benefit obligation was determined using actual returns realized on plan assets in the prior year. Contributions We do no t expect contribu tions to be paid to the U.S. Plan or the German Plan during the next fiscal year. The schedule of future expected pension payments is as follows: Projected Pension Year U.S Plan German Plan 2025 $ 342 $ 248 2026 342 249 2027 342 249 2028 342 247 2029 342 1,628 2030-2033 1,026 1,565 Total $ 2,736 $ 4,186 Defined Contribution Plans The Company also sponsors defined contribution plans for eligible employees. On a discretionary basis, the Company matches a portion of the employee contributions and or makes additional discretionary contributions. Gentherm recognized costs of $ 2,264 , $ 2,344 and $ 1,984 related to contributions to its defined contribution plans during the years ended December 31, 2024, 2023 and 2022 , respectively.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 11 — Commitments and Contingencies Legal and Other Contingencies The Company is subject to various legal actions and claims in the ordinary course of its business, which may include those arising out of breach of contracts, intellectual property rights, environmental matters, regulatory matters and employment-related matters. The Company establishes accruals for matters which it believes that losses are probable and can be reasonably estimated. Although it is not possible to predict with certainty the outcome of these matters, the Company is of the opinion that the ultimate resolution of these matters outstanding as of December 31, 2024 will not have a material adverse effect on its results of operations or financial position. Product liability and warranty reserves are recorded separately from legal reserves. Product Liability and Warranty Matters Our products subject us to warranty claims and, from time to time, product liability claims based on the Company’s products alleged failure to perform as expected or resulting in alleged bodily injury or property damage. If any of our products are or are alleged to be defective, we may be required to participate in a recall or other corrective action involving such products. The Company maintains warranty and product liability insurance coverage at levels based on commercial norms and historical claims experience. The Company can provide no assurances that it will not experience material warranty or product liability claims or liabilities in the future or that it will not incur significant costs to defend such claims. The Company accrues warranty obligations for products sold based on management estimates of future failure rates and current claim cost experience, with support from the sales, engineering, quality and legal functions. Using historical information available to the Company, including any claims filed by customers, the warranty accrual is adjusted quarterly to reflect management’s estimate of future claims. On February 14, 2024, the National Highway Traffic Safety Administration announced that Volkswagen Group of America, Inc. (“VW”) is recalling 261,257 vehicles from model years 2015-2020 to remedy an alleged problem with a suction jet pump seal inside the fuel tank system. VW informed Gentherm of its plan to conduct the recall on April 3, 2024. The suction jet pump is a product originally designed and manufactured by Alfmeier, the business Gentherm acquired in August 2022. The Company has not accepted any financial responsibility for the recall and intends to provide replacement parts for the recall at commercial pricing paid by VW. The Company is pursuing discussions with VW to advance its position and resolve this matter. No litigation has been threatened or filed as of the date of this report. If the Company is obligated to indemnify VW for the direct and indirect costs associated with the recall, such costs could be material. The Company has insurance policies that generally include coverage of the costs of a recall, subject to insured limits, although the Company’s costs related to manufacturing of replacement parts are generally not covered. In addition, the Company’s purchase agreement of Alfmeier includes indemnification provisions under which the Company believes it would have a claim against the sellers. Given the uncertainty that exists concerning the resolution of this matter, as of the date of this report, the Company cannot reasonably estimate the amount and timing of possible costs that may be incurred by the Company. The following is a reconciliation of the changes in accrued warranty costs: Year Ended December 31, 2024 2023 Balance at beginning of year $ 3,945 $ 2,380 Warranty claims paid ( 6,382 ) ( 2,252 ) Warranty expense for products shipped during the current period 5,812 3,955 Adjustments to warranty estimates from prior periods 247 ( 174 ) Adjustments due to currency translation ( 115 ) 36 Balance at end of year $ 3,507 $ 3,945 Employees Approximately 35 % of the Company’s workforce are members of industrial trade unions or worker councils and are employed under the terms of various labor agreements. In 2025, certain agreements will require a vote on the terms of their respective labor contracts.

Supplier Finance Program

Supplier Finance Program	12 Months Ended
	Dec. 31, 2024
Payables and Accruals [Abstract]
Supplier Finance Program	Note 12 — Supplier Finance Program Beginning in 2024, the Company became party to a supplier finance program with a third-party service provider (“Service Provider”), pursuant to which the Company has offered the opportunity to participate to certain of the Company's suppliers. The Company has no economic interest in a supplier’s participation and the Company has not pledged any assets to the Service Provider under this program. Under this program, the Company and supplier initially agree on the contractual payment terms for the goods to be procured for the Company in the ordinary course. A supplier’s participation in this program is voluntary and does not impact its contractual payment terms with the Company, including the payment amount and timing of when payments are due. A participating supplier has the sole discretion to determine whether to discount one or more invoices, if any, to the Service Provider in exchange for payment by the Service Provider on an earlier date than provided for in the contract with the Company. Amounts due to participating suppliers are included in accounts payable in the consolidated balance sheets until the Company makes payment to the Service Provider, even though the payment of such amount will be made to the supplier at an earlier date by the Service Provider. As of December 31, 2024, the Company had outstanding payment obligations to participating suppliers of $ 21,232 confirmed under the program. Payments of the Company’s obligations to the Service Provider are reported as operating cash flows in the consolidated statements of cash flows. The following is a reconciliation of the changes in confirmed obligations to participating suppliers: Year Ended December 31, 2024 Outstanding at beginning of year $ — Invoices confirmed 90,343 Invoices settled ( 69,111 ) Outstanding at end of year $ 21,232

Earnings Per Share

Earnings Per Share	12 Months Ended
	Dec. 31, 2024
Earnings Per Share [Abstract]
Earnings Per Share	Note 13 — Earnings Per Share Basic earnings per share are computed by dividing net income by the weighted average number of shares of Common Stock outstanding during the period. The Company’s diluted earnings per share give effect to all potential shares of Common Stock outstanding during a period that do not have an anti-dilutive impact to the calculation. In computing the diluted earnings per share, the treasury stock method is used in determining the number of shares assumed to be issued from the exercise of Common Stock equivalents. The following table illustrates earnings per share and the weighted average shares outstanding used in calculating basic and diluted earnings per share: Year Ended December 31, 2024 2023 2022 Net income $ 64,947 $ 40,343 $ 24,441 Basic weighted average shares of Common Stock outstanding 31,293,113 32,778,055 33,126,202 Dilutive effect of stock options, restricted stock awards and restricted stock units 183,373 288,862 376,952 Diluted weighted average shares of Common Stock outstanding 31,476,486 33,066,917 33,503,154 Basic earnings per share $ 2.08 $ 1.23 $ 0.74 Diluted earnings per share $ 2.06 $ 1.22 $ 0.73 See Note 18, "Accounting for Stock Based Compensation," for information about the Company’s different equity incentive plans.

Financial Instruments

Financial Instruments	12 Months Ended
	Dec. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Financial Instruments	Note 14 —Financial Instruments Derivative Financial Instruments The Company is exposed to various market risks including, but not limited to, changes in foreign currency exchange rates, changes in interest rates and price fluctuations of certain material commodities such as copper. Market risks for changes in interest rates relate primarily to its debt obligations under the Second Amended and Restated Credit Agreement. Foreign currency exchange risks are attributable to sales to foreign customers and purchases from foreign suppliers not denominated in a location’s functional currency, foreign plant operations, intercompany indebtedness, intercompany investments and include exposures to the Euro, Mexican Peso, Canadian Dollar, Hungarian Forint, North Macedonian Denar, Ukrainian Hryvnia, Japanese Yen, Chinese Renminbi, Korean Won, Czech Koruna and Vietnamese Dong. The Company regularly enters into derivative contracts with the objective of managing its financial and operational exposure arising from these risks by offsetting gains and losses on the underlying exposures with gains and losses on the financial instruments used to hedge them. The decision of whether and when to execute derivative financial instruments, along with the duration of the instrument, may vary from period to period depending on market conditions, the relative costs of the instruments and capacity to hedge. The duration is linked to the timing of the underlying exposure, with the connection between the two being regularly monitored. The Company does not enter into derivative financial instruments for speculative or trading purposes. Some derivative contracts do not qualify for hedge accounting; for other derivative contracts, we elect to not apply hedge accounting. The Company’s designated hedging relationships are formally documented at the inception of the hedge, and hedges must be highly effective in offsetting changes to future cash flows on hedged transactions both at the inception of a hedge and on an ongoing basis to be designated for hedge accounting treatment. For derivative contracts which can be classified as a cash flow hedge, the effective portion of the change in the fair value of the derivative is recorded to accumulated other comprehensive loss in the consolidated balance sheets. When the underlying hedge transaction is realized, the gain or loss included in accumulated other comprehensive loss is recorded in earnings in the consolidated statements of income on the same line as the gain or loss on the hedged item attributable to the hedged risk. The Company records the ineffective portion of foreign currency and copper commodity hedging instruments, if any, to cost of sales, in the consolidated statements of income. Cash flows associated with derivatives are reported in net cash provided by operating activities in the Company’s consolidated statements of cash flows. The Company uses an income approach to value derivative instruments, analyzing quoted market prices to calculate the forward values and then discounting such forward values to the present value using benchmark rates at commonly quoted intervals for the instrument’s full term. The Company is party to a floating-to-fixed interest rate swap agreement that is an undesignated hedge of the Company’s exposure to interest payment fluctuations on a portion of the Revolving Credit Facility borrowings. The periodic changes in fair value are recognized in interest expense, net. Information related to the recurring fair value measurement of derivative financial instruments in the consolidated balance sheet as of December 31, 2024 is as follows: Asset Derivatives Liability Derivatives Fair Value Notional Amount Balance Sheet Fair Balance Sheet Fair Net Asset/ Derivatives Designated as Cash Flow Hedges Foreign currency derivatives Level 2 $ 126,496 Other current assets $ — Other current liabilities $ 2,037 $ ( 2,037 ) Derivatives Not Designated as Hedging Instruments Interest rate contracts Level 2 $ 100,000 Other current assets $ 719 Other current liabilities $ — $ 719 Information related to the recurring fair value measurement of derivative financial instruments in the consolidated balance sheet as of December 31, 2023 is as follows: Asset Derivatives Liability Derivatives Fair Value Notional Amount Balance Sheet Fair Balance Sheet Fair Net Asset/ Derivatives Designated as Cash Flow Hedges Foreign currency derivatives Level 2 $ 101,109 Other current assets $ 8,655 Other current liabilities $ — $ 8,655 Derivatives Not Designated as Hedging Instruments Interest rate contracts Level 2 $ 100,000 Other current assets $ 2,062 Other current liabilities $ — $ 2,062 Information related to the effect of derivative instruments in the consolidated statements of income is as follows: Year Ended December 31, Location 2024 2023 2022 Derivatives Designated as Cash Flow Hedges Foreign currency derivatives Cost of sales – income $ 3,717 $ 8,630 $ 1,458 Other comprehensive (loss) income ( 11,259 ) 3,483 3,496 Total foreign currency derivatives $ ( 7,542 ) $ 12,113 $ 4,954 Commodity derivatives Cost of sales – income $ — $ — $ 19 Other comprehensive (loss) income — — ( 6 ) Total commodity derivatives $ — $ — $ 13 Derivatives Not Designated as Hedging Instruments Foreign currency derivatives Foreign currency gain (loss) $ — $ — $ ( 3,806 ) Total foreign currency derivatives $ — $ — $ ( 3,806 ) Interest rate contracts Interest expense, net $ ( 1,343 ) $ ( 710 ) $ 2,772 Total interest rate derivatives $ ( 1,343 ) $ ( 710 ) $ 2,772 The Com pany did no t incur any hedge ineffectiveness duri ng the years ended December 31, 2024 and 2023. Accounts Receivable Factoring The Company previously sold certain customer trade receivables on a non-recourse basis under factoring arrangements with designated financial institutions. The sale of receivables under these agreements was considered an off-balance sheet arrangement to the Company and was accounted for as a true sale and excluded from accounts receivable in the consolidated balance sheets. These factoring arrangements included a deferred purchase price component in which a portion of the purchase price for the receivable was paid by the financial institution in cash upon sale and the remaining portion was recorded as a deferred purchase price receivable and paid at a later date. Deferred purchase price receivables are recorded in other current assets within the consolidated balance sheets. Cash proceeds received upon the sale of the receivables are included in net cash provided by operating activities and the cash proceeds received on the deferred purchase price receivables are included in net cash used in investing activities. During the year ended December 31, 2024, the factoring agreements the Company was party to either expired or were terminated. Receivables factored and availability under receivables factoring agreements balances as of December 31, 2024 and 2023 were as follows: December 31, 2024 2023 Receivables factored and outstanding (a) $ 755 $ 18,532 (a) During the year ended December 31, 2024, the factoring agreements the Company was party to either expired or were terminated. As of December 31, 2024 there were remaining receivables factored and outstanding that will be collected in the future, however, no further factoring can occur under these factoring agreements. Trade receivables sold and factoring fees incurred during the years ended December 31, 2024 and 2023 were as follows: Year Ended December 31, 2024 2023 Trade receivables sold $ 98,761 $ 135,116 Factoring fees incurred 615 800

Fair Value Measurement

Fair Value Measurement	12 Months Ended
	Dec. 31, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurement	Note 15 — Fair Value Measurement Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Fair value measurements are based on one or more of the following three valuation techniques: Market : This approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities. Income : This approach uses valuation techniques to convert future amounts to a single present value amount based on current market expectations. Cost : This approach is based on the amount that would be required to replace the service capacity of an asset (replacement cost). The Company uses the following fair value hierarchy to measure fair value into three broad levels, which are described below: Level 1 : Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2 : Inputs, other than quoted market prices included in Level 1, that are observable either directly or indirectly for the asset or liability. Level 3 : Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. Items Measured at Fair Value on a Recurring Basis Except for derivative financial instruments (see Note 14) and pension plan assets (see Note 10), the Company has no material financial assets and liabilities that are carried at fair value at December 31, 2024 and 2023. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and also considers counterparty credit risk in its assessment of fair value. Items Measured at Fair Value on a Nonrecurring Basis The Company measures certain assets and liabilities at fair value on a non-recurring basis. As these nonrecurring fair value measurements are generally determined using unobservable inputs, these fair value measurements are classified within Level 3 of the fair value hierarchy. The Company utilized a third-party to assist in the Level 3 fair value estimates of goodwill of the Medical reporting unit (see Note 7). The estimated fair value was based on third-party valuation and management’s estimate, generally utilizing income and market approaches. As of December 31, 2024, and December 31, 2023 , there were no other significant assets or liabilities measured at fair value on a non-recurring basis. Items Not Carried at Fair Value The Company uses an income valuation technique to measure the fair values of its debt instruments by converting amounts of future cash flows to a single present value amount using rates based on current market expectations (Level 2 inputs). As of December 31, 2024, and 2023, the carrying values of the indebtedness under the Company’s Credit Agreement were not materially different than their estimated fair values because the interest rates on variable rate debt approximated rates currently available to the Company (see Note 9). The carrying amounts of financial instruments comprising cash and cash equivalents, short-term investments, accounts receivable, notes receivable and accounts payable approximate fair value because of the short maturities of these instruments.

Equity

Equity	12 Months Ended
	Dec. 31, 2024
Stockholders' Equity Note [Abstract]
Equity	Note 16 — Equity Common Stock The Company is authorized to issue up to 59,991,000 shares, of which 55,000,000 shares shall be Common Stock, without par value, and 4,991,000 shall be Preferred Stock, without par value. As of December 31, 2024 , an aggregate of 30,788,639 shares of its Common Stock were issued and outstanding. As of December 31, 2024, the re are no pref erred stock shares issued or outstanding. The Common Stock is listed on the Nasdaq Global Select Market under the symbol, “THRM”, and has the following rights and privileges: ▪ Voting rights. All shares of the Common Stock have identical rights and privileges. With limited exceptions, holders of common stock are entitled to one vote for each outstanding share of Common Stock held of record by each shareholder on all matters properly submitted for the vote of the Company’s shareholders. ▪ Dividend rights . Subject to applicable law, any contractual restrictions and the rights of the holders of outstanding preferred stock, if any, holders of Common Stock are entitled to receive ratably such dividends and other distributions that the Company’s Board of Directors, in its discretion, declares from time to time. ▪ Liquidation rights . Upon the dissolution, liquidation or winding up of the Company, subject to the rights of the holders of outstanding preferred stock, if any, holders of Common Stock are entitled to receive ratably the assets of the Company available for distribution to the Company’s shareholders in proportion to the number of shares of Common Stock held by each shareholder. ▪ Conversion, Redemption and Preemptive Rights . Holders of Common Stock have no conversion, redemption, sinking fund, preemptive, subscription or similar rights. Stock Repurchase Program In December 2020, the Board of Directors of Gentherm Incorporated (“Board of Directors”) authorized a stock repurchase program (the “2020 Stock Repurchase Program”). Under the 2020 Stock Repurchase Program, the Company was authorized to repurchase up to $ 150,000 of its issued and outstanding Common Stock over a three-year period, expiring December 15, 2023 . On November 1, 2023, the Board of Directors extended the maturity date of the program from December 15, 2023 to June 30, 2024 . During the year ended December 31, 2024 , the Company repurchased $ 20,000 in the open market under the 2020 Stock Repurchase Program with an average price paid per share of $ 52.65 . On November 1, 2023, following the above-noted extension, the Company entered into a Confirmation of Issuer Forward Repurchase Transaction agreement (the “ASR Agreement”) with Bank of America, N.A. (“Bank of America”) that provided for the Company to purchase shares of Common Stock in an aggregate amount of $ 60,000 (the “ASR Repurchase Amount”) under the 2020 Stock Repurchase Program. Under the terms of the ASR Agreement, on November 2, 2023, the Company paid $ 60,000 to Bank of America for an initial purchase of approximately 1.22 million shares of Common Stock, representing 80 % of ASR Repurchase Amount. The final settlement date occurred in the second quarter of 2024. During the year ended December 31, 2024 , the Company paid $ 286 in cash as the final settlement of the ASR Agreement. The 2020 Stock Repurchase Program had $ 17,491 of repurchase authorization remaining at the time of expiration. In June 2024, the Board of Directors authorized a new stock repurchase program (the “2024 Stock Repurchase Program”) to commence upon expiration of the 2020 Stock Repurchase Program on June 30, 2024. Under the 2024 Stock Repurchase Program, the Company is authorized to repurchase up to $ 150,000 of its issued and outstanding Common Stock over a three-year period, expiring June 30, 2027 . Repurchases may be made, from time to time, in amounts and at prices the Company deems appropriate, subject to market conditions, applicable legal requirements, debt covenants and other considerations. Any such repurchases may be executed using open market purchases, accelerated share repurchase programs, privately negotiated agreements or other transactions. Repurchases may be funded from cash on hand, available borrowings or proceeds from potential debt or other capital markets sources. During the year ended December 31, 2024 , the Company repurchased $ 29,883 under the 2024 Stock Repurchase Program with an average price paid per share of $ 46.73 . The 2024 Stock Repurchase Program had $ 120,117 of repurchase authorization remaining as of December 31, 2024. Stock repurchases are subject to excise tax, subject to specified exclusions and adjustments. Excise tax of $ 502 was charged to common stock for the year ended December 31, 2024 .

Reclassifications Out of Accumu

Reclassifications Out of Accumulated Other Comprehensive Loss	12 Months Ended
	Dec. 31, 2024
Equity [Abstract]
Reclassifications Out of Accumulated Other Comprehensive Loss	N ote 17 – Reclassifications Out of Accumulated Other Comprehensive Loss Reclassification adjustments and other activities impacting accumulated other comprehensive loss during the years ended December 31, 2024, 2023 and 2022 are as follows: Defined Foreign Commodity Hedge Derivatives Foreign Total Balance at December 31, 2023 $ ( 1,011 ) $ ( 34,830 ) $ — $ 5,681 $ ( 30,160 ) Other comprehensive loss before reclassifications ( 1,242 ) ( 45,519 ) — ( 3,648 ) ( 50,409 ) Income tax effect of other comprehensive loss before reclassifications 335 253 — 784 1,372 Amounts reclassified from accumulated other comprehensive loss into net income 91 — — ( 7,611 ) a ( 7,520 ) Income taxes reclassified into net income ( 24 ) — — 1,548 1,524 Net current period other comprehensive loss ( 840 ) ( 45,266 ) — ( 8,927 ) ( 55,033 ) Balance at December 31, 2024 $ ( 1,851 ) $ ( 80,096 ) $ — $ ( 3,246 ) $ ( 85,193 ) (a) The amounts reclassified from accumulated other comprehensive loss are included in cost of sales. See Note 14 for information related to the effect of foreign currency derivative instruments on our consolidated statements of income. Defined Foreign Commodity Hedge Derivatives Foreign Total Balance at December 31, 2022 $ ( 1,067 ) $ ( 48,269 ) $ — $ 2,847 $ ( 46,489 ) Other comprehensive income before reclassifications 54 13,125 — 13,086 26,265 Income tax effect of other comprehensive income before reclassifications ( 15 ) 314 — ( 2,770 ) ( 2,471 ) Amounts reclassified from accumulated other comprehensive loss into net income 23 — — ( 9,603 ) a ( 9,580 ) Income taxes reclassified into net income ( 6 ) — — 2,121 2,115 Net current period other comprehensive income 56 13,439 — 2,834 16,329 Balance at December 31, 2023 $ ( 1,011 ) $ ( 34,830 ) $ — $ 5,681 $ ( 30,160 ) (a) The amounts reclassified from accumulated other comprehensive loss are included in cost of sales. See Note 14 for information related to the effect of foreign currency derivative instruments on our consolidated statements of income. Defined Benefit Foreign Currency Commodity Hedge Derivatives Foreign Currency Total Balance at December 31, 2021 $ ( 2,893 ) $ ( 34,188 ) $ 5 $ 154 $ ( 36,922 ) Other comprehensive income (loss) before reclassifications 2,341 ( 13,786 ) 13 4,954 ( 6,478 ) Income tax effect of other comprehensive income (loss) before reclassifications ( 621 ) ( 295 ) ( 3 ) ( 1,092 ) ( 2,011 ) Amounts reclassified from accumulated other comprehensive loss into net income 137 — ( 19 ) a ( 1,458 ) a ( 1,340 ) Income taxes reclassified into net income ( 31 ) — 4 289 262 Net current period other comprehensive income (loss) 1,826 ( 14,081 ) ( 5 ) 2,693 ( 9,567 ) Balance at December 31, 2022 $ ( 1,067 ) $ ( 48,269 ) $ — $ 2,847 $ ( 46,489 ) (a) The amounts reclassified from accumulated other comprehensive loss are included in cost of sales. See Note 14 for information related to the effect of commodity and foreign currency derivative instruments on our consolidated statements of income. The Company expects all of the existing gains and losses related to foreign currency derivatives reported in accumulated other comprehensive loss as of December 31, 2024 to be reclassified into earnings during the next twelve months. See Note 14, "Financial Instruments," for additional information about derivative financial instruments and the effects from reclassification to net income.

Accounting for Stock Based Comp

Accounting for Stock Based Compensation	12 Months Ended
	Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]
Accounting for Stock Based Compensation	Note 18 — Accounting for Stock Based Compensation On May 18, 2023 the Company’s shareholders approved the Gentherm Incorporated 2023 Equity Incentive Plan (the “2023 Equity Plan”), covering 3,730,000 shares of the Common Stock, plus the number of shares of Common Stock that, as of the effective date of the 2023 Equity Plan, that were subject to awards granted under the Gentherm Incorporated 2013 Equity Incentive Plan (the “2013 Equity Plan”) and that, on or after the effective date of the 2023 Equity Plan, were forfeited, surrendered, terminated (other than by exercise), cancelled, lapsed or reacquired by the Company prior to vesting, without the delivery of any shares of Common Stock, and otherwise comply with the recycling provisions of the 2013 Equity Plan and 2023 Equity Plan. The 2023 Equity Plan permits the granting of various awards including stock options (including both nonqualified stock options and incentive stock options), stock appreciation rights ("SARs"), restricted stock, restricted stock units ("RSUs"), performance stock units (including performance-based RSUs under the 2013 Equity Plan, "PSUs") and performance units, and other awards to employees, outside directors and consultants and advisors of the Company. As of December 31, 2024 , the Company had an aggregate of 3,448,234 shares of Common Stock available to issue under the 2023 Equity Plan. During the three-year period ended December 31, 2024 , the Company has outstanding stock options, SARs, restricted stock awards and RSUs to employees, directors and consultants. These awards become available to the recipient upon the satisfaction of a vesting condition, either based on a period of service or based on the performance of a specific achievement. For equity-based awards with a service condition, the requisite service period typically ranges between two to four years for employees and consultants and one year for directors. As of December 31, 2024, there were 279,841 PSUs outstanding. These awards cliff vest after three-years based on the Company’s achievement of one of five separate performance metrics: a target return on invested capital ratio (“ROIC”), as defined in the award agreement, for a specified fiscal year; a target three-year cumulative Adjusted EBITDA (“Adjusted EBITDA”), as defined in the award agreement; a target annual and three-year growth in the expansion of Adjusted EBITDA Margin Rate (“Adjusted EBITDA Margin Rate”), as defined in the award agreement (as modified by the Company’s relative total shareholder return); the Company’s relative total shareholder return (“TSR”), as defined in the award agreement, during a specific three-year measurement period; and a target relative revenue growth relative to light vehicle production in the Company's relevant markets ("RRG"), as defined in the award agreement, during a specific three-year measurement period (in certain cases, as modified by the Company’s relative total shareholder return). In each case, awards will be earned at 50 % of the target number of shares for achieving a minimum threshold or up to 200 % of the target number of shares for exceeding the target, with a linear adjustment between threshold and target or between target and stretch performance goals. All other outstanding, unvested equity-based awards were service based. Equity-based award vesting may be accelerated at the discretion of the Board under conditions specified in the 2023 Equity Plan and the 2013 Equity Plan. Under FASB ASC Topic 718, the provisions of the PSUs that vest upon the achievement of relative TSR are considered a market condition, and therefore the effect of that market condition is reflected in the grant date fair value for this portion award. A third party was engaged to complete a Monte Carlo simulation to account for the market condition. That simulation takes into account the beginning stock price of our Common Stock, the expected volatilities for the relative TSR comparator group, the expected volatilities for the Company’s stock price, correlation coefficients, the expected risk-free rate of return and the expected dividend yield of the Company and the comparator group. The single grant-date fair value computed by this valuation method is recognized by the Company in accounting for the awards regardless of the actual future outcome of the relative TSR feature. The grant date fair value of the other PSUs and RSUs are calculated as the closing price of our Common Stock as quoted on Nasdaq on the grant date multiplied by the number of shares subject to the award. Each of ROIC, Adjusted EBITDA, Adjusted EBITDA Margin Rate and RRG are considered a performance condition and the grant-date fair value for ROIC PSUs, Adjusted EBITDA PSUs, Adjusted EBITDA Margin Rate and RRG PSUs correspond with management's expectation of the probable outcome of the performance condition as of the grant date. The Adjusted EBITDA Margin Rate PSUs and the RRG PSUs granted in 2024 are also subject to a relative TSR modifier that can adjust the total payout of PSUs by - 25 % if performance does not reach threshold or + 25 % if performance exceeds maximum. Therefore, the grant date fair value of the Adjusted EBITDA Margin Rate PSUs and RRG PSUs for 2024 were further impacted by the fair value of the relative TSR modifier. The total recognized and unrecognized stock based compensation expense is as follows: Stock Based Compensation Expense 2024 2023 2022 Unrecognized Stock Based Compensation Expense at December 31, 2024 Remaining Weighted Average Vesting Period RSUs $ 6,871 $ 6,216 $ 5,551 $ 7,395 1.92 PSUs 2,454 4,661 954 7,795 1.98 Restricted Stock 1,115 878 888 402 0.37 SARs ( 8 ) ( 128 ) ( 794 ) — — Total stock based compensation $ 10,432 $ 11,627 $ 6,599 $ 15,592 1.91 The related deferred tax benefit (expense) for the years ended December 31, 2024, 2023 and 2022 was $ 1,485 , $ 1,794 , and $( 444 ), respectively. If Gentherm were to realize expired stock based payment arrangements, they would be reported as a forfeit in the activity roll forward tables below. RSUs The following table summarizes RSU activity during the years ended December 31, 2024, 2023 and 2022: Unvested Restricted Stock Units Time Vesting Weighted-Average Outstanding at December 31, 2021 193,626 $ 56.02 Granted 117,507 66.86 Vested ( 95,692 ) 49.85 Forfeited ( 13,863 ) 70.52 Outstanding at December 31, 2022 201,578 $ 64.27 Granted 136,964 58.68 Vested ( 82,695 ) 59.43 Forfeited ( 23,986 ) 59.47 Outstanding at December 31, 2023 231,861 $ 63.19 Granted 184,959 54.20 Vested ( 129,477 ) 64.55 Forfeited ( 84,682 ) 57.71 Outstanding at December 31, 2024 202,661 $ 56.35 The total intrinsic value of RSUs vested during the years ended December 31, 2024, 2023 and 2022 was $ 8,358 , $ 4,915 and $ 4,774 , respectively. PSUs The following table summarizes PSU activity during the years ended December 31, 2024, 2023 and 2022: Unvested Performance Stock Units Performance Stock Unit Shares Weighted-Average Outstanding at December 31, 2021 319,336 $ 57.27 Granted 106,604 75.57 Performance Adjustment 42,746 58.30 Vested ( 133,477 ) 52.34 Forfeited ( 14,760 ) 65.02 Outstanding at December 31, 2022 320,449 $ 62.90 Granted 153,121 65.90 Performance Adjustment ( 59,928 ) 33.90 Vested ( 59,928 ) 49.25 Forfeited ( 28,737 ) 65.97 Outstanding at December 31, 2023 324,977 $ 74.10 Granted 235,388 60.68 Performance Adjustment ( 52,856 ) 79.49 Vested ( 27,850 ) 92.44 Forfeited ( 199,818 ) 61.35 Outstanding at December 31, 2024 279,841 $ 63.30 The total intrinsic value of PSUs vested during the years ended December 31, 2024, 2023 and 2022 was $ 2,574 , $ 2,951 and $ 6,986 , respectively. Restricted Stock The following table summarizes restricted stock activity during the years ended December 31, 2024, 2023 and 2022: Unvested Restricted Stock Shares Weighted-Average Outstanding at December 31, 2021 11,376 $ 70.33 Granted 13,600 73.54 Vested ( 11,376 ) 70.33 Forfeited — — Outstanding at December 31, 2022 13,600 $ 73.54 Granted 17,923 56.96 Vested ( 11,900 ) 73.54 Forfeited ( 1,700 ) 73.54 Outstanding at December 31, 2023 17,923 $ 56.96 Granted 21,296 50.72 Vested ( 17,923 ) 56.96 Forfeited — — Outstanding at December 31, 2024 21,296 $ 50.72 The compensation cost associated with restricted stock is estimated on the date of grant using quoted market prices (Level 1 input). The total fair value of restricted stock vested in 2024, 2023 and 2022 was $ 1,021 , $ 875 and $ 800 , respectively. SARs The following table summarizes SARs activity during the years ended December 31, 2024, 2023 and 2022: Stock Appreciation Rights Shares Weighted-Average Weighted-Average Aggregate Outstanding at December 31, 2021 55,600 $ 41.15 1.28 $ 2,544 Granted — — Exercised ( 40,850 ) 42.27 Forfeited — — Outstanding at December 31, 2022 14,750 $ 38.05 1.15 $ 402 Granted — — Exercised ( 12,500 ) 38.05 Forfeited — — Outstanding at December 31, 2023 2,250 $ 38.05 0.15 $ 32 Granted — — Exercised ( 2,250 ) 38.05 Forfeited — — Outstanding at December 31, 2024 — $ — — $ — Exercisable at December 31, 2024 — $ — — $ — The total intrinsic value of SARs exercised during the years ended December 31, 2024, 2023 and 2022 was $ 25 , $ 242 and $ 1,348 , respectively. Stock Options The following table summarizes stock option activity during the years ended December 31, 2024, 2023 and 2022: Options Shares Weighted-Average Weighted-Average Aggregate Outstanding at December 31, 2021 206,750 $ 36.72 2.60 $ 10,375 Granted — — Exercised ( 44,116 ) 37.87 Forfeited — — Outstanding at December 31, 2022 162,634 $ 36.41 2.68 $ 8,212 Granted — — Exercised ( 6,450 ) 40.79 Forfeited ( 16,500 ) $ 41.59 Outstanding at December 31, 2023 139,684 $ 35.59 0.90 $ 2,342 Granted — — Exercised ( 139,684 ) 35.59 Forfeited — — Outstanding at December 31, 2024 — $ — — $ — Exercisable at December 31, 2024 — $ — — $ — The total intrinsic value of stock options exercised during the years ended December 31, 2024, 2023 and 2022 was $ 2,071 , $ 201 and $ 1,582 , respectively.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Note 19 — Income Taxes The income tax provisions were calculated based upon the following components of earnings before income tax for the years ended December 31, 2024, 2023 and 2022: Year Ended December 31, 2024 2023 2022 (Loss) earnings before income tax: Domestic $ ( 54,073 ) $ ( 37,222 ) $ ( 34,211 ) Foreign 156,338 92,176 72,593 Earnings before income tax $ 102,265 $ 54,954 $ 38,382 The components of the provision for income taxes for the years ended December 31, 2024, 2023 and 2022 are summarized as follows: Year Ended December 31, 2024 2023 2022 Current income tax (benefit) expense: Federal $ ( 1,181 ) $ 3,510 $ 3,006 State and local 679 414 650 Foreign 27,240 23,759 17,607 Total current income tax expense 26,738 27,683 21,263 Deferred income tax (benefit) expense: Federal ( 7,944 ) ( 7,495 ) ( 5,971 ) State and local 66 444 ( 213 ) Foreign 18,458 ( 6,021 ) ( 1,138 ) Total deferred income tax expense (benefit) 10,580 ( 13,072 ) ( 7,322 ) Total income tax expense $ 37,318 $ 14,611 $ 13,941 No income taxes have been provided on indefinitely reinvested earnings of certain foreign subsidiaries at December 31, 2024 . In addition, deferred U.S. income taxes have not been provided on the undistributed earnings of the Company’s foreign subsidiaries since these earnings will not be taxable upon repatriation to the United States. These earnings will be primarily treated as previously taxed income from either the one-time transition tax or global intangible low-taxed income provision, or they will be offset with a 100 % dividend received deduction. To the extent dividends are paid within foreign tiered subsidiaries, withholding and income taxes may be incurred upon repatriation through the chain. Taxes of $ 5,088 have been accrued on undistributed earnings that are not indefinitely reinvested and are primarily related to China, Germany, Ukraine, North Macedonia, Czech Republic and Malta. As of December 31, 2024 , taxes have not been provided on $ 194,777 of undistributed earnings in various subsidiaries as those earnings have been indefinitely invested. If, in the future, these earnings were to be repatriated to foreign affiliates, additional tax provisions would be required. It is not practicable to determine the unrecognized deferred tax liability on these undistributed earnings. There are no other material liabilities for income taxes on the undistributed earnings of foreign subsidiaries, as the Company has concluded that such earnings are either indefinitely reinvested or should not give rise to additional income tax liabilities as a result of the distribution of such earnings. The deferred tax assets and deferred tax liabilities and related valuation allowance were comprised of the following as of December 31, 2024 and 2023: December 31, 2024 2023 Deferred tax assets: Net operating losses $ 35,966 $ 44,053 Intangible assets 10,893 4,314 Research and development credits 5,475 7,127 Property and equipment 4,132 4,800 Valuation reserves and accrued liabilities 8,446 11,221 Capitalized research and development costs 28,318 23,658 Stock compensation 2,039 3,227 Defined benefit obligation 1,514 1,691 Inventory 717 181 Other credits — 8,946 Other 8,707 9,154 Total deferred tax asset 106,207 118,372 Valuation allowance ( 25,272 ) ( 35,888 ) Deferred tax liabilities: Unrealized foreign currency exchange gains $ ( 1,092 ) $ — Undistributed profits of subsidiary ( 5,016 ) ( 4,609 ) Property and equipment ( 10,524 ) ( 12,627 ) Intangible assets ( 8,720 ) — Other ( 1,383 ) ( 1,550 ) Total deferred tax liability ( 26,735 ) ( 18,786 ) Net deferred tax asset $ 54,200 $ 63,698 Reconciliations between the statutory Federal income tax rate and the effective rate of income tax expense for the years ended December 31, 2024, 2023 and 2022 are as follows: Year Ended December 31, 2024 2023 2022 Statutory Federal income tax rate 21.0 % 21.0 % 21.0 % Increase (decrease) resulting from: Change in valuation allowance ( 9.0 )% ( 3.1 )% 6.4 % Effect of different tax rates of foreign jurisdictions ( 0.7 )% 0.9 % ( 4.9 )% Tax credits & deductions related to R&D ( 3.7 )% ( 8.5 )% ( 10.1 )% Goodwill impairment — 4.1 % — Non-deductible expenses 15.7 % 6.8 % 14.9 % Non-deductible expenses related to acquisitions — — 7.0 % Other foreign, state and local taxes 2.1 % 3.5 % 0.7 % Tax impact of foreign income 7.5 % 3.6 % 4.2 % Stock option compensation 1.0 % — ( 3.8 )% Audit settlements and statute expirations 11.0 % — — Incentive tax rates in foreign jurisdictions ( 5.5 )% ( 1.9 )% — Other ( 2.9 )% 0.2 % 0.9 % Effective rate 36.5 % 26.6 % 36.3 % The Company has Net Operating Loss (“NOL”) carryforwards as follows: Jurisdiction Amount as of December 31, 2024 Years of Expiration U.S. state income tax $ 41,396 2025 - 2043 Foreign 199,365 Never As of December 31, 2024, the Company has consolidated deferred tax assets of $ 106,207 with a valuation allowance of $ 25,272 principally related to tax net operating losses, credit carryforwards and other deferred tax assets in the U.S. and various foreign jurisdictions, and certain U.S. state income tax attributes. The Company has considered historical pre-tax income or loss and the four sources of income in determining the need for a valuation allowance when the realization of its deferred tax assets are not more likely than not. The four sources of income considered are 1) taxable income in prior carryback years where carryback is allowable, 2) future reversals of existing temporary differences, 3) consideration of reasonable and prudent tax planning strategies, and 4) forecasts of future taxable income, exclusive of reversing temporary differences and carryforwards. In the cases where a valuation allowance has been recorded, the evidence described above did not result in a conclusion that the deferred tax assets are more likely than not. The Company has NOL carryforwards in various states associated with the benefits of the state dividends received reduction and foreign royalty exclusion. The state NOL carryforwards generally expire at various dates from 2025 to 2043 . We have concluded that there is not sufficient evidence these NOL carryforwards will be utilized, and thus have not recognized the benefit of these NOL carryforwards as of December 31, 2024. At December 31, 2024, certain non-U.S. subsidiaries had gross NOL carryforwards totaling $ 199,365 which have no expiration date . The Company has a valuation allowance recorded of $ 15,263 recorded against deferred tax assets of $ 31,441 of the total non-U.S. subsidiaries’ net operating loss carryforwards as of December 31, 2024. The Company is subject to taxation in the United States and various state and foreign jurisdictions. As of December 31, 2024, the Company was no longer subject to U.S. Federal examinations by tax authorities for tax years before 2020 and was no longer subject to foreign examinations by tax authorities for tax years before 2015. The Company currently benefits from incentive tax rates in various non-U.S. jurisdictions with expiration dates from 2025 – 2029. Certain of the Company’s Chinese subsidiaries began to benefit from a reduced corporate income tax rate in 2024 as a result of their High and New Technology Enterprises (“HNTE”) status. For the years ended December 31, 2024, 2023 and 2022 , income in foreign jurisdictions with such holidays was $ 50,372 , $ 8,185 , and $ 2,414 , respectively. At December 31, 2024, 2023 and 2022, the Company had total unrecognized tax benefits of $ 8,266 , $ 5,486 and $ 6,185 , respectively, all of which, if recognized, would affect the effective income tax rates. The reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows: Year Ended December 31, 2024 2023 2022 Balance at beginning of year $ 5,486 $ 6,185 $ 5,665 Additions based on tax position related to current year 78 87 972 Additions based on tax position related to prior year 4,587 347 433 Reductions from settlements and statute of limitation expiration ( 1,636 ) ( 1,266 ) $ ( 610 ) Effect of foreign currency translation ( 249 ) 133 ( 275 ) Balance at end of year $ 8,266 $ 5,486 $ 6,185 The Company classifies income tax-related penalties and net interest as income tax expense. In the years ended December 31, 2024, 2023 and 2022 , income tax related interest and penalties were not material. It is reasonably possible that audit settlements, the conclusions of current examinations or the expiration of the statute of limitations in several jurisdictions could impact the Company’s unrecognized tax benefits. A reversal of approximately $ 4,000 is reasonably possible in the next 12 months due to the statute of limitations in various taxing jurisdictions as well as conclusion ongoing tax audits.

Segment Reporting

Segment Reporting	12 Months Ended
	Dec. 31, 2024
Segment Reporting [Abstract]
Segment Reporting	Note 20 — Segment Reporting The Company is organized under two reportable segments: Automotive and Medical. The Automotive reporting segment is comprised of the results from our global automotive businesses, including the design, development, manufacturing and sales of automotive climate and comfort systems, cable systems, battery performance solutions, lumbar and massage comfort solutions, valve systems, and electronic and software systems. The Medical reporting segment is comprised of the results from our patient temperature management business in the medical industry. Patient temperature management includes temperature management systems across multiple product categories addressing the needs of hyper-hypothermia therapy in intensive care, normothermia in surgical procedures and additional warming/cooling therapies utilized in acute and chronic care departments and non-hospital facilities. The Corporate and other unallocated expenses category includes certain enterprise and governance activities resulting in unallocated corporate costs and other activity and net costs that the Company may choose not to allocate directly to its business segments. Segment information is used by management, specifically our chief operating decision maker ("CODM"), the President and Chief Executive Officer , for making operating decisions for the Company. Our CODM uses operating income or loss to evaluate the performance and allocate resources for each of the Company’s segments. Operating income or loss is used to monitor budget versus actual results and year-over-year actual results to inform the decisions of how to allocate capital and resources within the Company. The measure of assets has not been disclosed for each segment as it is not regularly reviewed by the CODM. The table below presents segment information about the reported product revenues, operating income (loss), and significant segment expenses of the Company for the years ended December 31, 2024, 2023 and 2022: Year Ended December 31, Product Revenues 2024 2023 2022 Automotive $ 1,406,278 $ 1,422,952 $ 1,161,616 Medical 49,846 46,124 43,040 Total 1,456,124 1,469,076 1,204,656 Significant Segment Expenses and Operating Performance Automotive Cost of sales 1,058,989 1,090,941 898,260 Net research and development expenses 68,787 70,778 75,137 Selling, general and administrative expenses 65,924 72,090 62,858 Restructuring expenses, net 12,238 3,187 637 Impairment of intangible assets and property and equipment — — 6,291 Automotive operating income 200,340 185,956 118,433 Medical Cost of sales 25,868 24,619 24,938 Other operating expenses 21,836 24,230 22,131 Impairment of intangible assets and property and equipment 2,501 19,509 — Medical operating loss ( 359 ) ( 22,234 ) ( 4,029 ) Corporate and Other Unallocated Expenses Corporate and other unallocated expenses ( 92,966 ) ( 86,283 ) ( 66,097 ) Total consolidated operating income $ 107,015 $ 77,439 $ 48,307 Other Segment Disclosures Depreciation and Amortization Automotive $ 47,752 $ 45,845 $ 39,815 Medical 3,542 3,654 3,344 Corporate and other unallocated expenses 1,681 1,449 1,235 Total $ 52,975 $ 50,948 $ 44,394 Automotive and Medical segment product revenues by product category for each of the years ended December 31, 2024, 2023 and 2022 are as follows: Year Ended December 31, 2024 2023 2022 Climate Control Seat $ 468,820 $ 482,665 $ 426,046 Seat Heaters 297,866 308,588 283,970 Lumbar and Massage Comfort Solutions (a) 178,584 144,923 56,980 Steering Wheel Heaters 169,763 153,943 120,949 Valve Systems (a) 105,056 106,262 41,980 Automotive Cables 73,091 79,993 76,962 Battery Performance Solutions 58,183 75,484 71,907 Electronics 33,065 40,387 44,106 Other Automotive 21,850 30,707 38,716 Subtotal Automotive segment 1,406,278 1,422,952 1,161,616 Medical segment (a) 49,846 46,124 43,040 Total Company $ 1,456,124 $ 1,469,076 $ 1,204,656 (a) Includes product revenues from acquisitions since their respective acquisition dates (see Note 4). Revenue (based on shipment destination) by geographic area for each of the years ended December 31, 2024, 2023 and 2022 is as follows: Year Ended December 31, 2024 2023 2022 United States $ 504,444 $ 537,096 $ 472,468 China 224,221 221,512 183,419 Germany 105,927 102,383 75,367 South Korea 104,120 115,854 94,937 Czech Republic 78,785 69,714 49,293 Slovakia 55,085 44,946 34,686 Japan 53,730 60,879 57,718 Romania 52,616 53,982 47,532 Mexico 43,327 45,733 23,233 United Kingdom 41,098 34,765 22,380 Other 192,771 182,212 143,623 Total Non-U.S. 951,680 931,980 732,188 Total Company $ 1,456,124 $ 1,469,076 $ 1,204,656 Property and equipment, net, for each of the geographic areas in which the Company operates as of December 31, 2024 and 2023 is as follows: December 31, Property and equipment, net 2024 2023 Mexico $ 47,814 $ 39,943 China 44,767 45,429 United States 42,928 37,413 Germany 42,457 46,586 North Macedonia 25,374 27,675 Vietnam 20,920 21,664 Czech Republic 9,440 11,126 Hungary 7,994 9,097 Ukraine 5,174 5,986 Other 6,102 315 Total $ 252,970 $ 245,234

Valuation and Qualifying Accoun

Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2024
SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]
Valuation and Qualifying Accounts	SCHEDULE II — VALUATION AND QUALIFYING ACCOUNTS For the Years Ended December 31, 2024, 2023 and 2022 (In thousands) Description Balance at Charged to Other Activity Deductions Balance at Allowance for Deferred Income Tax Assets Year Ended December 31, 2022 $ 16,090 $ 2,482 $ 18,099 a $ — $ 36,671 Year Ended December 31, 2023 36,671 ( 1,746 ) 963 — 35,888 Year Ended December 31, 2024 35,888 ( 12,004 ) 1,388 — 25,272 Reserve for Inventory Year Ended December 31, 2022 $ 6,014 $ 15,923 $ ( 133 ) $ ( 2,558 ) $ 19,246 Year Ended December 31, 2023 19,246 6,867 3,876 ( 1,972 ) 28,017 Year Ended December 31, 2024 28,017 6,437 ( 346 ) ( 13,166 ) 20,942 (a) Includes amount relates to valuation allowance from acquisitions.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries and those entities in which it has a controlling financial interest. The Company evaluates its relationship with other entities for consolidation and to identify whether such entities are variable interest entities (“VIE”) and to assess whether the Company is the primary beneficiary of such entities. Investments in affiliates in which Gentherm does not have control but does have the ability to exercise significant influence over operating and financial policies are accounted for under the equity method. When Gentherm does not have the ability to exercise significant influence (generally when ownership interest is less than 20 %), investments in affiliates are measured at cost, less impairments, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. Intercompany transactions and balances between consolidated businesses have been eliminated.
Use of Estimates	Use of Estimates In preparing these consolidated financial statements, management was required to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. These estimates and assumptions are based on our historical experience, the terms of existing contracts, our evaluation of trends in the industry, information provided by our customers and suppliers and information available from other outside sources, as appropriate. These estimates and assumptions are subject to an inherent degree of uncertainty. We are not presently aware of any events or circumstances that would require us to update such estimates and assumptions or revise the carrying value of our assets or liabilities. Our estimates may change, however, as new events occur and additional information is obtained. As a result, actual results may differ significantly from our estimates, and any such differences may be material to our financial statements.
Business combinations	Business Combinations In accordance with ASC Topic 805, “Business Combinations,” acquisitions are recorded using the acquisition method of accounting. The Company includes the operating results of acquired entities from their respective dates of acquisition. The Company recognizes and measures the identifiable assets acquired, liabilities assumed, and any non-controlling interest as of the acquisition date fair value. The excess, if any, of total consideration transferred in a business combination over the fair value of identifiable assets acquired, liabilities assumed and any non-controlling interest is recognized as goodwill. Costs incurred as a result of a business combination other than costs related to the issuance of debt or equity securities are recorded in the period the costs are incurred. During the measurement period, which may be up to one year from the acquisition date, the Company may record adjustments to assets acquired and liabilities assumed with the corresponding offset to goodwill.
Revenue Recognition	Revenue Recognition Revenue is recognized from agreements containing enforceable rights and obligations, when promised goods are delivered or services are completed. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by the Company from a customer, are excluded from product revenues. Shipping and handling fees billed to customers are included in product revenues, while costs of shipping and handling are included in cost of sales. Automotive Revenues The Company generates revenue from the production of automotive parts sold to its customers under long-term supply agreements (“LTAs”). The duration of an LTA is generally consistent with the life cycle of a vehicle; however, a LTA does not reach the level of a performance obligation until Gentherm receives either a purchase order and/or a materials release from its customer for a specific number of production parts at a specified price, at which point an enforceable contract exists. Revenue is recognized when control of the production parts has transferred to the customer according to the terms of the contract, which typically occurs at a point in time when the parts are shipped or delivered to the customer’s premises. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring production parts. Transaction price is determined based on the price and quantity of parts specified in the contract with the customer at the time of shipment, adjusted for discrete price adjustments and consideration payable to a customer. Discrete price reductions may occur to remain competitive with market prices. These price reductions are negotiated based on changes in product specifications, product content/cost or other commercial factors. Some of these amounts include estimates of variable consideration which are recorded at the most likely amount to which the Company expects to be entitled based on historical experience and input from customer negotiations. From time to time, the Company provides cash incentives to customers in exchange for new business awards. The Company evaluates the underlying economics of each amount of consideration payable to a customer to determine the proper accounting by understanding the reasons for the payment, the rights and obligations resulting from the payment, the nature of the promises in the contract, and other relevant facts and circumstances. When the Company concludes that the payment is incurred only if the new business is obtained and the Company expects to recover the amounts from the customer over the term of the new business arrangement, the Company recognizes these payments as an asset. The Company amortizes the asset as a reduction of revenue as products related to the payment are transferred to the customer, based on the total amount of products expected to be sold over the term of the arrangement (generally 5 to 10 years following start of production). The Company evaluates the amounts capitalized each reporting period for recoverability and recognizes a reduction of revenue for any amounts that are no longer expected to be recovered over the term of the business arrangement. Payments to customers that are not capitalized are recognized as a reduction to revenue at the time of the commitment to make such payments. As of December 31, 2024 and 2023 , total capitalized payments to customers were $ 14,276 and $ 7,305 , respectively. There have been no impairment losses in relation to the costs capitalized. During the year ended December 31, 2024 and 2023 , $ 447 and $ 179 , respectively, was amortized into product revenues. The Company has no material contract assets or contract liabilities as of December 31, 2024. Medical Revenues Revenues from our patient temperature management business unit are generated from the sale of products and equipment. Our medical products and equipment focus on patient temperature management. The Company sells medical products and equipment primarily through distributor and group purchasing organization agreements. These agreements allow member participants to the distributor or group purchasing organization to make purchases at discounted prices negotiated by the distributor or group purchasing organization. A rebate is incurred at the point in time a member participant purchases product covered under these types of agreements. Rebates are accounted for as variable consideration, using an expected value, probability weighted approach, based on the level of sales to the distributor and the time lag between the initial sale and the rebate claim in determining the transaction price of a contract. Revenue is recognized when control of the medical products or equipment has transferred to the customer according to the terms of the contract, which typically occurs at the point in time when the parts are either shipped or delivered to the customer’s premises.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments purchased with original maturities of less than 90 days to be cash equivalents. The Company had cash and cash equivalents of $ 106,905 and $ 125,251 held in foreign jurisdictions as of December 31, 2024 and 2023 , respectively.
Concentration of Credit Risk	Concentration of Credit Risk The following is a summary of the percentage of product revenues and accounts receivable from the Company's customers with a percentage of net sales greater than 10 percent: Percentage of Total Product Revenues Percentage of Total Net Accounts Receivable Year Ended December 31, Year Ended December 31, 2024 2023 2022 2024 2023 Lear 16 % 15 % 16 % 16 % 17 % Adient 11 % 13 % 15 % 11 % 19 %
Accounts Receivable	Accounts Receivable Accounts receivable are stated at the invoiced amount, less allowance for doubtful accounts for estimated amounts not expected to be collected, and do not bear interest. The Company establishes and maintains allowances for the inability or unwillingness of customers to make required payments on their accounts receivable balances. These allowances reflect management's estimate of credit losses over the remaining expected life of such assets, measured primarily using historical write-off experience by industry and regional economic data, as well as current conditions and forecasts that affect the collectability of the reported amount. We write-off accounts receivable when they become uncollectible. As of December 31, 2024 and 2023 , the Company’s accounts receivable are reflected net of reserves of $ 1,605 and $ 1,171 , respectively. Changes in the allowance for doubtful accounts were not significant during the years ended December 31, 2024 and 2023. In the Asia-Pacific region, the Company receives bank notes from certain customers to settle trade receivables. The collection of such bank notes is included in operating cash flows based on the substance of the underlying transactions, which are operating in nature. Bank notes held by the Company are classified as notes receivable within other current assets. The Company may hold such bank notes until maturity, exchange them with suppliers to settle liabilities, or sell them to third-party financial institutions in exchange for cash.
Inventory	Inventory The Company’s inventory is measured at the lower of cost or net realizable value. Raw materials, components and consumables are measured using the weighted average cost method. Work-in-process and finished goods are measured using the first-in first-out method. If the net realizable value expected on the reporting date is below cost, a write-down is recorded to adjust inventory to its net realizable value. We recognize a reserve for obsolete and slow-moving inventories based on estimates of future sales and an inventory item’s capacity to be repurposed for a different use. We consider the number of months' supply on hand based on current planned requirements, uncommitted future projections and historical usage in estimating the inventory reserve.
Property and Equipment	Property and Equipment Property and equipment is recorded at cost less accumulated depreciation. Expenditures for general repairs and maintenance are charged to expense as incurred. When property or equipment is retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the accounts. Gains or losses from retirements and disposals are recorded as operating income or expense. Depreciation is computed using the straight-line method. The estimated useful lives of the Company’s property and equipment are as follows: Asset Category Useful Life Buildings and improvements 1 to 30 years Plant and equipment 10 years Production tooling 2 to 10 years Leasehold improvements Term of lease Information technology 1 to 5 years The Company recognized depreciation expense of $ 45,503 , $ 42,186 and $ 33,730 for the years ended December 31, 2024, 2023 and 2022 , respectively.
Tooling	Tooling The Company incurs costs related to tooling used in the manufacture of products sold to its customers. In some cases, the Company enters into contracts with its customers whereby the Company incurs the costs to design, develop and purchase tooling and is then reimbursed by the customer under a reimbursement contract. Tooling costs that will be reimbursed by customers are included in other current assets in the accompanying consolidated balance sheets at the lower of accumulated cost or the customer reimbursable amount. As of December 31, 2024 and 2023 , the Company had $ 19,740 and $ 16,877 , respectively, of reimbursable tooling costs capitalized. Company-owned tooling is included in property and equipment and depreciated over its expected useful life, generally two to ten years .
Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets Goodwill and other intangible assets recorded in conjunction with business combinations are based on the Company’s estimate of fair value, as of the date of acquisition. Amortization of other intangible assets is computed using the straight-line method. The fair value and corresponding useful lives for acquired intangible assets are listed below as follows: Asset Category Useful Life Customer relationships 8 to 15 years Technology 5 to 12 years Product development costs 5 to 10 years Trade names Indefinite Software development costs 4 to 5 years Our business strategy largely centers on designing products based upon internally developed and purchased technology, and we protect certain technology with patents that have value to our business strategy. All costs associated with the development and issuance of new patents are expensed as incurred. Such costs are classified as net research and development expenses in the accompanying consolidated statements of income.
Valuation of long-lived assets	Valuation of Long-lived Assets The carrying value of long-lived assets held for use, including definite-lived intangible assets, is periodically evaluated when events or circumstances warrant such a review. The carrying value of a long-lived asset held for use is considered impaired when the anticipated separately identifiable undiscounted cash flows from the asset are less than the carrying value of the asset. In that event, a loss is recognized based on the amount by which the carrying value exceeds the estimated fair value of the long-lived asset. Impairment losses on long-lived assets held for sale are recognized if the carrying value of the asset is in excess of the asset’s estimated fair value, reduced for the cost to dispose of the asset.
Impairments of Other Intangible Assets and Goodwill	Impairments of Other Intangible Assets and Goodwill Goodwill is tested for impairment at least annually as of December 31 and whenever events or changes in circumstances indicate that the carrying value may not be recoverable. In conducting our annual impairment assessment testing, we first perform a qualitative assessment of whether it is more likely than not that a reporting unit’s fair value is less than its carrying amount. If not, no further goodwill impairment testing is performed. If it is more likely than not that a reporting unit’s fair value is less than its carrying amount, or if we elect not to perform a qualitative assessment of a reporting unit, we then compare the fair value of the reporting unit to the related net book value. If the net book value of a reporting unit exceeds its fair value, an impairment loss is measured and recognized. The Company utilizes an income approach to estimate the fair value of a reporting unit and a market valuation approach to further support this analysis (level 3). The income approach is based on projected debt-free cash flow that is discounted to the present value using discount factors that consider the timing and risk of cash flows. We believe that this approach is appropriate because it provides a fair value estimate based on the reporting unit’s expected long-term operating cash flow performance. This approach also mitigates the impact of cyclical trends that occur in our industry. Fair value is estimated using internally developed forecasts, as well as commercial and discount rate assumptions. The discount rate used is the value-weighted average of our estimated cost of equity and of debt (“cost of capital”) derived using both known and estimated customary market metrics. Our weighted average cost of capital is adjusted to reflect risk, if necessary. Other significant assumptions include terminal value growth rates and terminal value margin rates. While there are inherent uncertainties related to the assumptions used and to management’s application of these assumptions to this analysis, we believe that the income approach provides a reasonable estimate of the fair value of a reporting unit. The Company performs its indefinite-lived intangible asset impairment assessment annually as of December 31, and between annual assessments if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount. See Note 7, "Goodwill and Other Intangibles," for additional information about the goodwill impairment analysis.
Investments in Non-Consolidated Affiliates	Investments in Non-consolidated Affiliates During 2021, the Company’s Automotive segment invested $ 5,200 for an ownership interest in Carrar Ltd. (“Carrar”), an Israel-based technology developer of advanced thermal management systems for the electric mobility market. In June 2023, the Company made an additional investment in Carrar of $ 500 . In December 2023, we recorded a non-cash impairment charge of $ 2,900 in other income (loss). In 2024 there was an increase in the fair value of the Company's investment in Carrar of $ 1,097 due to observable transactions, resulting in a carrying value of $ 3,897 as of December 31, 2024. The Company determined that Carrar is a VIE; however, the Company does not have a controlling financial interest or have the power to direct the activities that most significantly affect the economic performance of the investment. Therefore, the Company has concluded that it is not the primary beneficiary. Gentherm’s investment in Carrar is measured at cost, less impairments, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer, and is recorded in other non-current assets. During 2021, the Company’s Automotive segment invested $ 2,357 for an ownership interest in Forciot Oy (“Forciot”), a Finland-based technology developer of sensors for touch, motion and force measurement. Gentherm’s investment in Forciot is measured at cost, less impairments, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer, and is recorded in other non-current assets. In December 2021, the Company committed to make a $ 5,000 investment in Autotech Fund III, L.P., pursuant to a limited partnership agreement. As a limited partner, the Company will periodically make capital contributions toward this total commitment amount over the expected ten-year life of the fund. The Company has made contributions totaling approximately $ 1,765 to the Autotech Fund III, L.P. as of December 31, 2024 . This fund focuses broadly on the automotive industry and compliments the Company’s innovation strategy.
Research and Development Expenses	Research and Development Expenses Research and development activities are expensed as incurred. Such costs and related reimbursements are classified as net research and development expenses in the accompanying consolidated statements of income.
Leases	Leases The Company determines whether a contractual arrangement is or contains a lease at contract inception. A lease liability and corresponding right-of-use asset are measured and recognized based on the present value of lease payments. To determine the present value of lease payments, the Company uses its incremental borrowing rate as of the lease commencement date, unless there is a rate implicit in the lease agreement. The incremental borrowing rate is based on the Company’s credit rating, determined on a fully collateralized loan basis from information available at commencement date, and the duration of the lease term (the “reference rate”). For leases at foreign subsidiaries denominated in U.S. Dollars, a risk premium associated with the borrower subsidiary’s country is added to the reference rate. For significant leases at foreign subsidiaries denominated in a foreign currency, the U.S. Dollar risk free rate with a duration similar to that of the lease term is subtracted from the reference rate and a corresponding foreign currency risk free rate with a duration similar to that of the lease term is added to the reference rate. Operating lease assets are included in operating lease right-of-use assets and the related liabilities are included in current lease liabilities and non-current lease liabilities in the accompanying consolidated balance sheets. Assets under finance leases are included in property and equipment, net, and the related liabilities are included in current maturities of long-term debt, and long-term debt on the Company’s consolidated balance sheets. For all classes of underlying assets, the Company accounts for leases that contain separate lease and non-lease components as containing a single lease component. The Company does not recognize lease right-of-use assets and lease liabilities from leases with an original lease term of 12 months or less and, instead, recognizes rent payments on a straight-line basis over the lease term in the consolidated statements of income.
Income Taxes	Income Taxes The Company records income tax expense using the liability method which specifies that deferred tax assets and liabilities be measured each year based on the difference between the financial statement and tax base of assets and liabilities at the applicable enacted tax rates. A valuation allowance is provided for deferred tax assets when management considers it more likely than not that the asset will not be realized. At December 31, 2024 and 2023, a valuation allowance has been provided for certain deferred tax assets which the Company has concluded are more likely than not to not be realized. If future annual taxable income were to be significantly less than current and projected levels, there is a risk that certain of our deferred tax assets not already provided for by the valuation allowance would expire prior to utilization. The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognizes interest and penalties related to income tax matters in income tax expense.
Derivative Financial Instruments - Hedge Accounting	Derivative Financial Instruments – Hedge Accounting All derivative instruments are required to be reported on the balance sheet at fair value unless the transactions qualify and are designated as normal purchases or sales. Changes in fair value are reported currently through earnings unless they meet hedge accounting criteria. The Company’s designated hedging relationships are formally documented at the inception of the hedge, and hedges must be highly effective in offsetting changes to future cash flows on hedged transactions both at the inception of a hedge and on an ongoing basis to be designated for hedge accounting treatment. The Company accounts for its designated derivative financial instruments as cash flow hedges. For derivative contracts which are designated as a cash flow hedge, the effective portion of the change in the fair value of the derivative contract is recorded to accumulated other comprehensive loss (“AOCI”) in the accompanying consolidated balance sheets. When the underlying hedge transaction is realized, the gain or loss included in AOCI is recorded into earnings in the accompanying consolidated statements of income on the same line as the gain or loss on the hedged item attributable to the hedged risk. Any ineffective portion of the gain or loss is recognized in the accompanying consolidated statements of income under cost of goods sold for foreign currency derivatives and commodity derivatives. These hedging transactions and the respective correlations meet the requirements for hedge accounting. Exposure to fluctuations in interest rates and certain commodity prices are managed by entering into swaps with various counterparties. The Company does not enter into derivative transactions for speculative or trading purposes. As part of the hedging program approval process, Gentherm identifies the specific financial risk which the derivative transaction will minimize, the appropriate hedging instrument to be used to reduce the risk and the correlation between the financial risk and the hedging instrument. Hedge positions, as well as the correlation between the transaction risks and the hedging instruments, are reviewed on an ongoing basis.
Earnings Per Share	Earnings per Share Basic earnings per share is computed by dividing net income by the weighted average number of shares of the Company's common stock, no par value ("Common Stock") outstanding during the respective period. The Company’s diluted earnings per share give effect to all potential shares of Common Stock outstanding during a period that do not have an anti-dilutive impact to the calculation. In computing the number of diluted shares outstanding, the treasury stock method is used in order to arrive at a net number of shares created upon the conversion of Common Stock equivalents.
Stock Based Compensation	Stock Based Compensation Stock based payments that involve the issuance of Common Stock to employees, including grants of employee stock options, restricted stock, and time-based and performance-based restricted stock units, are recognized in the consolidated financial statements as compensation expense based upon the fair value on the date of grant. Stock based payments that are satisfied only by the payment of cash, such as stock appreciation rights, are accounted for as liabilities. The liability is reported at market value of the vested portion of the underlying units. During each period, the change in the liability is recorded as compensation expense.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements Segment Reporting In November 2023, the FASB issued ASU 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures". ASU 2023-07 requires a public entity to disclose, on an annual and interim basis, significant segment expenses that are included within each reported measure of segment profit or loss and regularly reviewed by the chief operating decision maker ("CODM"), the title and position of the CODM, clarification regarding the CODM's use of multiple measures of a segment's profit or loss in assessing segment performance (this must include a measure that is consistent with the measurement principles under GAAP, but may also include additional measures of a segment's profit or loss), and a description of the composition of amounts within an "Other" segment line item. Further, ASU 2023-07 requires that all annual disclosures about a reportable segment's profit or loss and assets currently required by Topic 280 to be provided in interim periods. The Company adopted ASU 2023-07 as of December 31, 2024. See Note 20, “Segment Reporting” for the disclosures related to the adoption of ASU 2023-07.
Recently Issued Accounting Pronouncements Not Yet Adopted	Recently Issued Accounting Pronouncements Not Yet Adopted Income Taxes In December 2023, the FASB issued ASU 2023-09, "Income Taxes (Topic 740): Improvements to Income Tax Disclosures". ASU 2023-09 enhances income tax disclosures to further disaggregate the effective tax rate reconciliation and income taxes paid. This update is effective for fiscal years beginning after December 15, 2024. ASU 2023-09 should be adopted prospectively, but retrospective application is permitted. Further, early adoption is permitted. We are currently in the process of determining the impact the implementation of ASU 2023-09 will have on the Company’s financial statement disclosures. Disaggregation of Income Statement Expenses In November 2024, the FASB issued ASU 2024-03, "Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40) ". ASU 2024-03 enhances disclosures around certain costs and expenses. This update is effective for annual reporting periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027. ASU 2024-03 should be adopted retrospectively to all periods presented in the financial statements and early adoption is permitted. We are currently in the process of determining the impact the implementation of ASU 2024-03 will have on the Company’s financial statement disclosures.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Summary of Percentage of Product Revenues and Accounts Receivable	The following is a summary of the percentage of product revenues and accounts receivable from the Company's customers with a percentage of net sales greater than 10 percent: Percentage of Total Product Revenues Percentage of Total Net Accounts Receivable Year Ended December 31, Year Ended December 31, 2024 2023 2022 2024 2023 Lear 16 % 15 % 16 % 16 % 17 % Adient 11 % 13 % 15 % 11 % 19 %
Estimated Useful Lives of Property and Equipment	Depreciation is computed using the straight-line method. The estimated useful lives of the Company’s property and equipment are as follows: Asset Category Useful Life Buildings and improvements 1 to 30 years Plant and equipment 10 years Production tooling 2 to 10 years Leasehold improvements Term of lease Information technology 1 to 5 years
Fair Value and Corresponding Useful Lives for Acquired Intangibles Assets	Amortization of other intangible assets is computed using the straight-line method. The fair value and corresponding useful lives for acquired intangible assets are listed below as follows: Asset Category Useful Life Customer relationships 8 to 15 years Technology 5 to 12 years Product development costs 5 to 10 years Trade names Indefinite Software development costs 4 to 5 years

Restructuring (Tables)

Restructuring (Tables)	12 Months Ended
	Dec. 31, 2024
Restructuring and Related Activities [Abstract]
Summary of Restructuring Expenses, Net by Reportable Segment	Restructuring expenses, net by reporting segment for the years ended December 31, 2024, 2023 and 2022 was as follows: Year Ended December 31, 2024 2023 2022 Automotive $ 12,238 $ 3,187 $ 637 Medical 20 363 — Corporate 852 1,189 — Total $ 13,110 $ 4,739 $ 637
Summary of Restructuring Activity for All Restructuring Initiatives	The following table summarizes restructuring activity for all restructuring initiatives for the years ended December 31, 2024 and 2023: Employee Separation Costs Other Related Costs, net (a) Total Balance at December 31, 2022 $ 588 $ — $ 588 Additions, charged to restructuring expenses, net 3,892 993 4,885 Change in estimate ( 146 ) — ( 146 ) Cash payments ( 2,224 ) ( 878 ) ( 3,102 ) Non-cash utilization — ( 115 ) ( 115 ) Currency translation and other 40 — 40 Balance at December 31, 2023 $ 2,150 $ — $ 2,150 Additions, charged to restructuring expenses, net 10,896 2,214 13,110 Cash payments ( 9,593 ) ( 1,333 ) ( 10,926 ) Non-cash utilization — ( 881 ) ( 881 ) Currency translation and other ( 165 ) — ( 165 ) Balance at December 31, 2024 $ 3,288 $ — $ 3,288 (a) Includes gain on sale of the Greenville facility

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2024
Alfmeier
Business Acquisition [Line Items]
Summary of Product Revenues and Operating Income	The following table provides product revenues and operating income from Alfmeier that are included in our consolidated financial statements for the year ended December 31, 2022, following the August 1, 2022 acquisition date: Year Ended December 31, 2022 Product revenues $ 98,960 Net loss ( 2,675 )
Summary of Unaudited Pro Forma Information	The following unaudited pro forma information represents our product revenues and net income as if the acquisition of Alfmeier had occurred as of January 1, 2022: Year Ended December 31, 2022 Product revenues $ 1,348,295 Net income 17,645
Dacheng
Business Acquisition [Line Items]
Summary of Product Revenues and Operating Income	The results of Dacheng's operations are reported within the Medical segment from the acquisition date. The following table provides product revenues and operating income from Dacheng that are included in our consolidated financial statements for the year ended December 31, 2022, following the July13, 2022 acquisition date: Year Ended December 31, 2022 Product revenues $ 3,499 Net loss ( 217 )

Details of Certain Financial _2

Details of Certain Financial Statement Components (Tables)	12 Months Ended
	Dec. 31, 2024
Financial Statement Components [Abstract]
Details of Certain Financial Statement Components	December 31, 2024 2023 Inventory: Raw materials, net $ 137,511 $ 126,013 Work in process, net 19,059 15,704 Finished goods, net 70,786 64,175 Total inventory, net $ 227,356 $ 205,892 Other current assets: Income tax and other tax receivable $ 20,611 $ 16,017 Billable tooling 19,740 16,877 Notes receivable 11,190 18,226 Prepaid expenses 6,305 7,889 Receivables due from factor 1,111 4,422 Short-term derivative financial instruments 719 10,717 Other 4,737 4,272 Total other current assets $ 64,413 $ 78,420 Property and equipment: Machinery and equipment $ 260,578 $ 236,277 Buildings and improvements 117,953 130,374 Information technology 45,157 41,543 Production tooling 37,765 28,033 Leasehold improvements 23,262 12,269 Construction in progress 36,846 27,461 Total property and equipment 521,561 475,957 Less: accumulated depreciation ( 268,591 ) ( 230,723 ) Total property and equipment, net $ 252,970 $ 245,234 Other current liabilities: Accrued employee liabilities $ 42,277 $ 43,176 Income tax and other taxes payable 26,385 19,327 Liabilities from discounts and rebates 20,501 22,916 Restructuring 3,288 2,150 Accrued warranty 3,507 3,945 Short-term derivative financial instruments 2,037 — Other 7,829 9,291 Total other current liabilities $ 105,824 $ 100,805

Goodwill and Other Intangibles

Goodwill and Other Intangibles (Tables)	12 Months Ended
	Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Changes in the Carrying Amount of Goodwill, By Reportable Segment	Changes in the carrying amount of goodwill, by reportable segment, for the years ended December 31, 2024 and 2023 were as follows: Automotive Medical Total Balance as of December 31, 2022 $ 73,069 $ 46,705 $ 119,774 Impairment of goodwill — ( 19,509 ) ( 19,509 ) Currency translation and other 3,627 181 3,808 Balance as of December 31, 2023 $ 76,696 $ 27,377 $ 104,073 Currency translation and other ( 3,942 ) ( 528 ) ( 4,470 ) Balance as of December 31, 2024 $ 72,754 $ 26,849 $ 99,603
Summary of Other Intangible Assets and Accumulated Amortization Balances	Other intangible assets and accumulated amortization balances as of December 31, 2024 and 2023 were as follows: Gross Accumulated Accumulated Net Carrying Definite-lived: Customer relationships $ 109,608 $ ( 67,787 ) $ ( 5,477 ) $ 36,344 Technology 43,458 ( 29,976 ) ( 24 ) 13,458 Product development costs 18,019 ( 17,849 ) — 170 Software development 1,007 ( 201 ) — 806 Indefinite-lived: Tradenames 7,003 — ( 530 ) 6,473 Balance as of December 31, 2024 $ 179,095 $ ( 115,813 ) $ ( 6,031 ) $ 57,251 Gross Accumulated Accumulated Net Carrying Definite-lived: Customer relationships $ 115,465 $ ( 67,923 ) $ ( 5,814 ) $ 41,728 Technology 45,861 ( 29,292 ) ( 25 ) 16,544 Product development costs 19,434 ( 19,270 ) — 164 Software development 1,007 — — 1,007 Indefinite-lived: Tradenames 7,039 — — 7,039 Balance as of December 31, 2023 $ 188,806 $ ( 116,485 ) $ ( 5,839 ) $ 66,482
Summary of Estimate of Future Amortization of Other Intangible Assets	An estimate of future amortization of other intangible assets, is as follows: 2025 $ 6,860 2026 6,424 2027 6,337 2028 6,276 2029 5,598

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2024
Leases [Abstract]
Components of Lease Expense and Other Information	Components of lease expense for the years ended December 31, 2024, 2023 and 2022 were as follows: Year Ended December 31, 2024 2023 2022 Lease cost: Operating lease cost $ 10,747 $ 9,606 $ 8,040 Amortization of ROU assets - finance leases 370 390 168 Interest on lease liabilities - finance leases 14 28 16 Short-term lease cost 3,684 2,651 1,773 Sublease income — — ( 101 ) Total lease cost $ 14,815 $ 12,675 $ 9,896 Other information related to leases is as follows: Year Ended December 31, 2024 2023 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases $ 10,428 $ 9,249 Operating cash flows for finance leases 14 81 Financing cash flows for finance leases 383 390 Right-of-use lease assets obtained in exchange for lease obligations: Operating leases $ 30,720 $ 4,704 December 31, 2024 December 31, 2023 Weighted average remaining lease term: Operating leases 9.3 years 5.6 years Finance leases 1.5 years 1.9 years Weighted average discount rate: Operating leases 6.09 % 4.96 % Finance leases 3.46 % 3.53 %
Summary of Operating Leases Under all Non-Cancellable Operating Leases	A summary of operating leases as of December 31, 2024, under all non-cancellable operating leases with terms exceeding one year is as follows: 2025 $ 9,285 2026 7,450 2027 5,701 2028 5,208 2029 4,911 2030 or later 26,593 Total future minimum lease payments 59,148 Less imputed interest ( 14,579 ) Total $ 44,569
Summary of Finance Leases Under all Non-Cancellable Finance Leases	A summary of finance leases as of December 31, 2024, under all non-cancellable finance leases with terms exceeding one year is as follows: 2025 $ 137 2026 64 Total $ 201

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2024
Debt Disclosure [Abstract]
Summary of Company's Debt	The following table summarizes the Company’s debt as of December 31, 2024 and 2023: December 31, 2024 2023 Interest Principal Interest Principal Credit Agreement: U.S. Revolving Note (U.S. Dollar denominations) 5.86 % $ 220,000 6.58 % $ 222,000 Other loans — — 3.90 % 233 Finance leases 3.46 % 201 3.53 % 605 Total debt 220,201 222,838 Current maturities ( 137 ) ( 621 ) Long-term debt, less current maturities $ 220,064 $ 222,217
Principal Maturities of Debt	The scheduled principal maturities of our debt as of December 31, 2024 were as follows: U.S. Other Debt Total 2025 $ — $ 137 $ 137 2026 — 64 64 2027 220,000 — 220,000 2028 — — — 2029 — — — Total $ 220,000 $ 201 $ 220,201

Pension and Other Post Retire_2

Pension and Other Post Retirement Benefit Plans (Tables)	12 Months Ended
	Dec. 31, 2024
Retirement Benefits [Abstract]
Components of Net Periodic Benefit Cost for Company's Defined Benefit Plans	The components of net periodic benefit cost for the Company’s defined benefit plans for the years ended December 31, 2024, 2023 and 2022 were as follows: U.S. Plan German Plan Year Ended December 31, Year Ended December 31, 2024 2023 2022 2024 2023 2022 Net periodic benefit cost: Service cost $ — $ — $ — $ — $ — $ — Interest cost 101 115 56 234 217 92 Expected return on plan assets — — — ( 130 ) ( 115 ) ( 109 ) Amortization of prior service cost and actuarial loss — — 22 19 23 114 Net periodic benefit cost $ 101 $ 115 $ 78 $ 123 $ 125 $ 97 Assumptions: Discount rate 4.45 % 4.65 % 1.80 % 4.56 % 4.10 % 1.08 % Long-term return on assets N/A N/A N/A 3.20 % 3.20 % 2.90 %
Reconciliation of Change in Benefit Obligation, Change in Plan Assets and Balance Sheet Classification	A reconciliation of the change in benefit obligation and the change in plan assets for the years ended December 31, 2024 and 2023 is as follows: U.S. Plan German Plan As of December 31, As of December 31, 2024 2023 2024 2023 Change in projected benefit obligation: Balance at beginning of year $ 2,602 $ 2,811 $ 5,406 $ 5,398 Interest cost 101 115 234 217 Paid pension distributions ( 342 ) ( 342 ) ( 256 ) ( 290 ) Actuarial (gain) loss ( 30 ) 18 1,259 ( 89 ) Exchange rate impact — — ( 362 ) 170 Balance at end of year $ 2,331 $ 2,602 $ 6,281 $ 5,406 Change in plan assets: Balance at beginning of year $ — $ — $ 4,145 $ 3,918 Actual return on plan assets — — 104 98 Contributions — — — — Paid pension distributions — — — — Exchange rate impact — — ( 244 ) 129 Balance at end of year $ — $ — $ 4,005 $ 4,145 Underfunded Status $ ( 2,331 ) $ ( 2,602 ) $ ( 2,276 ) $ ( 1,261 ) Balance sheet classification: Other current liabilities $ ( 342 ) $ ( 357 ) $ ( 248 ) $ ( 297 ) Pension benefit obligation ( 1,989 ) ( 2,245 ) ( 2,028 ) ( 964 ) Accumulated other comprehensive loss (pre-tax): Actuarial losses 194 223 2,063 899 Assumptions: Discount rate 4.85 % 4.45 % 3.38 % 4.56 %
Summary of Pre-tax Amounts in AOCI Expected to Be Recognized in Net Periodic Benefit Cost	Pre-tax amounts included in AOCI that are expected to be recognized in net periodic benefit cost during the year ended December 31, 2025 are as follows: U.S Plan German Plan Actuarial losses $ — $ 71
Summary of Accumulated Benefit Obligations	The accumulated benefit obligations were as follows: U.S. Plan German Plan As of December 31, As of December 31, 2024 2023 2024 2023 Accumulated benefit obligation $ 2,331 $ 2,602 $ 6,281 $ 5,406
Schedule of Future Expected Pension Payments	The schedule of future expected pension payments is as follows: Projected Pension Year U.S Plan German Plan 2025 $ 342 $ 248 2026 342 249 2027 342 249 2028 342 247 2029 342 1,628 2030-2033 1,026 1,565 Total $ 2,736 $ 4,186

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Reconciliation of Changes in Accrued Warranty Costs	The following is a reconciliation of the changes in accrued warranty costs: Year Ended December 31, 2024 2023 Balance at beginning of year $ 3,945 $ 2,380 Warranty claims paid ( 6,382 ) ( 2,252 ) Warranty expense for products shipped during the current period 5,812 3,955 Adjustments to warranty estimates from prior periods 247 ( 174 ) Adjustments due to currency translation ( 115 ) 36 Balance at end of year $ 3,507 $ 3,945

Supplier Finance Program (Table

Supplier Finance Program (Tables)	12 Months Ended
	Dec. 31, 2024
Payables and Accruals [Abstract]
Summary of Reconciliation of Changes in Confirmed Obligations to Participating Suppliers	The following is a reconciliation of the changes in confirmed obligations to participating suppliers: Year Ended December 31, 2024 Outstanding at beginning of year $ — Invoices confirmed 90,343 Invoices settled ( 69,111 ) Outstanding at end of year $ 21,232

Earnings Per Share (Tables)

Earnings Per Share (Tables)	12 Months Ended
	Dec. 31, 2024
Earnings Per Share [Abstract]
Earnings per Share and Weighted Average Shares Outstanding Used in Calculating Basic and Diluted Earnings per Share	The following table illustrates earnings per share and the weighted average shares outstanding used in calculating basic and diluted earnings per share: Year Ended December 31, 2024 2023 2022 Net income $ 64,947 $ 40,343 $ 24,441 Basic weighted average shares of Common Stock outstanding 31,293,113 32,778,055 33,126,202 Dilutive effect of stock options, restricted stock awards and restricted stock units 183,373 288,862 376,952 Diluted weighted average shares of Common Stock outstanding 31,476,486 33,066,917 33,503,154 Basic earnings per share $ 2.08 $ 1.23 $ 0.74 Diluted earnings per share $ 2.06 $ 1.22 $ 0.73

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Information Related to Recurring Fair Value Measurement of Derivative Financial Instruments in the Consolidated Balance Sheet	Information related to the recurring fair value measurement of derivative financial instruments in the consolidated balance sheet as of December 31, 2024 is as follows: Asset Derivatives Liability Derivatives Fair Value Notional Amount Balance Sheet Fair Balance Sheet Fair Net Asset/ Derivatives Designated as Cash Flow Hedges Foreign currency derivatives Level 2 $ 126,496 Other current assets $ — Other current liabilities $ 2,037 $ ( 2,037 ) Derivatives Not Designated as Hedging Instruments Interest rate contracts Level 2 $ 100,000 Other current assets $ 719 Other current liabilities $ — $ 719 Information related to the recurring fair value measurement of derivative financial instruments in the consolidated balance sheet as of December 31, 2023 is as follows: Asset Derivatives Liability Derivatives Fair Value Notional Amount Balance Sheet Fair Balance Sheet Fair Net Asset/ Derivatives Designated as Cash Flow Hedges Foreign currency derivatives Level 2 $ 101,109 Other current assets $ 8,655 Other current liabilities $ — $ 8,655 Derivatives Not Designated as Hedging Instruments Interest rate contracts Level 2 $ 100,000 Other current assets $ 2,062 Other current liabilities $ — $ 2,062
Information Related to Effect of Derivative Instruments in the Consolidated Statements of Income	Information related to the effect of derivative instruments in the consolidated statements of income is as follows: Year Ended December 31, Location 2024 2023 2022 Derivatives Designated as Cash Flow Hedges Foreign currency derivatives Cost of sales – income $ 3,717 $ 8,630 $ 1,458 Other comprehensive (loss) income ( 11,259 ) 3,483 3,496 Total foreign currency derivatives $ ( 7,542 ) $ 12,113 $ 4,954 Commodity derivatives Cost of sales – income $ — $ — $ 19 Other comprehensive (loss) income — — ( 6 ) Total commodity derivatives $ — $ — $ 13 Derivatives Not Designated as Hedging Instruments Foreign currency derivatives Foreign currency gain (loss) $ — $ — $ ( 3,806 ) Total foreign currency derivatives $ — $ — $ ( 3,806 ) Interest rate contracts Interest expense, net $ ( 1,343 ) $ ( 710 ) $ 2,772 Total interest rate derivatives $ ( 1,343 ) $ ( 710 ) $ 2,772
Summary of Receivables Factored and Availability Under Receivables Factoring Agreements	Receivables factored and availability under receivables factoring agreements balances as of December 31, 2024 and 2023 were as follows: December 31, 2024 2023 Receivables factored and outstanding (a) $ 755 $ 18,532 (a) During the year ended December 31, 2024, the factoring agreements the Company was party to either expired or were terminated. As of December 31, 2024 there were remaining receivables factored and outstanding that will be collected in the future, however, no further factoring can occur under these factoring agreements.
Summary of Trade Receivables Sold and Factoring Fees Incurred	Trade receivables sold and factoring fees incurred during the years ended December 31, 2024 and 2023 were as follows: Year Ended December 31, 2024 2023 Trade receivables sold $ 98,761 $ 135,116 Factoring fees incurred 615 800

Reclassifications Out of Accu_2

Reclassifications Out of Accumulated Other Comprehensive Loss (Tables)	12 Months Ended
	Dec. 31, 2024
Equity [Abstract]
Schedule of Reclassification Adjustments and Other Activities Impacting Accumulated Other Comprehensive Loss	Reclassification adjustments and other activities impacting accumulated other comprehensive loss during the years ended December 31, 2024, 2023 and 2022 are as follows: Defined Foreign Commodity Hedge Derivatives Foreign Total Balance at December 31, 2023 $ ( 1,011 ) $ ( 34,830 ) $ — $ 5,681 $ ( 30,160 ) Other comprehensive loss before reclassifications ( 1,242 ) ( 45,519 ) — ( 3,648 ) ( 50,409 ) Income tax effect of other comprehensive loss before reclassifications 335 253 — 784 1,372 Amounts reclassified from accumulated other comprehensive loss into net income 91 — — ( 7,611 ) a ( 7,520 ) Income taxes reclassified into net income ( 24 ) — — 1,548 1,524 Net current period other comprehensive loss ( 840 ) ( 45,266 ) — ( 8,927 ) ( 55,033 ) Balance at December 31, 2024 $ ( 1,851 ) $ ( 80,096 ) $ — $ ( 3,246 ) $ ( 85,193 ) (a) The amounts reclassified from accumulated other comprehensive loss are included in cost of sales. See Note 14 for information related to the effect of foreign currency derivative instruments on our consolidated statements of income. Defined Foreign Commodity Hedge Derivatives Foreign Total Balance at December 31, 2022 $ ( 1,067 ) $ ( 48,269 ) $ — $ 2,847 $ ( 46,489 ) Other comprehensive income before reclassifications 54 13,125 — 13,086 26,265 Income tax effect of other comprehensive income before reclassifications ( 15 ) 314 — ( 2,770 ) ( 2,471 ) Amounts reclassified from accumulated other comprehensive loss into net income 23 — — ( 9,603 ) a ( 9,580 ) Income taxes reclassified into net income ( 6 ) — — 2,121 2,115 Net current period other comprehensive income 56 13,439 — 2,834 16,329 Balance at December 31, 2023 $ ( 1,011 ) $ ( 34,830 ) $ — $ 5,681 $ ( 30,160 ) (a) The amounts reclassified from accumulated other comprehensive loss are included in cost of sales. See Note 14 for information related to the effect of foreign currency derivative instruments on our consolidated statements of income. Defined Benefit Foreign Currency Commodity Hedge Derivatives Foreign Currency Total Balance at December 31, 2021 $ ( 2,893 ) $ ( 34,188 ) $ 5 $ 154 $ ( 36,922 ) Other comprehensive income (loss) before reclassifications 2,341 ( 13,786 ) 13 4,954 ( 6,478 ) Income tax effect of other comprehensive income (loss) before reclassifications ( 621 ) ( 295 ) ( 3 ) ( 1,092 ) ( 2,011 ) Amounts reclassified from accumulated other comprehensive loss into net income 137 — ( 19 ) a ( 1,458 ) a ( 1,340 ) Income taxes reclassified into net income ( 31 ) — 4 289 262 Net current period other comprehensive income (loss) 1,826 ( 14,081 ) ( 5 ) 2,693 ( 9,567 ) Balance at December 31, 2022 $ ( 1,067 ) $ ( 48,269 ) $ — $ 2,847 $ ( 46,489 ) (a) The amounts reclassified from accumulated other comprehensive loss are included in cost of sales. See Note 14 for information related to the effect of commodity and foreign currency derivative instruments on our consolidated statements of income.

Accounting for Stock Based Co_2

Accounting for Stock Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2024
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Summary of Recognized and Unrecognized Stock-based Compensation Expense	The total recognized and unrecognized stock based compensation expense is as follows: Stock Based Compensation Expense 2024 2023 2022 Unrecognized Stock Based Compensation Expense at December 31, 2024 Remaining Weighted Average Vesting Period RSUs $ 6,871 $ 6,216 $ 5,551 $ 7,395 1.92 PSUs 2,454 4,661 954 7,795 1.98 Restricted Stock 1,115 878 888 402 0.37 SARs ( 8 ) ( 128 ) ( 794 ) — — Total stock based compensation $ 10,432 $ 11,627 $ 6,599 $ 15,592 1.91
Summary of PSU Activity	The following table summarizes PSU activity during the years ended December 31, 2024, 2023 and 2022: Unvested Performance Stock Units Performance Stock Unit Shares Weighted-Average Outstanding at December 31, 2021 319,336 $ 57.27 Granted 106,604 75.57 Performance Adjustment 42,746 58.30 Vested ( 133,477 ) 52.34 Forfeited ( 14,760 ) 65.02 Outstanding at December 31, 2022 320,449 $ 62.90 Granted 153,121 65.90 Performance Adjustment ( 59,928 ) 33.90 Vested ( 59,928 ) 49.25 Forfeited ( 28,737 ) 65.97 Outstanding at December 31, 2023 324,977 $ 74.10 Granted 235,388 60.68 Performance Adjustment ( 52,856 ) 79.49 Vested ( 27,850 ) 92.44 Forfeited ( 199,818 ) 61.35 Outstanding at December 31, 2024 279,841 $ 63.30
Restricted Stock Activity	The following table summarizes restricted stock activity during the years ended December 31, 2024, 2023 and 2022: Unvested Restricted Stock Shares Weighted-Average Outstanding at December 31, 2021 11,376 $ 70.33 Granted 13,600 73.54 Vested ( 11,376 ) 70.33 Forfeited — — Outstanding at December 31, 2022 13,600 $ 73.54 Granted 17,923 56.96 Vested ( 11,900 ) 73.54 Forfeited ( 1,700 ) 73.54 Outstanding at December 31, 2023 17,923 $ 56.96 Granted 21,296 50.72 Vested ( 17,923 ) 56.96 Forfeited — — Outstanding at December 31, 2024 21,296 $ 50.72
SARs Activity	The following table summarizes SARs activity during the years ended December 31, 2024, 2023 and 2022: Stock Appreciation Rights Shares Weighted-Average Weighted-Average Aggregate Outstanding at December 31, 2021 55,600 $ 41.15 1.28 $ 2,544 Granted — — Exercised ( 40,850 ) 42.27 Forfeited — — Outstanding at December 31, 2022 14,750 $ 38.05 1.15 $ 402 Granted — — Exercised ( 12,500 ) 38.05 Forfeited — — Outstanding at December 31, 2023 2,250 $ 38.05 0.15 $ 32 Granted — — Exercised ( 2,250 ) 38.05 Forfeited — — Outstanding at December 31, 2024 — $ — — $ — Exercisable at December 31, 2024 — $ — — $ —
Summary of Stock Option Activity	The following table summarizes stock option activity during the years ended December 31, 2024, 2023 and 2022: Options Shares Weighted-Average Weighted-Average Aggregate Outstanding at December 31, 2021 206,750 $ 36.72 2.60 $ 10,375 Granted — — Exercised ( 44,116 ) 37.87 Forfeited — — Outstanding at December 31, 2022 162,634 $ 36.41 2.68 $ 8,212 Granted — — Exercised ( 6,450 ) 40.79 Forfeited ( 16,500 ) $ 41.59 Outstanding at December 31, 2023 139,684 $ 35.59 0.90 $ 2,342 Granted — — Exercised ( 139,684 ) 35.59 Forfeited — — Outstanding at December 31, 2024 — $ — — $ — Exercisable at December 31, 2024 — $ — — $ —
RSU
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted Stock Activity	The following table summarizes RSU activity during the years ended December 31, 2024, 2023 and 2022: Unvested Restricted Stock Units Time Vesting Weighted-Average Outstanding at December 31, 2021 193,626 $ 56.02 Granted 117,507 66.86 Vested ( 95,692 ) 49.85 Forfeited ( 13,863 ) 70.52 Outstanding at December 31, 2022 201,578 $ 64.27 Granted 136,964 58.68 Vested ( 82,695 ) 59.43 Forfeited ( 23,986 ) 59.47 Outstanding at December 31, 2023 231,861 $ 63.19 Granted 184,959 54.20 Vested ( 129,477 ) 64.55 Forfeited ( 84,682 ) 57.71 Outstanding at December 31, 2024 202,661 $ 56.35

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2024
Income Tax Disclosure [Abstract]
Earnings Before Income Taxes	The income tax provisions were calculated based upon the following components of earnings before income tax for the years ended December 31, 2024, 2023 and 2022: Year Ended December 31, 2024 2023 2022 (Loss) earnings before income tax: Domestic $ ( 54,073 ) $ ( 37,222 ) $ ( 34,211 ) Foreign 156,338 92,176 72,593 Earnings before income tax $ 102,265 $ 54,954 $ 38,382
Provision for Income Taxes	The components of the provision for income taxes for the years ended December 31, 2024, 2023 and 2022 are summarized as follows: Year Ended December 31, 2024 2023 2022 Current income tax (benefit) expense: Federal $ ( 1,181 ) $ 3,510 $ 3,006 State and local 679 414 650 Foreign 27,240 23,759 17,607 Total current income tax expense 26,738 27,683 21,263 Deferred income tax (benefit) expense: Federal ( 7,944 ) ( 7,495 ) ( 5,971 ) State and local 66 444 ( 213 ) Foreign 18,458 ( 6,021 ) ( 1,138 ) Total deferred income tax expense (benefit) 10,580 ( 13,072 ) ( 7,322 ) Total income tax expense $ 37,318 $ 14,611 $ 13,941
Deferred Tax Assets and Deferred Tax Liabilities	The deferred tax assets and deferred tax liabilities and related valuation allowance were comprised of the following as of December 31, 2024 and 2023: December 31, 2024 2023 Deferred tax assets: Net operating losses $ 35,966 $ 44,053 Intangible assets 10,893 4,314 Research and development credits 5,475 7,127 Property and equipment 4,132 4,800 Valuation reserves and accrued liabilities 8,446 11,221 Capitalized research and development costs 28,318 23,658 Stock compensation 2,039 3,227 Defined benefit obligation 1,514 1,691 Inventory 717 181 Other credits — 8,946 Other 8,707 9,154 Total deferred tax asset 106,207 118,372 Valuation allowance ( 25,272 ) ( 35,888 ) Deferred tax liabilities: Unrealized foreign currency exchange gains $ ( 1,092 ) $ — Undistributed profits of subsidiary ( 5,016 ) ( 4,609 ) Property and equipment ( 10,524 ) ( 12,627 ) Intangible assets ( 8,720 ) — Other ( 1,383 ) ( 1,550 ) Total deferred tax liability ( 26,735 ) ( 18,786 ) Net deferred tax asset $ 54,200 $ 63,698
Reconciliations Between Statutory Federal Income Tax Rate and Effective Rate	Reconciliations between the statutory Federal income tax rate and the effective rate of income tax expense for the years ended December 31, 2024, 2023 and 2022 are as follows: Year Ended December 31, 2024 2023 2022 Statutory Federal income tax rate 21.0 % 21.0 % 21.0 % Increase (decrease) resulting from: Change in valuation allowance ( 9.0 )% ( 3.1 )% 6.4 % Effect of different tax rates of foreign jurisdictions ( 0.7 )% 0.9 % ( 4.9 )% Tax credits & deductions related to R&D ( 3.7 )% ( 8.5 )% ( 10.1 )% Goodwill impairment — 4.1 % — Non-deductible expenses 15.7 % 6.8 % 14.9 % Non-deductible expenses related to acquisitions — — 7.0 % Other foreign, state and local taxes 2.1 % 3.5 % 0.7 % Tax impact of foreign income 7.5 % 3.6 % 4.2 % Stock option compensation 1.0 % — ( 3.8 )% Audit settlements and statute expirations 11.0 % — — Incentive tax rates in foreign jurisdictions ( 5.5 )% ( 1.9 )% — Other ( 2.9 )% 0.2 % 0.9 % Effective rate 36.5 % 26.6 % 36.3 %
Net Operating Loss Carryforwards	The Company has Net Operating Loss (“NOL”) carryforwards as follows: Jurisdiction Amount as of December 31, 2024 Years of Expiration U.S. state income tax $ 41,396 2025 - 2043 Foreign 199,365 Never
Reconciliation of Unrecognized Tax Benefits	The reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows: Year Ended December 31, 2024 2023 2022 Balance at beginning of year $ 5,486 $ 6,185 $ 5,665 Additions based on tax position related to current year 78 87 972 Additions based on tax position related to prior year 4,587 347 433 Reductions from settlements and statute of limitation expiration ( 1,636 ) ( 1,266 ) $ ( 610 ) Effect of foreign currency translation ( 249 ) 133 ( 275 ) Balance at end of year $ 8,266 $ 5,486 $ 6,185

Segment Reporting (Tables)

Segment Reporting (Tables)	12 Months Ended
	Dec. 31, 2024
Segment Reporting [Abstract]
Segment Information about Reported Product Revenues,Depreciation and Amortization and Operating Income (Loss)	The table below presents segment information about the reported product revenues, operating income (loss), and significant segment expenses of the Company for the years ended December 31, 2024, 2023 and 2022: Year Ended December 31, Product Revenues 2024 2023 2022 Automotive $ 1,406,278 $ 1,422,952 $ 1,161,616 Medical 49,846 46,124 43,040 Total 1,456,124 1,469,076 1,204,656 Significant Segment Expenses and Operating Performance Automotive Cost of sales 1,058,989 1,090,941 898,260 Net research and development expenses 68,787 70,778 75,137 Selling, general and administrative expenses 65,924 72,090 62,858 Restructuring expenses, net 12,238 3,187 637 Impairment of intangible assets and property and equipment — — 6,291 Automotive operating income 200,340 185,956 118,433 Medical Cost of sales 25,868 24,619 24,938 Other operating expenses 21,836 24,230 22,131 Impairment of intangible assets and property and equipment 2,501 19,509 — Medical operating loss ( 359 ) ( 22,234 ) ( 4,029 ) Corporate and Other Unallocated Expenses Corporate and other unallocated expenses ( 92,966 ) ( 86,283 ) ( 66,097 ) Total consolidated operating income $ 107,015 $ 77,439 $ 48,307 Other Segment Disclosures Depreciation and Amortization Automotive $ 47,752 $ 45,845 $ 39,815 Medical 3,542 3,654 3,344 Corporate and other unallocated expenses 1,681 1,449 1,235 Total $ 52,975 $ 50,948 $ 44,394
Segment Information About Reported Segment Product Revenues by Product Category	Automotive and Medical segment product revenues by product category for each of the years ended December 31, 2024, 2023 and 2022 are as follows: Year Ended December 31, 2024 2023 2022 Climate Control Seat $ 468,820 $ 482,665 $ 426,046 Seat Heaters 297,866 308,588 283,970 Lumbar and Massage Comfort Solutions (a) 178,584 144,923 56,980 Steering Wheel Heaters 169,763 153,943 120,949 Valve Systems (a) 105,056 106,262 41,980 Automotive Cables 73,091 79,993 76,962 Battery Performance Solutions 58,183 75,484 71,907 Electronics 33,065 40,387 44,106 Other Automotive 21,850 30,707 38,716 Subtotal Automotive segment 1,406,278 1,422,952 1,161,616 Medical segment (a) 49,846 46,124 43,040 Total Company $ 1,456,124 $ 1,469,076 $ 1,204,656 (a) Includes product revenues from acquisitions since their respective acquisition dates (see Note 4).
Product Revenues Information by Geographic Area	Revenue (based on shipment destination) by geographic area for each of the years ended December 31, 2024, 2023 and 2022 is as follows: Year Ended December 31, 2024 2023 2022 United States $ 504,444 $ 537,096 $ 472,468 China 224,221 221,512 183,419 Germany 105,927 102,383 75,367 South Korea 104,120 115,854 94,937 Czech Republic 78,785 69,714 49,293 Slovakia 55,085 44,946 34,686 Japan 53,730 60,879 57,718 Romania 52,616 53,982 47,532 Mexico 43,327 45,733 23,233 United Kingdom 41,098 34,765 22,380 Other 192,771 182,212 143,623 Total Non-U.S. 951,680 931,980 732,188 Total Company $ 1,456,124 $ 1,469,076 $ 1,204,656
Schedule of Property and Equipment, Net by Geographic Area	Property and equipment, net, for each of the geographic areas in which the Company operates as of December 31, 2024 and 2023 is as follows: December 31, Property and equipment, net 2024 2023 Mexico $ 47,814 $ 39,943 China 44,767 45,429 United States 42,928 37,413 Germany 42,457 46,586 North Macedonia 25,374 27,675 Vietnam 20,920 21,664 Czech Republic 9,440 11,126 Hungary 7,994 9,097 Ukraine 5,174 5,986 Other 6,102 315 Total $ 252,970 $ 245,234

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	1 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Basis Of Presentation And Accounting Policies [Line Items]
Amortization of capitalized costs into product revenues		$ 447,000	$ 179,000
Cash and cash equivalents		134,134,000	149,673,000
Capitalized payments to customers		14,276,000	7,305,000
Capitalized cost, impairment loss		0
Allowance for doubtful accounts		1,605,000	1,171,000
Depreciation expense		45,503,000	42,186,000	$ 33,730,000
Investment amount		3,897,000			$ 5,200,000
Investment made	$ 500,000	1,097,000
Non-cash impairment charges			2,900,000
Forciot Oy | Gentherm Automotive Segment
Basis Of Presentation And Accounting Policies [Line Items]
Investment amount					2,357,000
Autotech Fund III, L.P.
Basis Of Presentation And Accounting Policies [Line Items]
Investment commitment		$ 1,765,000			$ 5,000,000
Capital contribution description		As a limited partner, the Company will periodically make capital contributions toward this total commitment amount over the expected ten-year life of the fund.
Production Tooling
Basis Of Presentation And Accounting Policies [Line Items]
Reimbursable tooling capitalized within prepaid expenses and other current assets		$ 19,740,000	16,877,000
Foreign Jurisdictions
Basis Of Presentation And Accounting Policies [Line Items]
Cash and cash equivalents		$ 106,905,000	$ 125,251,000
Minimum
Basis Of Presentation And Accounting Policies [Line Items]
Period of products expected to be sold		5 years
Minimum | Production Tooling
Basis Of Presentation And Accounting Policies [Line Items]
Property plant and equipment, estimated useful life		2 years
Maximum
Basis Of Presentation And Accounting Policies [Line Items]
Original maturities of highly liquid investments		90 days
Period of products expected to be sold		10 years
Maximum | Production Tooling
Basis Of Presentation And Accounting Policies [Line Items]
Property plant and equipment, estimated useful life		10 years
Entities Ownership Interest
Basis Of Presentation And Accounting Policies [Line Items]
Ownership interest		20%

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Summary of Percentage of Product Revenues and Accounts Receivable (Details) - Customer Concentration Risk	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Lear | Sales Revenue, Net
Segment Reporting Information [Line Items]
Concentration risk percentage	16%	15%	16%
Lear | Accounts Receivable, Net
Segment Reporting Information [Line Items]
Concentration risk percentage	16%	17%
Adient | Sales Revenue, Net
Segment Reporting Information [Line Items]
Concentration risk percentage	11%	13%	15%
Adient | Accounts Receivable, Net
Segment Reporting Information [Line Items]
Concentration risk percentage	11%	19%

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Estimated Useful Lives of Property and Equipment (Detail)	Dec. 31, 2024
Plant and Equipment
Property Plant And Equipment [Line Items]
Property plant and equipment, estimated useful life	10 years
Leasehold Improvements
Property Plant And Equipment [Line Items]
Leasehold improvements	us-gaap:UsefulLifeTermOfLeaseMember
Minimum | Buildings and Improvements
Property Plant And Equipment [Line Items]
Property plant and equipment, estimated useful life	1 year
Minimum | Production Tooling
Property Plant And Equipment [Line Items]
Property plant and equipment, estimated useful life	2 years
Minimum | Information Technology
Property Plant And Equipment [Line Items]
Property plant and equipment, estimated useful life	1 year
Maximum | Buildings and Improvements
Property Plant And Equipment [Line Items]
Property plant and equipment, estimated useful life	30 years
Maximum | Production Tooling
Property Plant And Equipment [Line Items]
Property plant and equipment, estimated useful life	10 years
Maximum | Information Technology
Property Plant And Equipment [Line Items]
Property plant and equipment, estimated useful life	5 years

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Fair Value and Corresponding Useful Lives for Acquired Intangibles Assets (Detail)	12 Months Ended
	Dec. 31, 2024
Customer Related | Minimum
Finite Lived Intangible Assets [Line Items]
Weighted Average Life (in years)	8 years
Customer Related | Maximum
Finite Lived Intangible Assets [Line Items]
Weighted Average Life (in years)	15 years
Technology | Minimum
Finite Lived Intangible Assets [Line Items]
Weighted Average Life (in years)	5 years
Technology | Maximum
Finite Lived Intangible Assets [Line Items]
Weighted Average Life (in years)	12 years
Software Development Costs | Minimum
Finite Lived Intangible Assets [Line Items]
Weighted Average Life (in years)	4 years
Software Development Costs | Maximum
Finite Lived Intangible Assets [Line Items]
Weighted Average Life (in years)	5 years
Product Development Costs | Minimum
Finite Lived Intangible Assets [Line Items]
Weighted Average Life (in years)	5 years
Product Development Costs | Maximum
Finite Lived Intangible Assets [Line Items]
Weighted Average Life (in years)	10 years

Acquisitions - Additional Infor

Acquisitions - Additional Information (Detail) - USD ($) $ in Thousands	Aug. 01, 2022	Jul. 13, 2022
Alfmeier
Business Acquisition [Line Items]
Acquisition date	Aug. 01, 2022
Percentage of equity interests acquired	100%
Total consideration	$ 170,700
Dacheng
Business Acquisition [Line Items]
Acquisition date		Jul. 13, 2022
Percentage of equity interests acquired		100%
Total consideration		$ 35,048

Acquisitions - Summary of Produ

Acquisitions - Summary of Product Revenues and Operating Income (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Business Acquisition [Line Items]
Product revenues	$ 1,456,124	$ 1,469,076	$ 1,204,656
Type of Revenue [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember	us-gaap:ProductMember
Operating income (loss)	$ 107,015	$ 77,439	$ 48,307
Alfmeier
Business Acquisition [Line Items]
Product revenues			$ 98,960
Type of Revenue [Extensible List]			us-gaap:ProductMember
Net loss			$ (2,675)
Dacheng
Business Acquisition [Line Items]
Product revenues			$ 3,499
Type of Revenue [Extensible List]			us-gaap:ProductMember
Net loss			$ (217)

Acquisitions - Summary of Unaud

Acquisitions - Summary of Unaudited Pro Forma Information (Detail) - Alfmeier $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)
Business Acquisition [Line Items]
Product revenues	$ 1,348,295
Net income	$ 17,645

Restructuring - Additional Info

Restructuring - Additional Information (Detail) - USD ($) $ in Thousands		1 Months Ended	12 Months Ended
		Feb. 28, 2025	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Restructuring Cost And Reserve [Line Items]
Restructuring expenses			$ 13,110	$ 4,739	$ 637
Cash payments for restructuring expenses			10,926	3,102
Benefit from sale of previously reserved inventory			4,554
Non-cash impairment charges				2,900
Impairment of goodwill				19,509
Subsequent Event | Maximum
Restructuring Cost And Reserve [Line Items]
Restructuring expenses		$ 21,000
Restructuring charges for capital expenditures		5,000
Subsequent Event | Minimum
Restructuring Cost And Reserve [Line Items]
Restructuring expenses		13,000
Restructuring charges for capital expenditures		3,000
Property and Equipment
Restructuring Cost And Reserve [Line Items]
Non-cash impairment charges					690
Intangible Assets
Restructuring Cost And Reserve [Line Items]
Non-cash impairment charges					5,601
Inventory
Restructuring Cost And Reserve [Line Items]
Non-cash impairment charges				6,064	9,378
Other Restructuring Activities
Restructuring Cost And Reserve [Line Items]
Other restructuring costs			1,286	834	581
Other Restructuring Activities | Automotive Segments
Restructuring Cost And Reserve [Line Items]
Other restructuring costs			474
Other Restructuring Activities | Maximum
Restructuring Cost And Reserve [Line Items]
Additional restructuring costs			1,000
Other Restructuring Activities | Subsequent Event | Maximum
Restructuring Cost And Reserve [Line Items]
Future restructuring expenses expected		5,000
Other Restructuring Activities | Subsequent Event | Minimum
Restructuring Cost And Reserve [Line Items]
Future restructuring expenses expected		3,000
2023 Manufacturing Footprint Rationalization
Restructuring Cost And Reserve [Line Items]
Restructuring expenses			2,990
2023 Manufacturing Footprint Rationalization | Greenville, South Carolina manufacturing facility
Restructuring Cost And Reserve [Line Items]
Gain on sale of manufacturing facility			1,927
2023 Manufacturing Footprint Rationalization | Maximum
Restructuring Cost And Reserve [Line Items]
Additional restructuring costs			1,000
Employee Separation Costs
Restructuring Cost And Reserve [Line Items]
Cash payments for restructuring expenses			9,593	2,224
Employee Separation Costs | Other Restructuring Activities
Restructuring Cost And Reserve [Line Items]
Restructuring expenses			876	3,208	$ 56
Employee Separation Costs | 2023 Manufacturing Footprint Rationalization
Restructuring Cost And Reserve [Line Items]
Restructuring expenses			1,839	538
Other Restructuring
Restructuring Cost And Reserve [Line Items]
Cash payments for restructuring expenses	[1]		1,333	878
Other Costs | 2023 Manufacturing Footprint Rationalization
Restructuring Cost And Reserve [Line Items]
Restructuring expenses			2,381	$ 159
Employee Severance Retention and Termination Costs | Subsequent Event | Maximum
Restructuring Cost And Reserve [Line Items]
Restructuring expenses		11,000
Employee Severance Retention and Termination Costs | Subsequent Event | Minimum
Restructuring Cost And Reserve [Line Items]
Restructuring expenses		$ 7,000
Employee Separation Costs Related to Structural Cost Reductions | Other Restructuring Activities | Automotive Segments
Restructuring Cost And Reserve [Line Items]
Restructuring expenses			6,216
Employee Separation Costs Related To Relocation Of Electronic Component Manufacturing Facility | Other Restructuring Activities | Automotive Segments
Restructuring Cost And Reserve [Line Items]
Restructuring expenses			$ 1,965
[1] Includes gain on sale of the Greenville facility

Restructuring - Summary of Rest

Restructuring - Summary of Restructuring Expenses, Net by Reportable Segment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Restructuring Cost And Reserve [Line Items]
Restructuring expenses	$ 13,110	$ 4,739	$ 637
Operating Segments | Automotive Segments
Restructuring Cost And Reserve [Line Items]
Restructuring expenses	12,238	3,187	$ 637
Operating Segments | Medical Segments
Restructuring Cost And Reserve [Line Items]
Restructuring expenses	20	363
Operating Segments | Corporate Segments
Restructuring Cost And Reserve [Line Items]
Restructuring expenses	$ 852	$ 1,189

Restructuring and Impairments -

Restructuring and Impairments - Summary of Restructuring Activity for All Restructuring Initiatives (Detail) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023
Restructuring Cost And Reserve [Line Items]
Balance, beginning of period		$ 2,150	$ 588
Additions, charged to restructuring expenses, net		13,110	4,885
Change in estimate			(146)
Cash payments		(10,926)	(3,102)
Non-cash utilization		(881)	(115)
Currency translation and other		(165)	40
Balance, end of period		3,288	2,150
Employee Separation Costs
Restructuring Cost And Reserve [Line Items]
Balance, beginning of period		2,150	588
Additions, charged to restructuring expenses, net		10,896	3,892
Change in estimate			(146)
Cash payments		(9,593)	(2,224)
Currency translation and other		(165)	40
Balance, end of period		3,288	2,150
Other Restructuring
Restructuring Cost And Reserve [Line Items]
Additions, charged to restructuring expenses, net	[1]	2,214	993
Cash payments	[1]	(1,333)	(878)
Non-cash utilization	[1]	$ (881)	$ (115)
[1] Includes gain on sale of the Greenville facility

Details of Certain Financial _3

Details of Certain Financial Statement Components (Detail) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Inventory:
Raw materials, net	$ 137,511	$ 126,013
Work in process, net	19,059	15,704
Finished goods, net	70,786	64,175
Total inventory, net	227,356	205,892
Other current assets:
Income tax and other tax receivable	20,611	16,017
Billable tooling	19,740	16,877
Prepaid expenses	6,305	7,889
Short-term derivative financial instruments	719	10,717
Other	4,737	4,272
Total other current assets	64,413	78,420
Property and equipment:
Machinery and equipment	260,578	236,277
Buildings and improvements	117,953	130,374
Information technology	45,157	41,543
Production tooling	37,765	28,033
Leasehold improvements	23,262	12,269
Construction in progress	36,846	27,461
Total property and equipment	521,561	475,957
Less: accumulated depreciation	(268,591)	(230,723)
Total property and equipment, net	252,970	245,234
Other current liabilities:
Accrued employee liabilities	42,277	43,176
Income tax and other taxes payable	26,385	19,327
Liabilities from discounts and rebates	20,501	22,916
Restructuring	3,288	2,150
Accrued warranty	3,507	3,945	$ 2,380
Short-term derivative financial instruments	2,037
Other	7,829	9,291
Total other current liabilities	105,824	100,805
Related Party
Other current assets:
Notes receivable	11,190	18,226
Receivables due from factor	$ 1,111	$ 4,422

Goodwill and Other Intangible_2

Goodwill and Other Intangibles - Summary of Changes in the Carrying Amount of Goodwill, By Reportable Segment (Detail) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2024	Dec. 31, 2023
Goodwill [Line Items]
Balance, beginning of period		$ 104,073
Impairment of goodwill			$ (19,509)
Balance, end of period		99,603	104,073
Operating Segments
Goodwill [Line Items]
Balance, beginning of period	$ 119,774	104,073	119,774
Impairment of goodwill			(19,509)
Currency translation and other		(4,470)	3,808
Balance, end of period		99,603	104,073
Automotive Segments | Operating Segments
Goodwill [Line Items]
Balance, beginning of period	73,069	76,696	73,069
Currency translation and other		(3,942)	3,627
Balance, end of period		72,754	76,696
Medical Segments | Operating Segments
Goodwill [Line Items]
Balance, beginning of period	46,705	27,377	46,705
Impairment of goodwill	$ (19,509)		(19,509)
Currency translation and other		(528)	181
Balance, end of period		$ 26,849	$ 27,377

Goodwill and Other Intangible_3

Goodwill and Other Intangibles - Summary of Other Intangible Assets and Accumulated Amortization Balances (Detail) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Intangible Assets [Line Items]
Gross Carrying Value	$ 179,095	$ 188,806
Accumulated Amortization	(115,813)	(116,485)
Accumulated Impairment	(6,031)	(5,839)
Net Carrying Value	57,251	66,482
Net Carrying Value	57,251	66,482
Customer Relationship
Intangible Assets [Line Items]
Gross Carrying Value	109,608	115,465
Accumulated Amortization	(67,787)	(67,923)
Accumulated Impairment	(5,477)	(5,814)
Net Carrying Value	36,344	41,728
Technology
Intangible Assets [Line Items]
Gross Carrying Value	43,458	45,861
Accumulated Amortization	(29,976)	(29,292)
Accumulated Impairment	(24)	(25)
Net Carrying Value	13,458	16,544
Product Development Costs
Intangible Assets [Line Items]
Gross Carrying Value	18,019	19,434
Accumulated Amortization	(17,849)	(19,270)
Net Carrying Value	170	164
Software Development
Intangible Assets [Line Items]
Gross Carrying Value	1,007	1,007
Accumulated Amortization	(201)
Net Carrying Value	806	1,007
Tradenames
Intangible Assets [Line Items]
Gross Carrying Value	7,003	7,039
Accumulated Impairment	(530)
Net Carrying Value	$ 6,473	$ 7,039

Goodwill and Other Intangible_4

Goodwill and Other Intangibles - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended	12 Months Ended
	Mar. 31, 2024	Jun. 30, 2023	Dec. 31, 2023	Dec. 31, 2024	Dec. 31, 2022
Goodwill And Other Intangible Assets [Line Items]
Carrying value percentage					10%
Intangible assets			$ 66,482	$ 57,251
Non-cash impairment charges			2,900
Other intangible assets			8,290	7,019	$ 9,018
Impairment of goodwill			19,509
Operating Segments
Goodwill And Other Intangible Assets [Line Items]
Impairment of goodwill			19,509
Operating Segments | Medical Segments
Goodwill And Other Intangible Assets [Line Items]
Impairment of goodwill		$ 19,509	19,509
Technology
Goodwill And Other Intangible Assets [Line Items]
Intangible assets			16,544	13,458
Customer Relationship
Goodwill And Other Intangible Assets [Line Items]
Intangible assets			$ 41,728	$ 36,344
Trade Names [Member] | Medical Segments
Goodwill And Other Intangible Assets [Line Items]
Non-cash impairment charges	$ 530

Goodwill and Other Intangible_5

Goodwill and Other Intangibles - Summary of Estimate of Future Amortization of Other Intangible Assets (Detail) $ in Thousands	Dec. 31, 2024 USD ($)
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2025	$ 6,860
2026	6,424
2027	6,337
2028	6,276
2029	$ 5,598

Leases - Additional Information

Leases - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2025	Dec. 31, 2024
Lessee, Lease, Description [Line Items]
Future undiscounted payments		$ 19,878
Scenario Forecast
Lessee, Lease, Description [Line Items]
Cash proceeds	$ 3,740
Loss on sale	$ 2,311
Minimum
Lessee, Lease, Description [Line Items]
Lessee operating and finance lease remaining term including land		1 year
Lessee operating and finance lease remaining term excluding land		1 year
Initial lease terms		2 years
Maximum
Lessee, Lease, Description [Line Items]
Lessee operating and finance lease remaining term including land		38 years
Lessee operating and finance lease remaining term excluding land		9 years
Initial lease terms		15 years

Leases - Components of Lease Ex

Leases - Components of Lease Expense and Other Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Lease cost:
Operating lease cost	$ 10,747	$ 9,606	$ 8,040
Amortization of ROU assets - finance leases	370	390	168
Interest on lease liabilities - finance leases	14	28	16
Short-term lease cost	3,684	2,651	1,773
Sublease income			(101)
Total lease cost	14,815	12,675	$ 9,896
Operating cash flows for operating leases	10,428	9,249
Operating cash flows for finance leases	14	81
Financing cash flows for finance leases	383	390
Right-of-use lease assets obtained in exchange for lease obligations, Operating leases	$ 30,720	$ 4,704
Weighted-average remaining lease term, Operating leases	9 years 3 months 18 days	5 years 7 months 6 days
Weighted-average remaining lease term, Finance leases	1 year 6 months	1 year 10 months 24 days
Weighted-average discount rate, Operating leases	6.09%	4.96%
Weighted-average discount rate, Finance leases	3.46%	3.53%

Leases - Summary of Operating L

Leases - Summary of Operating Leases Under all Non-Cancellable Operating Leases (Detail) $ in Thousands	Dec. 31, 2024 USD ($)
Leases [Abstract]
2025	$ 9,285
2026	7,450
2027	5,701
2028	5,208
2029	4,911
2030 or later	26,593
Total future minimum lease payments	59,148
Less imputed interest	(14,579)
Total	$ 44,569

Leases - Summary of Finance Lea

Leases - Summary of Finance Leases Under all Non-Cancellable Finance Leases (Detail) $ in Thousands	Dec. 31, 2024 USD ($)
Leases [Abstract]
2025	$ 137
2026	64
Total	$ 201

Summary of Company's Debt (Deta

Summary of Company's Debt (Detail) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Debt Instrument [Line Items]
Total debt	$ 220,201	$ 222,838
Current maturities	(137)	(621)
Long-term debt, less current maturities	$ 220,064	$ 222,217
U.S. Revolving Note (U.S. Dollar Denominations)
Debt Instrument [Line Items]
Interest Rate	5.86%	6.58%
Total debt	$ 220,000	$ 222,000
Other Loans
Debt Instrument [Line Items]
Interest Rate		3.90%
Total debt		$ 233
Finance Leases
Debt Instrument [Line Items]
Interest Rate	3.46%	3.53%
Total debt	$ 201	$ 605

Debt - Additional Information (

Debt - Additional Information (Detail) - USD ($)				12 Months Ended
	Jun. 10, 2027	Jun. 27, 2024	Jun. 10, 2022	Dec. 31, 2024	Dec. 31, 2022	Dec. 31, 2023
Debt Instrument [Line Items]
Maximum percentage of stock of non US subsidiaries pledge to secure obligation				66%
Unamortized deferred debt issuance costs written off					$ 144,000
Second Amended and Restated Credit Agreement
Debt Instrument [Line Items]
Remaining borrowing capacity				$ 280,000,000
Second Amended and Restated Credit Agreement | Federal Funds Rate
Debt Instrument [Line Items]
Interest rate				0.50%
Second Amended and Restated Credit Agreement | SOFR Rate
Debt Instrument [Line Items]
Interest rate				1%
Term SOFR Rate Loans | Second Amended and Restated Credit Agreement | Minimum
Debt Instrument [Line Items]
Interest rate				1.125%
Term SOFR Rate Loans | Second Amended and Restated Credit Agreement | Maximum
Debt Instrument [Line Items]
Interest rate				2.125%
Base Rate Loans | Second Amended and Restated Credit Agreement | Minimum
Debt Instrument [Line Items]
Interest rate				0.125%
Base Rate Loans | Second Amended and Restated Credit Agreement | Maximum
Debt Instrument [Line Items]
Interest rate				1.125%
Revolving Credit Facility
Debt Instrument [Line Items]
Maximum borrowing capacity increase subject to specified conditions			$ 200,000,000
Revolving Credit Facility | Second Amended and Restated Credit Agreement
Debt Instrument [Line Items]
Maximum borrowing capacity			500,000,000
Increase in maximum borrowing capacity			25,000,000
Debt issuance cost			1,520,000
Revolving Credit Facility | Second Amended and Restated Credit Agreement | Minimum
Debt Instrument [Line Items]
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage				0.175%
Revolving Credit Facility | Second Amended and Restated Credit Agreement | Maximum
Debt Instrument [Line Items]
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage				0.30%
Revolving Credit Facility | Letters of Credit
Debt Instrument [Line Items]
Line of credit, outstanding amount				$ 2,838,000		$ 0
Revolving Credit Facility | Swing Line Loans
Debt Instrument [Line Items]
Maximum borrowing capacity			50,000,000
Revolving Credit Facility | Revolving Note (U.S. Dollar)
Debt Instrument [Line Items]
Debt maturity date		Jun. 27, 2024
Standby Letters of Credit | Second Amended and Restated Credit Agreement
Debt Instrument [Line Items]
Maximum borrowing capacity			$ 15,000,000
Scenario Forecast | Revolving Credit Facility | Second Amended and Restated Credit Agreement
Debt Instrument [Line Items]
Debt maturity date	Jun. 10, 2027

Principal Maturities of Debt (D

Principal Maturities of Debt (Detail) $ in Thousands	Dec. 31, 2024 USD ($)
Debt Instrument [Line Items]
Debt maturing in 2025	$ 137
Debt maturing in 2026	64
Debt maturing in 2027	220,000
Total	220,201
US and Euro Denominated Revolving Note
Debt Instrument [Line Items]
Debt maturing in 2027	220,000
Total	220,000
Other Debt
Debt Instrument [Line Items]
Debt maturing in 2025	137
Debt maturing in 2026	64
Total	$ 201

Pension and Other Post Retire_3

Pension and Other Post Retirement Benefit Plans - Components of Net Periodic Benefit Cost for Company's Defined Benefit Plans (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
United States
Net periodic benefit cost:
Interest cost	$ 101	$ 115	$ 56
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Interest Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]	Selling, General and Administrative Expense	Selling, General and Administrative Expense	Selling, General and Administrative Expense
Amortization of prior service cost and actuarial loss			$ 22
Net periodic benefit cost	$ 101	$ 115	$ 78
Assumptions:
Discount rate	4.45%	4.65%	1.80%
German Plan
Net periodic benefit cost:
Interest cost	$ 234	$ 217	$ 92
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Interest Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]	Selling, General and Administrative Expense	Selling, General and Administrative Expense	Selling, General and Administrative Expense
Expected return on plan assets	$ (130)	$ (115)	$ (109)
Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Expected Return (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax	Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax	Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax
Amortization of prior service cost and actuarial loss	$ 19	$ 23	$ 114
Net periodic benefit cost	$ 123	$ 125	$ 97
Assumptions:
Discount rate	4.56%	4.10%	1.08%
Long-term return on assets	3.20%	3.20%	2.90%

Pension and Other Post Retire_4

Pension and Other Post Retirement Benefit Plans - Reconciliation of Change in Benefit Obligation, Change in Plan Assets and Balance Sheet Classification (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Balance sheet classification:
Pension benefit obligation	$ (4,017)	$ (3,209)
United States
Change in projected benefit obligation:
Balance at beginning of year	2,602	2,811
Interest cost	101	115	$ 56
Paid pension distributions	(342)	(342)
Actuarial (gain) loss	(30)	18
Balance at end of year	2,331	2,602	2,811
Change in plan assets:
Underfunded Status	(2,331)	(2,602)
Balance sheet classification:
Other current liabilities	(342)	(357)
Pension benefit obligation	(1,989)	(2,245)
Accumulated other comprehensive loss (pre-tax):
Actuarial losses	$ 194	$ 223
Discount rate	4.85%	4.45%
German Plan
Change in projected benefit obligation:
Balance at beginning of year	$ 5,406	$ 5,398
Interest cost	234	217	92
Paid pension distributions	(256)	(290)
Actuarial (gain) loss	1,259	(89)
Exchange rate impact	(362)	170
Balance at end of year	6,281	5,406	5,398
Change in plan assets:
Balance at beginning of year	4,145	3,918
Actual return on plan assets	104	98
Exchange rate impact	(244)	129
Balance at end of year	4,005	4,145	$ 3,918
Underfunded Status	(2,276)	(1,261)
Balance sheet classification:
Other current liabilities	(248)	(297)
Pension benefit obligation	(2,028)	(964)
Accumulated other comprehensive loss (pre-tax):
Actuarial losses	$ 2,063	$ 899
Discount rate	3.38%	4.56%

Pension and Other Post Retire_5

Pension and Other Post Retirement Benefit Plans - Summary of Pre-tax Amounts in AOCI Expected to Be Recognized in Net Periodic Benefit Cost (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
United States
Defined Benefit Plan Disclosure [Line Items]
Actuarial losses		$ 194	$ 223
German Plan
Defined Benefit Plan Disclosure [Line Items]
Actuarial losses		$ 2,063	$ 899
German Plan | Scenario Forecast
Defined Benefit Plan Disclosure [Line Items]
Actuarial losses	$ 71

Pension and Other Post Retire_6

Pension and Other Post Retirement Benefit Plans - Summary of Accumulated Benefit Obligations (Detail) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
United States
Defined Benefit Plan Disclosure [Line Items]
Accumulated benefit obligation	$ 2,331	$ 2,602
German Plan
Defined Benefit Plan Disclosure [Line Items]
Accumulated benefit obligation	$ 6,281	$ 5,406

Pension and Other Post Retire_7

Pension and Other Post Retirement Benefit Plans - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
401(k) Plan
Defined Benefit Plan Disclosure [Line Items]
Cost recognized for contributions to defined contribution plan	$ 2,264,000	$ 2,344,000	$ 1,984,000
United States
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, expected employer contribution in next fiscal year	0
German Plan
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, expected employer contribution in next fiscal year	$ 0

Pension and Other Post Retire_8

Pension and Other Post Retirement Benefit Plans - Schedule of Future Expected Pension Payments (Detail) $ in Thousands	Dec. 31, 2024 USD ($)
United States
Defined Benefit Plan Disclosure [Line Items]
2025	$ 342
2026	342
2027	342
2028	342
2029	342
2030-2033	1,026
Total projected pension benefit payments	2,736
German Plan
Defined Benefit Plan Disclosure [Line Items]
2025	248
2026	249
2027	249
2028	247
2029	1,628
2030-2033	1,565
Total projected pension benefit payments	$ 4,186

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - Vehicle	12 Months Ended
	Dec. 31, 2024	Feb. 14, 2024
Loss Contingencies [Line Items]
Number of vehicles recalled		261,257
Labor Agreements
Loss Contingencies [Line Items]
Percentage of workforce as members of industrial trade unions or worker councils	35%

Commitments and Contingencies_2

Commitments and Contingencies - Reconciliation of Changes in Accrued Warranty Costs (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Loss Contingency [Abstract]
Balance at beginning of year	$ 3,945	$ 2,380
Warranty claims paid	(6,382)	(2,252)
Warranty expense for products shipped during the current period	5,812	3,955
Adjustments to warranty estimates from prior periods	247	(174)
Adjustments due to currency translation	(115)	36
Balance at end of year	$ 3,507	$ 3,945

Supplier Finance Program - Addi

Supplier Finance Program - Additional Information (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Payables and Accruals [Abstract]
Outstanding payment obligations to suppliers	$ 21,232	$ 0
Supplier Finance Program, Obligation, Statement of Financial Position [Extensible Enumeration]	Net Cash Provided by (Used in) Operating Activities

Supplier Finance Program - Summ

Supplier Finance Program - Summary of Reconciliation of Changes in Confirmed Obligations to Participating Suppliers (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2024 USD ($)
Supplier Finance Program, Obligation [Roll Forward]
Outstanding at beginning of year	$ 0
Invoices confirmed	90,343
Invoices settled	(69,111)
Outstanding at end of year	$ 21,232

Earnings Per Share (Detail)

Earnings Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Earnings Per Share [Abstract]
Net income	$ 64,947	$ 40,343	$ 24,441
Basic weighted average shares of Common Stock outstanding	31,293,113	32,778,055	33,126,202
Dilutive effect of stock options, restricted stock awards and restricted stock units	183,373	288,862	376,952
Diluted weighted average shares of Common Stock outstanding	31,476,486	33,066,917	33,503,154
Basic earnings per share	$ 2.08	$ 1.23	$ 0.74
Diluted earnings per share	$ 2.06	$ 1.22	$ 0.73

Financial Instruments - Additio

Financial Instruments - Additional Information (Detail) - USD ($)		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Derivative [Line Items]
Trade receivables		$ 98,761,000	$ 135,116,000
Factoring fees		615,000	800,000
Factoring receivables not yet paid	[1]	755,000	18,532,000
Interest Rate Swap
Derivative [Line Items]
Hedge Ineffectiveness Incurred		0	0
Foreign Currency Derivatives
Derivative [Line Items]
Gain (loss) on derivatives		$ (7,542,000)	$ 12,113,000	$ 4,954,000
Foreign Currency Derivatives | Derivatives Not Designated as Hedging Instruments
Derivative [Line Items]
Gain (loss) on derivatives				(3,806,000)
Foreign Currency Derivatives | Derivatives Not Designated as Hedging Instruments | Foreign Currency Gain (Loss)
Derivative [Line Items]
Gain (loss) on derivatives				$ (3,806,000)
[1] During the year ended December 31, 2024, the factoring agreements the Company was party to either expired or were terminated. As of December 31, 2024 there were remaining receivables factored and outstanding that will be collected in the future, however, no further factoring can occur under these factoring agreements.

Information Related to Recurrin

Information Related to Recurring Fair Value Measurement of Derivative Financial Instruments in the Consolidated Balance Sheet (Detail) - Fair Value, Inputs, Level 2 - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Foreign Currency Derivatives | Designated as Hedging Instrument
Derivatives Fair Value [Line Items]
Notional Amount	$ 126,496	$ 101,109
Net Asset/ (Liabilities)	(2,037)	8,655
Foreign Currency Derivatives | Designated as Hedging Instrument | Other Current Assets
Derivatives Fair Value [Line Items]
Asset Derivatives, Fair Value	0	8,655
Foreign Currency Derivatives | Designated as Hedging Instrument | Other current liabilities
Derivatives Fair Value [Line Items]
Liabilities Derivatives, Fair Value	2,037
Interest Rate Contracts | Derivatives Not Designated as Hedging Instruments
Derivatives Fair Value [Line Items]
Notional Amount	100,000	100,000
Net Asset/ (Liabilities)	719	2,062
Interest Rate Contracts | Derivatives Not Designated as Hedging Instruments | Other Current Assets
Derivatives Fair Value [Line Items]
Asset Derivatives, Fair Value	$ 719	$ 2,062

Information Related to Effect o

Information Related to Effect of Derivative Instruments in the Consolidated Statements of Income (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Foreign Currency Derivatives
Derivative Instruments Gain Loss [Line Items]
Total foreign currency derivatives	$ (7,542)	$ 12,113	$ 4,954
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Other Comprehensive Income (Loss), Net of Tax	Other Comprehensive Income (Loss), Net of Tax	Other Comprehensive Income (Loss), Net of Tax
Commodity Hedges
Derivative Instruments Gain Loss [Line Items]
Total commodity derivatives			$ 13
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]			Other Comprehensive Income (Loss), Net of Tax
Other comprehensive (loss) income | Foreign Currency Derivatives
Derivative Instruments Gain Loss [Line Items]
Total foreign currency derivatives	$ (11,259)	$ 3,483	$ 3,496
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Other Comprehensive Income (Loss), Net of Tax	Other Comprehensive Income (Loss), Net of Tax	Other Comprehensive Income (Loss), Net of Tax
Other comprehensive (loss) income | Commodity Hedges
Derivative Instruments Gain Loss [Line Items]
Total commodity derivatives			$ (6)
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]			Other Comprehensive Income (Loss), Net of Tax
Derivatives Not Designated as Hedging Instruments | Foreign Currency Derivatives
Derivative Instruments Gain Loss [Line Items]
Total foreign currency derivatives			$ (3,806)
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]			Gain (Loss), Foreign Currency Transaction, before Tax
Derivatives Not Designated as Hedging Instruments | Interest Rate Contracts
Derivative Instruments Gain Loss [Line Items]
Total interest rate derivatives	$ (1,343)	$ (710)	$ 2,772
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Interest Income (Expense), Operating	Interest Income (Expense), Operating	Interest Income (Expense), Operating
Cost of sales | Foreign Currency Derivatives
Derivative Instruments Gain Loss [Line Items]
Total foreign currency derivatives	$ 3,717	$ 8,630	$ 1,458
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Cost of Goods and Services Sold	Cost of Goods and Services Sold	Cost of Goods and Services Sold
Cost of sales | Commodity Hedges
Derivative Instruments Gain Loss [Line Items]
Total commodity derivatives			$ 19
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]			Cost of Goods and Services Sold
Foreign Currency Gain (Loss) | Derivatives Not Designated as Hedging Instruments | Foreign Currency Derivatives
Derivative Instruments Gain Loss [Line Items]
Total foreign currency derivatives			$ (3,806)
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]			Gain (Loss), Foreign Currency Transaction, before Tax
Interest Expense, Net | Derivatives Not Designated as Hedging Instruments | Interest Rate Contracts
Derivative Instruments Gain Loss [Line Items]
Total interest rate derivatives	$ (1,343)	$ (710)	$ 2,772
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Interest Income (Expense), Operating	Interest Income (Expense), Operating	Interest Income (Expense), Operating

Financial Instruments - Summary

Financial Instruments - Summary of Receivables Factored and Availability Under Receivables Factoring Agreements (Details) - USD ($) $ in Thousands		Dec. 31, 2024	Dec. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Receivables factored and outstanding	[1]	$ 755	$ 18,532
[1] During the year ended December 31, 2024, the factoring agreements the Company was party to either expired or were terminated. As of December 31, 2024 there were remaining receivables factored and outstanding that will be collected in the future, however, no further factoring can occur under these factoring agreements.

Financial Instruments - Summa_2

Financial Instruments - Summary of Trade Receivables Sold and Factoring Fees Incurred (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Trade receivables sold	$ 98,761	$ 135,116
Factoring fees incurred	$ 615	$ 800

Fair Value Measurement - Additi

Fair Value Measurement - Additional Information (Detail) - USD ($)	Dec. 31, 2024	Dec. 31, 2023
Fair Value, Recurring Basis
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Financial assets, fair value	$ 0	$ 0
Financial liabilities, fair value	0	0
Fair Value, Nonrecurring Basis
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Financial assets, fair value	0	0
Financial liabilities, fair value	$ 0	$ 0

Equity - Additional Information

Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands			6 Months Ended	12 Months Ended
	Nov. 02, 2023	Nov. 01, 2023	Jun. 30, 2024	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2020
Class Of Stock [Line Items]
Common Stock, shares authorized				55,000,000	55,000,000
Preferred stock, shares authorized				4,991,000
Common Stock, shares issued				30,788,639	31,542,001
Common Stock, shares outstanding				30,788,639	31,542,001
Preferred stock, shares issued				0
Preferred stock, shares outstanding				0
Cash paid to repurchased shares				$ 51,585	$ 91,094
Excise tax				502
ASR Agreement
Class Of Stock [Line Items]
Cash paid to repurchased shares				$ 286
Initial repurchase, shares	1,220,000
Initial repurchase, percentage	80%
ASR Agreement | Bank of America
Class Of Stock [Line Items]
Cash paid to repurchased shares	$ 60,000
2020 Stock Repurchase Program
Class Of Stock [Line Items]
Average price paid per share				$ 52.65
Cash paid to repurchased shares				$ 20,000
Remaining authorized repurchase amount			$ 17,491
Stock repurchase program period						3 years
Stock repurchase program expiration date		Jun. 30, 2024				Dec. 15, 2023
2020 Stock Repurchase Program | ASR Agreement
Class Of Stock [Line Items]
Share repurchase authorized aggregate amount		$ 60,000
2024 Stock Repurchase Program
Class Of Stock [Line Items]
Average price paid per share				$ 46.73
Cash paid to repurchased shares				$ 29,883
Remaining authorized repurchase amount				$ 120,117
Stock repurchase program period			3 years
Stock repurchase program expiration date				Jun. 30, 2027
Maximum
Class Of Stock [Line Items]
Shares issued				59,991,000
Maximum | 2020 Stock Repurchase Program
Class Of Stock [Line Items]
Stock repurchase program, authorized to repurchase amount						150,000
Maximum | 2024 Stock Repurchase Program
Class Of Stock [Line Items]
Stock repurchase program, authorized to repurchase amount			150,000,000,000

Schedule of Reclassification Ad

Schedule of Reclassification Adjustments and Other Activities Impacting Accumulated Other Comprehensive Loss (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024		Dec. 31, 2023		Dec. 31, 2022
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning Balance	$ (30,160)		$ (46,489)		$ (36,922)
Other comprehensive income (loss) before reclassifications	(50,409)		26,265		(6,478)
Income tax effect of other comprehensive income (loss) before reclassifications	1,372		(2,471)		(2,011)
Amounts reclassified from accumulated other comprehensive loss into net income	(7,520)		(9,580)		(1,340)
Income taxes reclassified into net income	1,524		2,115		262
Other comprehensive (loss) income, net of tax	(55,033)		16,329		(9,567)
Ending Balance	(85,193)		(30,160)		(46,489)
Defined Benefit Pension Plans
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning Balance	(1,011)		(1,067)		(2,893)
Other comprehensive income (loss) before reclassifications	(1,242)		54		2,341
Income tax effect of other comprehensive income (loss) before reclassifications	335		(15)		(621)
Amounts reclassified from accumulated other comprehensive loss into net income	91		23		137
Income taxes reclassified into net income	(24)		(6)		(31)
Other comprehensive (loss) income, net of tax	(840)		56		1,826
Ending Balance	(1,851)		(1,011)		(1,067)
Foreign Currency Translation Adjustments
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning Balance	(34,830)		(48,269)		(34,188)
Other comprehensive income (loss) before reclassifications	(45,519)		13,125		(13,786)
Income tax effect of other comprehensive income (loss) before reclassifications	253		314		(295)
Other comprehensive (loss) income, net of tax	(45,266)		13,439		(14,081)
Ending Balance	(80,096)		(34,830)		(48,269)
Commodity Hedge Derivatives
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning Balance	0				5
Other comprehensive income (loss) before reclassifications			0		13
Income tax effect of other comprehensive income (loss) before reclassifications			0		(3)
Amounts reclassified from accumulated other comprehensive loss into net income			0	[1]	(19)	[2]
Income taxes reclassified into net income			0		4
Other comprehensive (loss) income, net of tax			0		(5)
Ending Balance			0
Foreign Currency Hedge Derivatives
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning Balance	5,681		2,847		154
Other comprehensive income (loss) before reclassifications	(3,648)		13,086		4,954
Income tax effect of other comprehensive income (loss) before reclassifications	784		(2,770)		(1,092)
Amounts reclassified from accumulated other comprehensive loss into net income	(7,611)	[3]	(9,603)	[1]	(1,458)	[2]
Income taxes reclassified into net income	1,548		2,121		289
Other comprehensive (loss) income, net of tax	(8,927)		2,834		2,693
Ending Balance	$ (3,246)		$ 5,681		$ 2,847
[1] The amounts reclassified from accumulated other comprehensive loss are included in cost of sales. See Note 14 for information related to the effect of foreign currency derivative instruments on our consolidated statements of income. The amounts reclassified from accumulated other comprehensive loss are included in cost of sales. See Note 14 for information related to the effect of commodity and foreign currency derivative instruments on our consolidated statements of income. The amounts reclassified from accumulated other comprehensive loss are included in cost of sales. See Note 14 for information related to the effect of foreign currency derivative instruments on our consolidated statements of income.

Accounting for Stock Based Co_3

Accounting for Stock Based Compensation - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	May 18, 2023	Dec. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Performance based restricted stock units outstanding	21,296	17,923	13,600		11,376
Awards vesting period	1 year 10 months 28 days
Shareholder Return Award Performance Measurement Period	3 years
Deferred tax benefit (expense)	$ 1,485	$ 1,794	$ (444)
Total intrinsic value of options exercised	2,071	201	1,582
Total fair value of restricted stock vested	$ 1,021	$ 875	$ 800
Performance Based Restricted Stock Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Performance based restricted stock units outstanding	279,841	324,977	320,449		319,336
Awards vesting period	1 year 11 months 23 days
Awards vesting condition	Company’s achievement of one of five separate performance metrics: a target return on invested capital ratio (“ROIC”), as defined in the award agreement, for a specified fiscal year; a target three-year cumulative Adjusted EBITDA (“Adjusted EBITDA”), as defined in the award agreement; a target annual and three-year growth in the expansion of Adjusted EBITDA Margin Rate (“Adjusted EBITDA Margin Rate”), as defined in the award agreement (as modified by the Company’s relative total shareholder return); the Company’s relative total shareholder return (“TSR”), as defined in the award agreement, during a specific three-year measurement period; and a target relative revenue growth relative to light vehicle production in the Company's relevant markets ("RRG"), as defined in the award agreement, during a specific three-year measurement period (in certain cases, as modified by the Company’s relative total shareholder return).
Stock option achieving minimum threshold	50%
Stock option achieving maximum threshold	200%
Percentage of decrease in total payout	25%
Percentage of increase in total payout	25%
Total intrinsic value of stock units vested	$ 2,574	$ 2,951	$ 6,986
ROIC
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Awards vesting period	3 years
RSU
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Awards vesting period	1 year 11 months 1 day
Total intrinsic value of stock units vested	$ 8,358	4,915	4,774
Stock Appreciation Rights (SARs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total intrinsic value of options exercised	$ 25	$ 242	$ 1,348
Employee and Consultants | Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based compensation, requisite service period	2 years
Employee and Consultants | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based compensation, requisite service period	4 years
Director
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based compensation, requisite service period	1 year
2023 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares authorized for grant	3,448,234
Number of shares authorized for grant				3,730,000

Accounting for Stock Based Co_4

Accounting for Stock Based Compensation - Summary of Recognized and Unrecognized Stock-based Compensation Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-Based Compensation Expense	$ 10,432	$ 11,627	$ 6,599
Unrecognized Stock-Based Compensation Expense	$ 15,592
Remaining Weighted Average Vesting Period	1 year 10 months 28 days
RSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-Based Compensation Expense	$ 6,871	6,216	5,551
Unrecognized Stock-Based Compensation Expense	$ 7,395
Remaining Weighted Average Vesting Period	1 year 11 months 1 day
PSUs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-Based Compensation Expense	$ 2,454	4,661	954
Unrecognized Stock-Based Compensation Expense	$ 7,795
Remaining Weighted Average Vesting Period	1 year 11 months 23 days
Restricted Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-Based Compensation Expense	$ 1,115	878	888
Unrecognized Stock-Based Compensation Expense	$ 402
Remaining Weighted Average Vesting Period	4 months 13 days
SARs
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-Based Compensation Expense	$ (8)	$ (128)	$ (794)

Accounting for Stock Based Co_5

Accounting for Stock Based Compensation - Summarizes RSU Activity (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding at beginning of period, Shares	17,923	13,600	11,376
Granted, Shares	21,296	17,923	13,600
Vested, Shares	(17,923)	(11,900)	(11,376)
Forfeited, Shares		(1,700)
Outstanding at end of period, Shares	21,296	17,923	13,600
Outstanding at beginning of period, Weighted-Average Grant Date Fair Value	$ 56.96	$ 73.54	$ 70.33
Granted, Weighted-Average Grant Date Fair Value	50.72	56.96	73.54
Vested, Weighted-Average Grant Date Fair Value	56.96	73.54	70.33
Forfeited, Weighted-Average Grant Date Fair Value		73.54
Outstanding at end of period, Weighted-Average Grant Date Fair Value	$ 50.72	$ 56.96	$ 73.54
RSU | Time Vesting Shares [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding at beginning of period, Shares	231,861	201,578	193,626
Granted, Shares	184,959	136,964	117,507
Vested, Shares	(129,477)	(82,695)	(95,692)
Forfeited, Shares	(84,682)	(23,986)	(13,863)
Outstanding at end of period, Shares	202,661	231,861	201,578
Outstanding at beginning of period, Weighted-Average Grant Date Fair Value	$ 63.19	$ 64.27	$ 56.02
Granted, Weighted-Average Grant Date Fair Value	54.2	58.68	66.86
Vested, Weighted-Average Grant Date Fair Value	64.55	59.43	49.85
Forfeited, Weighted-Average Grant Date Fair Value	57.71	59.47	70.52
Outstanding at end of period, Weighted-Average Grant Date Fair Value	$ 56.35	$ 63.19	$ 64.27

Accounting for Stock Based Co_6

Accounting for Stock Based Compensation - Summarizes PSU Activity (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding at beginning of period, Shares	17,923	13,600	11,376
Granted, Shares	21,296	17,923	13,600
Vested, Shares	(17,923)	(11,900)	(11,376)
Forfeited, Shares		(1,700)
Outstanding at end of period, Shares	21,296	17,923	13,600
Outstanding at beginning of period, Weighted-Average Grant Date Fair Value	$ 56.96	$ 73.54	$ 70.33
Granted, Weighted-Average Grant Date Fair Value	50.72	56.96	73.54
Vested, Weighted-Average Grant Date Fair Value	56.96	73.54	70.33
Forfeited, Weighted-Average Grant Date Fair Value		73.54
Outstanding at end of period, Weighted-Average Grant Date Fair Value	$ 50.72	$ 56.96	$ 73.54
Performance Based Units
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Outstanding at beginning of period, Shares	324,977	320,449	319,336
Granted, Shares	235,388	153,121	106,604
Performance Adjustment, Shares	(52,856)	(59,928)	42,746
Vested, Shares	(27,850)	(59,928)	(133,477)
Forfeited, Shares	(199,818)	(28,737)	(14,760)
Outstanding at end of period, Shares	279,841	324,977	320,449
Outstanding at beginning of period, Weighted-Average Grant Date Fair Value	$ 74.1	$ 62.9	$ 57.27
Granted, Weighted-Average Grant Date Fair Value	60.68	65.9	75.57
Performance Adjustment, Weighted-Average Grant Date Fair Value	79.49	33.9	58.3
Vested, Weighted-Average Grant Date Fair Value	92.44	49.25	52.34
Forfeited, Weighted-Average Grant Date Fair Value	61.35	65.97	65.02
Outstanding at end of period, Weighted-Average Grant Date Fair Value	$ 63.3	$ 74.1	$ 62.9

Accounting for Stock Based Co_7

Accounting for Stock Based Compensation - Summarizes Restricted Stock Activity (Detail) - $ / shares	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Outstanding at beginning of period, Shares	17,923	13,600	11,376
Granted, Shares	21,296	17,923	13,600
Vested, Shares	(17,923)	(11,900)	(11,376)
Forfeited, Shares		(1,700)
Outstanding at end of period, Shares	21,296	17,923	13,600
Outstanding at beginning of period, Weighted-Average Grant Date Fair Value	$ 56.96	$ 73.54	$ 70.33
Granted, Weighted-Average Grant Date Fair Value	50.72	56.96	73.54
Vested, Weighted-Average Grant Date Fair Value	56.96	73.54	70.33
Forfeited, Weighted-Average Grant Date Fair Value		73.54
Outstanding at end of period, Weighted-Average Grant Date Fair Value	$ 50.72	$ 56.96	$ 73.54

Accounting for Stock Based Co_8

Accounting for Stock Based Compensation - Summarizes SARs Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock Options Outstanding, beginning balance, Shares	139,684	162,634	206,750
Exercised, Shares	(139,684)	(6,450)	(44,116)
Forfeited, Shares	0	(16,500)	0
Stock Options Outstanding, ending balance, Shares		139,684	162,634	206,750
Exercisable, Ending Balance	0
Stock Options Outstanding, beginning balance, Weighted-Average Exercise Price	$ 35.59	$ 36.41	$ 36.72
Exercised, Weighted-Average Exercise Price	35.59	40.79	37.87
Forfeited, Weighted-Average Exercise Price	0	41.59	0
Stock Options Outstanding, ending balance, Weighted-Average Exercise Price	0	$ 35.59	$ 36.41	$ 36.72
Exercisable, Weighted Average Exercise Price	$ 0
Stock Options Outstanding, Weighted-Average Remaining Contractual Term		10 months 24 days	2 years 8 months 4 days	2 years 7 months 6 days
Outstanding, Aggregate Intrinsic Value		$ 2,342	$ 8,212	$ 10,375
Exercisable, Aggregate Intrinsic Value	$ 0
Stock Appreciation Rights (SARs)
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock Options Outstanding, beginning balance, Shares	2,250	14,750	55,600
Exercised, Shares	(2,250)	(12,500)	(40,850)
Stock Options Outstanding, ending balance, Shares		2,250	14,750	55,600
Exercisable, Ending Balance	0
Stock Options Outstanding, beginning balance, Weighted-Average Exercise Price	$ 38.05	$ 38.05	$ 41.15
Exercised, Weighted-Average Exercise Price	38.05	38.05	42.27
Stock Options Outstanding, ending balance, Weighted-Average Exercise Price		$ 38.05	$ 38.05	$ 41.15
Exercisable, Weighted Average Exercise Price	$ 0
Stock Options Outstanding, Weighted-Average Remaining Contractual Term		1 month 24 days	1 year 1 month 24 days	1 year 3 months 10 days
Outstanding, Aggregate Intrinsic Value		$ 32	$ 402	$ 2,544
Exercisable, Aggregate Intrinsic Value	$ 0

Accounting for Stock Based Co_9

Accounting for Stock Based Compensation - Summarizes Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Share-Based Payment Arrangement [Abstract]
Stock Options Outstanding, beginning balance, Shares	139,684	162,634	206,750
Exercised, Shares	(139,684)	(6,450)	(44,116)
Forfeited, Shares	0	(16,500)	0
Stock Options Outstanding, ending balance, Shares		139,684	162,634	206,750
Stock Options Exercisable, Shares	0
Stock Options Outstanding, beginning balance, Weighted-Average Exercise Price	$ 35.59	$ 36.41	$ 36.72
Exercised, Weighted-Average Exercise Price	35.59	40.79	37.87
Forfeited, Weighted-Average Exercise Price	0	41.59	0
Stock Options Outstanding, ending balance, Weighted-Average Exercise Price	0	$ 35.59	$ 36.41	$ 36.72
Exercisable, Weighted-Average Exercise Price	$ 0
Stock Options Outstanding, Weighted-Average Remaining Contractual Term		10 months 24 days	2 years 8 months 4 days	2 years 7 months 6 days
Stock Options Outstanding, Aggregate Intrinsic Value		$ 2,342	$ 8,212	$ 10,375
Exercisable, Aggregate Intrinsic Value	$ 0

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Taxes [Line Items]
Undistributed earnings offsetting with dividend received deduction percent	100%
Indefinitely reinvested earnings of foreign subsidiaries	$ 0
Undistributed earnings of foreign subsidiaries	5,088,000
Undistributed earnings	194,777,000
Deferred tax assets	106,207,000	$ 118,372,000
Valuation allowance	25,272,000	35,888,000
Total unrecognized tax benefits	8,266,000	5,486,000	$ 6,185,000	$ 5,665,000
Unrecognized tax benefits reversal resulting from lapse of applicable statute of limitations	$ 4,000,000
U.S. State | Earliest Tax Year
Income Taxes [Line Items]
Operating loss carryforward, year of expiration	2025
U.S. State | Latest Tax Year
Income Taxes [Line Items]
Operating loss carryforward, year of expiration	2043
Non-U.S. Subsidiaries
Income Taxes [Line Items]
Operating loss carryforward, amount	$ 199,365,000
Net operating loss carryforward, year of expiration	no expiration date
Valuation allowance	$ 15,263,000
Deferred tax assets	$ 31,441,000
Foreign Jurisdictions
Income Taxes [Line Items]
Income tax holiday, description	The Company currently benefits from incentive tax rates in various non-U.S. jurisdictions with expiration dates from 2025 – 2029.
Income tax holiday, income in foreign jurisdictions	$ 50,372,000	$ 8,185,000	$ 2,414,000

Income Taxes - Earnings Before

Income Taxes - Earnings Before Income Taxes and Tax Provisions - (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Earnings (loss) before income tax:
Domestic	$ (54,073)	$ (37,222)	$ (34,211)
Foreign	156,338	92,176	72,593
Earnings before income tax	$ 102,265	$ 54,954	$ 38,382

Income Taxes - Provision for In

Income Taxes - Provision for Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Current income tax expense:
Federal	$ (1,181)	$ 3,510	$ 3,006
State and local	679	414	650
Foreign	27,240	23,759	17,607
Total current income tax expense	26,738	27,683	21,263
Deferred income tax (benefit) expense:
Federal	(7,944)	(7,495)	(5,971)
State and local	66	444	(213)
Foreign	18,458	(6,021)	(1,138)
Total deferred (benefit) income tax expense	10,580	(13,072)	(7,322)
Total income tax expense	$ 37,318	$ 14,611	$ 13,941

Income Taxes - Deferred Tax Ass

Income Taxes - Deferred Tax Assets and Deferred Tax Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Deferred tax assets:
Net operating losses	$ 35,966	$ 44,053
Intangible assets	10,893	4,314
Research and development credits	5,475	7,127
Property and equipment	4,132	4,800
Valuation reserves and accrued liabilities	8,446	11,221
Capitalized research and development costs	28,318	23,658
Stock compensation	2,039	3,227
Defined benefit obligation	1,514	1,691
Inventory	717	181
Other credits		8,946
Other	8,707	9,154
Total deferred tax asset	106,207	118,372
Valuation allowance	(25,272)	(35,888)
Deferred tax liabilities:
Unrealized foreign currency exchange gains	(1,092)
Undistributed profits of subsidiary	(5,016)	(4,609)
Property and equipment	(10,524)	(12,627)
Intangible assets	(8,720)
Other	(1,383)	(1,550)
Total deferred tax liability	(26,735)	(18,786)
Net deferred tax asset	$ 54,200	$ 63,698

Income Taxes - Reconciliations

Income Taxes - Reconciliations Between Statutory Federal Income Tax Rate and Effective Rate (Detail)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Statutory Federal income tax rate	21%	21%	21%
Increase (decrease) resulting from:
Change in valuation allowance	(9.00%)	(3.10%)	6.40%
Effect of different tax rates of foreign jurisdictions	(0.70%)	0.90%	(4.90%)
Tax credits & deductions related to R&D	(3.70%)	(8.50%)	(10.10%)
Goodwill impairment	0%	4.10%
Non-deductible expenses	15.70%	6.80%	14.90%
Non-deductible expenses related to acquisitions	0%		7%
Other foreign, state and local taxes	2.10%	3.50%	0.70%
Tax impact of foreign income	7.50%	3.60%	4.20%
Stock Option Compensation	1%		(3.80%)
Audit settlements and statute expirations	11%
Incentive tax rates in foreign jurisdictions	(5.50%)	(1.90%)
Other	(2.90%)	0.20%	0.90%
Effective rate	36.50%	26.60%	36.30%

Income Taxes - Net Operating Lo

Income Taxes - Net Operating Loss Carryforwards (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2024 USD ($)
U.S. state income tax
Operating Loss Carryforwards [Line Items]
Operating loss carryforward, amount	$ 41,396
U.S. state income tax | Minimum
Operating Loss Carryforwards [Line Items]
Operating loss carryforward, year of expiration	2025
U.S. state income tax | Maximum
Operating Loss Carryforwards [Line Items]
Operating loss carryforward, year of expiration	2043
Foreign, Never
Operating Loss Carryforwards [Line Items]
Operating loss carryforward, amount	$ 199,365
Operating loss carryforward, year of expiration	Never

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Unrecognized Tax Benefits (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Balance at beginning of year	$ 5,486	$ 6,185	$ 5,665
Additions based on tax position related to current year	78	87	972
Additions based on tax position related to prior year	4,587	347	433
Reductions from settlements and statute of limitation expiration	(1,636)	(1,266)	(610)
Effect of foreign currency translation	(249)	133	(275)
Balance at end of year	$ 8,266	$ 5,486	$ 6,185

Segment Reporting - Additional

Segment Reporting - Additional Information (Details)	12 Months Ended
	Dec. 31, 2024 Segment
Segment Reporting [Abstract]
Number of reportable segments	2
Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]	srt:ChiefExecutiveOfficerMember
Segment reporting, CODM, profit (loss) measure, how used, description	Our CODM uses operating income or loss to evaluate the performance and allocate resources for each of the Company’s segments. Operating income or loss is used to monitor budget versus actual results and year-over-year actual results to inform the decisions of how to allocate capital and resources within the Company.

Segment Reporting - Segment Inf

Segment Reporting - Segment Information about Reported Product Revenues, Depreciation and Amortization and Operating Income (Loss) (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Product Revenues
Product revenues	$ 1,456,124	$ 1,469,076	$ 1,204,656
Significant Segment Expenses and Operating Performance
Cost of sales	1,089,693	1,117,452	931,006
Net research and development expenses	88,697	94,358	85,722
Selling, general and administrative expenses	155,108	155,579	132,693
Restructuring expenses, net	13,110	4,739	637
Impairment of intangible assets and property and equipment	2,501		6,291
Operating income (loss)	107,015	77,439	48,307
Other segment disclosures
Depreciation and amortization	52,975	50,948	44,394
Operating Segments
Product Revenues
Product revenues	1,456,124	1,469,076	1,204,656
Corporate and Other Unallocated Expenses
Significant Segment Expenses and Operating Performance
Other operating expenses	(92,966)	(86,283)	(66,097)
Corporate and other unallocated expenses	(92,966)	(86,283)	(66,097)
Other segment disclosures
Depreciation and amortization	1,681	1,449	1,235
Automotive Segments
Product Revenues
Product revenues	1,406,278	1,422,952	1,161,616
Automotive Segments | Operating Segments
Product Revenues
Product revenues	1,406,278	1,422,952	1,161,616
Significant Segment Expenses and Operating Performance
Cost of sales	1,058,989	1,090,941	898,260
Net research and development expenses	68,787	70,778	75,137
Selling, general and administrative expenses	65,924	72,090	62,858
Restructuring expenses, net	12,238	3,187	637
Impairment of intangible assets and property and equipment			6,291
Operating income (loss)	200,340	185,956	118,433
Other segment disclosures
Depreciation and amortization	47,752	45,845	39,815
Medical Segments | Operating Segments
Product Revenues
Product revenues	49,846	46,124	43,040
Significant Segment Expenses and Operating Performance
Cost of sales	25,868	24,619	24,938
Restructuring expenses, net	20	363
Other operating expenses	21,836	24,230	22,131
Impairment of intangible assets and property and equipment	2,501	19,509
Operating income (loss)	(359)	(22,234)	(4,029)
Corporate and other unallocated expenses	21,836	24,230	22,131
Other segment disclosures
Depreciation and amortization	$ 3,542	$ 3,654	$ 3,344

Segment Reporting - Segment I_2

Segment Reporting - Segment Information About Reported Segment Product Revenues by Product Category (Detail) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Segment Reporting Information [Line Items]
Product revenues		$ 1,456,124	$ 1,469,076	$ 1,204,656
Automotive Segments
Segment Reporting Information [Line Items]
Product revenues		1,406,278	1,422,952	1,161,616
Automotive Segments | Climate Control Seat
Segment Reporting Information [Line Items]
Product revenues		468,820	482,665	426,046
Automotive Segments | Seat Heaters
Segment Reporting Information [Line Items]
Product revenues		297,866	308,588	283,970
Automotive Segments | Steering Wheel Heaters
Segment Reporting Information [Line Items]
Product revenues		169,763	153,943	120,949
Automotive Segments | Lumbar and Massage Comfort Solutions
Segment Reporting Information [Line Items]
Product revenues	[1]	178,584	144,923	56,980
Automotive Segments | Valve Systems
Segment Reporting Information [Line Items]
Product revenues	[1]	105,056	106,262	41,980
Automotive Segments | Automotive Cables
Segment Reporting Information [Line Items]
Product revenues		73,091	79,993	76,962
Automotive Segments | Battery Performance Solutions
Segment Reporting Information [Line Items]
Product revenues		58,183	75,484	71,907
Automotive Segments | Electronics
Segment Reporting Information [Line Items]
Product revenues		33,065	40,387	44,106
Automotive Segments | Other Automotive
Segment Reporting Information [Line Items]
Product revenues		21,850	30,707	38,716
Industrial Segments | Medical
Segment Reporting Information [Line Items]
Product revenues	[1]	$ 49,846	$ 46,124	$ 43,040
[1] Includes product revenues from acquisitions since their respective acquisition dates (see Note 4).

Segment Reporting (Detail)

Segment Reporting (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Segment Reporting Information [Line Items]
Product revenues	$ 1,456,124	$ 1,469,076	$ 1,204,656
United States
Segment Reporting Information [Line Items]
Product revenues	504,444	537,096	472,468
China
Segment Reporting Information [Line Items]
Product revenues	224,221	221,512	183,419
South Korea
Segment Reporting Information [Line Items]
Product revenues	104,120	115,854	94,937
Germany
Segment Reporting Information [Line Items]
Product revenues	105,927	102,383	75,367
Czech Republic
Segment Reporting Information [Line Items]
Product revenues	78,785	69,714	49,293
Slovakia
Segment Reporting Information [Line Items]
Product revenues	55,085	44,946	34,686
Japan
Segment Reporting Information [Line Items]
Product revenues	53,730	60,879	57,718
Romania
Segment Reporting Information [Line Items]
Product revenues	52,616	53,982	47,532
Mexico
Segment Reporting Information [Line Items]
Product revenues	43,327	45,733	23,233
United Kingdom
Segment Reporting Information [Line Items]
Product revenues	41,098	34,765	22,380
Other
Segment Reporting Information [Line Items]
Product revenues	192,771	182,212	143,623
Non U.S.
Segment Reporting Information [Line Items]
Product revenues	$ 951,680	$ 931,980	$ 732,188

Segment Reporting - Segment Rep

Segment Reporting - Segment Reporting About Property and Equipment, Net by Geographic Areas (Detail) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Segment Reporting Information [Line Items]
Property and equipment, net	$ 252,970	$ 245,234
Mexico
Segment Reporting Information [Line Items]
Property and equipment, net	47,814	39,943
China
Segment Reporting Information [Line Items]
Property and equipment, net	44,767	45,429
United States
Segment Reporting Information [Line Items]
Property and equipment, net	42,928	37,413
Germany
Segment Reporting Information [Line Items]
Property and equipment, net	42,457	46,586
North Macedonia
Segment Reporting Information [Line Items]
Property and equipment, net	25,374	27,675
Vietnam
Segment Reporting Information [Line Items]
Property and equipment, net	20,920	21,664
Czech Republic
Segment Reporting Information [Line Items]
Property and equipment, net	9,440	11,126
Hungary
Segment Reporting Information [Line Items]
Property and equipment, net	7,994	9,097
Ukraine
Segment Reporting Information [Line Items]
Property and equipment, net	5,174	5,986
Other
Segment Reporting Information [Line Items]
Property and equipment, net	$ 6,102	$ 315

Valuation and Qualifying Acco_2

Valuation and Qualifying Accounts (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Allowance for Deferred Income Tax Assets
Valuation And Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Period	$ 35,888	$ 36,671	$ 16,090
Charged to Costs and Expenses	(12,004)	(1,746)	2,482
Other Activity	1,388	963	18,099
Balance at End of Period	25,272	35,888	36,671
Reserve for Inventory
Valuation And Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Period	28,017	19,246	6,014
Charged to Costs and Expenses	6,437	6,867	15,923
Other Activity	(346)	3,876	(133)
Deductions from Reserves	(13,166)	(1,972)	(2,558)
Balance at End of Period	$ 20,942	$ 28,017	$ 19,246